



Market snapshot



			_	
Equities - India	Close	Chg .%	CYTD.%	
Sensex	83,216	-0.1	6.5	
Nifty-50	25,492	-0.1	7.8	
Nifty-M 100	59,843	0.6	4.6	
Equities-Global	Close	Chg .%	CYTD.%	
S&P 500	6,729	0.1	14.4	
Nasdaq	23,005	-0.2	19.1	
FTSE 100	9,683	-0.5	18.5	
DAX	23,570	-0.7	18.4	
Hang Seng	9,268	-0.9	27.1	
Nikkei 225	50,276	-1.2	26.0	
Commodities	Close	Chg .%	CYTD.%	
Brent (US\$/Bbl)	64	0.2	-13.9	
Gold (\$/OZ)	4,001	0.6	52.5	
Cu (US\$/MT)	10,698	0.4	23.6	
Almn (US\$/MT)	2,835	0.2	12.2	
Currency	Close	Chg .%	CYTD.%	
USD/INR	88.7	0.0	3.6	
USD/EUR	1.2	0.2	11.7	
USD/JPY	153.4	0.2	-2.4	
YIELD (%)	Close	1MChg	CYTD chg	
10 Yrs G-Sec	6.5	0.00	-0.2	
10 Yrs AAA Corp	7.2	0.01	0.0	
Flows (USD b)	7-Nov	MTD	CYTD	
FIIs	0.52	-0.05	-16.8	
DIIs	0.75	2.63	74.5	
Volumes (INRb)	7-Nov	MTD*	YTD*	
Cash	1,265	1170	1069	
F&O	2,35,458	2,91,837	2,30,243	

Note: Flows, MTD includes provisional numbers.



Today's top research idea

Britannia Industries: Growth visibility improving; swift margin recovery; Upgrade to Buy

- While we have been constructive on the packaged food industry following the GST rate revision (majorly from 18% to 5%), given that these are pure-play businesses expected to witness limited transitional impact, BRIT stands out as a key beneficiary. With 60-65% of its portfolio comprising LUPs/price pack (INR5/10 price packs), the company is well positioned to capitalize on the GST rate revision.
- We expect the earnings growth trend to improve from 2HFY26 onwards, given: 1) improving macro drivers for consumption, 2) market share gains as the rate reduction narrows the pricing gap between organized and unorganized players, 3) continued focus on distribution expansion, 4) product innovation serving as a key impetus, and 5) softening of key raw material costs (peak cost cycle is behind).
- We model an 11% and 16% revenue and PAT CAGR for FY25-28E. With positive green shoots in growth, we upgrade BRIT to a BUY rating with a TP of INR7,150 (premised on 50x Sep'27E EPS).


Research covered

Cos/Sector	Key Highlights
Britannia Industries	Growth visibility improving; swift margin recovery; Upgrade to Buy
Other Updates	Bajaj Auto Divi's Lab. Hindalco Inds. Trent Cholam. Inv. & Fin. Power Fin. Corpn. Torrent Pharma Cummins India Apollo Hospitals ABB Hitachi Energy Lupin Kalyan Jewellers Multi Comm. Exc. Hexaware Tech. Natl. Aluminium Amber Enter. Aegis Logistics Amara Raja Ener. Fine Organic JK Lakshmi Cem. Happy Forgings Indigo Paints Go Fashions EcoScope Petronet LNG Global Health Anant Raj JSW Cement Craftsman Auto SignatureGlobal Birla Corporation VA Tech Wabag Prince Pipes

П

Chart of the Day: Britannia Industries (Growth visibility improving; swift margin recovery)

We expect volume growth to have declined 3% YoY in 2QFY26



Source: Company, MOFSL

^{*}Average





In the news today



Kindly click on textbox for the detailed news link

1

FPIs resume selling after a brief pause in Oct; withdraw Rs 12,569 cr in Nov

After a brief pause in October, foreign portfolio investors have resumed selling, pulling out a net Rs 12,569 crore from Indian equities so far in November amid weak global cues and risk-off sentiment.

2

Adani may pip Vedanta to emerge highest bidder for Jaiprakash Associates

Adani Enterprises Ltd is likely to emerge as the highest bidder to acquire Jaiprakash Associates Ltd (JAL) through insolvency process as its offers to pay acquisition amount in two years have been found better than Vedanta's bid to make payments in five years, sources said.

3

Vedanta Resources to invest \$1.5 billion to launch CopperTech in US

Vedanta Resources has announced plans to launch a US-based subsidiary CopperTech Metals, which would in turn own and operate its Konkola Copper Mines in Zambia, a move which comes at a time when the Trump-led administration was trying to jack up domestic mining and cut imports.

4

Blue Energy plans an electric invasion in trucks on routes below 500 km

Blue Energy Motors, a Mumbaibased outfit, plans ₹3,500 crore push to electrify short-haul trucking with 1,200 batteryswapping stations and "energyas-a-service" model to rival diesel costs.

6

Green clearance decision deferred for ArcelorMittal Nippon plant in Andhra

An Expert Appraisal Committee under the MoEFCC has deferred its decision on granting environmental clearance to ArcelorMittal Nippon Steel India Limited's proposed 8.2 million tons per annum steel plant at Anakapalli District of Andhra Pradesh

7

Italy approves with conditions Iveco sale to Tata Motors

The Italian government has given its conditional approval to the sale of truck-maker Iveco to India's Tata Motors. Tata Motors has agreed to buy Iveco in a deal valued at 3.8 billion euros (\$4.36 billion)

5

Housing prices rise 7-19% across Indian metros in July-September 2025

Property prices across metros in India continued their unabated upward march in the July-September quarter of 2025, supported by strong end-user demand in the premium segment, elevated input costs, and a limited supply of quality, ready-to-move-in inventory, according to digital real estate transaction and advisory



Britannia Industries

Estimate change	1
TP change	1
Rating change	1

Bloomberg	BRIT IN
Equity Shares (m)	241
M.Cap.(INRb)/(USDb)	1483.1 / 16.7
52-Week Range (INR)	6337 / 4506
1, 6, 12 Rel. Per (%)	3/11/3
12M Avg Val (INR M)	2070

Financials & Valuations (INR b)

2026E	2027E	2028E
1077		
19/./	223.6	246.8
10.2	13.1	10.4
37.3	42.7	47.7
18.9	19.1	19.4
26.1	30.5	34.6
108.4	126.4	143.5
18.0	16.6	13.5
211.8	258.7	320.8
55.2	53.7	49.5
42.9	43.8	41.9
71.0	62.5	56.4
56.6	48.5	42.7
29.0	23.7	19.1
39.0	33.7	29.8
1.3	1.3	1.3
	37.3 18.9 26.1 108.4 18.0 211.8 55.2 42.9 71.0 56.6 29.0 39.0	10.2 13.1 37.3 42.7 18.9 19.1 26.1 30.5 108.4 126.4 18.0 16.6 211.8 258.7 55.2 53.7 42.9 43.8 71.0 62.5 56.6 48.5 29.0 23.7 39.0 33.7

Shareholding Pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	50.6	50.6	50.6
DII	19.4	18.7	16.4
FII	15.0	15.6	17.9
Others	15.0	15.2	15.2

FII includes depository receipts

CMP: INR6,158 TP: INR7,150 (+16%) Upgrade to Buy

Growth visibility improving; swift margin recovery

- Britannia Industries (BRIT) posted consolidated revenue growth of 4% YoY in 2QFY26 (below). Adjusted for the GST transition impact, sales growth would have been ~6-6.5% YoY, as the business faced short-term headwinds in September due to de-stocking. BRIT expects the transitional impact to normalize progressively in 3QFY26. By the end of October, the company had revised ~65% of its SKUs with updated grammages and prices, with full completion expected by mid-November. Rural markets continued to outpace urban markets. The company remains focused on driving healthy, volume-led growth through region- and consumer-centric products, enhanced distribution, and strong price competitiveness.
- GM expanded 20bp YoY and 140bp QoQ to 41.7% (above), driven by relatively stable commodity prices. Employee expenses declined 22% YoY on account of SAR devaluation, while other expenses declined ~7% YoY, leading to a beat on EBITDA margin, which expanded 290bp YoY to 19.7% (above). BRIT has normalized its A&P spends, with annual A&P spends as a % of sales for FY26 expected to revert to historical levels. We model an EBITDA margin of ~19% for FY26-28.
- While we have been constructive on the packaged food industry following the GST rate revision (majorly from 18% to 5%), given that these are pure-play businesses expected to witness limited transitional impact, BRIT stands out as a key beneficiary. With 60-65% of its portfolio comprising LUPs/price pack (INR5/10 price packs), the company is well positioned to capitalize on the GST rate revision. We expect the earnings growth trend to improve from 2HFY26 onwards, given: 1) improving macro drivers for consumption, 2) market share gains as the rate reduction narrows the pricing gap between organized and unorganized players, 3) continued focus on distribution expansion, 4) product innovation serving as a key impetus, and 5) softening of key raw material costs (peak cost cycle is behind). We model an 11% and 16% revenue and PAT CAGR for FY25-28E. With positive green shoots in growth, we upgrade BRIT to a BUY rating with a TP of INR7,150 (premised on 50x Sep'27E EPS).

Miss on revenue but beat on EBITDA

- Revenue growth at ~4%: BRIT's consolidated total revenue rose 3.7% YoY to INR48.4b (est. INR50.2b). Adjusted for the GST transition impact, sales would have grown ~6-6.5% YoY. Consolidated net sales (excluding other operating income) rose 4% YoY to INR47.5b (est. INR49.3b) in 2Q. Other operating income declined 13% YoY to INR0.9b (on a high base). On account of the GST transition, we believe volume decline would have been in low single digits.
- Lower operating expenses boost margin: Consolidated gross margin expanded 20bp YoY and 140bp QoQ to 41.7% (est. 40.8%), driven by relatively stable commodity prices. Employee expenses declined 22% YoY, while other expenses declined ~7% YoY, leading to a beat on EBITDA margin, which expanded 290bp YoY and 330bp QoQ to 19.7% (est. of 17.4%).



- **Double-digit PAT growth**: EBITDA rose 22% YoY to INR9.5b (est. INR8.7b). APAT rose 23% YoY to INR6.6b (est. INR6.1b).
- In 1HFY26, net sales/EBITDA/APAT grew 6%/11%/11% YoY, respectively.

Highlights from the management commentary

- Around 60%-65% of BRIT's portfolio comprises LUPs/price packs (INR5/10).
- The company expects the transitional impact to normalize progressively in 3QFY26. As of end-October, the company had revised ~65% of its SKUs, and by mid-November, all SKUs are expected to reflect revised grammages and prices.
- Adjusted for the GST transition, BRIT sales growth in 2QFY26 could have been higher by 2-2.5%, as September sales were impacted by 6-7%.
- The top three national-level players command ~70% of the market share, while significant regional players account for ~10-12%. The remaining 15% is held by value players.
- Dairy is trending below BRIT's expectations. The cheese market, which had witnessed high growth until last year, has now moderated. BRIT expects cheese growth to rebound in the near term.


Valuation and view

- We raise our EPS estimates by 3-5% for FY26-28.
- We remain constructive on the packaged food industry, as the GST rate cut from 18% to 5% is expected to boost volume growth. With 60-65% of BRIT's portfolio comprising INR5/10 price packs, the company stands out as one of the key beneficiaries of this rate revision.
- We expect earnings growth trend to improve from 2HFY26 onwards, given: 1) improving macro drivers for consumption, 2) market share gains as the rate reduction narrows the pricing gap between organized and unorganized players, 3) continued focus on distribution expansion, 4) product innovation serving as a key impetus, and 5) softening of key raw material prices (the peak cost cycle is behind). We model 11% and 16% revenue and PAT CAGR for FY25-28E. With positive green shoots in growth, we upgrade BRIT to a BUY rating with a TP of INR7,150 (premised on 50x Sep'27E EPS).

Y/E March		FY25 FY26E				FY25	FY26E	FY26	Var.			
•	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	(%)
Base business volume growth (%)	8.0	8.0	6.0	3.0	2.0	-3.0	10.0	11.0	6.3	5.0	4.0	
Net Revenue	41,299	45,662	44,633	43,756	45,349	47,522	50,882	50,204	1,75,350	1,93,956	49,315	(3.6)
YoY change (%)	4.0	4.5	6.5	9.0	9.8	4.1	14.0	14.7	6.0	10.6	8.0	
Other operating income	1,204	1,013	1,293	566	874	885	925	1,036	4,077	3,719	950	(6.9)
YoY change (%)	194.6	62.4	100.5	2.4	-27.4	-12.7	-28.5	83.0	82.8	-8.8	-6.3	
Total Revenue	42,503	46,676	45,926	44,322	46,222	48,406	51,807	51,240	1,79,427	1,97,675	50,265	(3.7)
YoY change (%)	6.0	5.3	7.9	8.9	8.8	3.7	12.8	15.6	7.0	10.2	7.7	
Gross Profit	18,449	19,381	17,784	17,773	18,631	20,177	21,603	21,623	73,386	82,035	20,508	(1.6)
Margins (%)	43.4	41.5	38.7	40.1	40.3	41.7	41.7	42.2	40.9	41.5	40.8	
EBITDA	7,537	7,834	8,449	8,052	7,571	9,545	10,170	9,976	31,872	37,262	8,738	9.2
Margins (%)	17.7	16.8	18.4	18.2	16.4	19.7	19.6	19.5	17.8	18.9	17.4	
YoY growth (%)	9.4	-10.2	2.9	2.3	0.4	21.8	20.4	23.9	0.5	16.9	11.5	
Depreciation	739	761	824	810	820	851	860	870	3,133	3,401	837	
Interest	290	346	446	307	262	347	375	390	1,388	1,373	300	
Other Income	556	460	625	630	570	521	620	694	2,271	2,405	600	
PBT	7,064	7,187	7,804	7,566	7,059	8,869	9,555	9,410	29,621	34,893	8,201	8.1
Tax	1,762	1,836	1,961	1,928	1,809	2,286	2,408	2,280	7,487	8,782	2,067	
Rate (%)	24.9	25.5	25.1	25.5	25.6	25.8	25.2	24.2	25.3	25.2	25.2	
Adjusted PAT	5,295	5,317	5,823	5,591	5,201	6,551	7,118	7,133	22,027	26,003	6,107	7.3
YoY change (%)	16.3	-9.3	4.3	4.2	-1.8	23.2	22.2	27.6	3.1	18.1	14.9	

E: MOFSL Estimates

Neutral





Bajaj Auto

Estimate change	\leftarrow
TP change	\leftarrow
Rating change	\leftarrow

Bloomberg	BJAUT IN
Equity Shares (m)	279
M.Cap.(INRb)/(USDb)	2435.5 / 27.5
52-Week Range (INR)	10190 / 7088
1, 6, 12 Rel. Per (%)	-4/7/-17
12M Avg Val (INR M)	3636

Financials & Valuations (INR b)

2026E	2027E	2028E
565	629	699
114.8	126.7	140.8
20.3	20.1	20.1
94.6	103.5	113.8
339	371	408
13.2	9.4	9.9
1,260	1,381	1,508
28.1	28.1	28.2
26.5	26.4	26.5
67.9	67.4	68.7
25.7	23.5	21.4
6.9	6.3	5.8
2.6	2.9	3.2
2.7	3.4	3.8
	565 114.8 20.3 94.6 339 13.2 1,260 28.1 26.5 67.9 25.7 6.9 2.6	565 629 114.8 126.7 20.3 20.1 94.6 103.5 339 371 13.2 9.4 1,260 1,381 28.1 28.1 26.5 26.4 67.9 67.4 25.7 23.5 6.9 6.3 2.6 2.9

Shareholding pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	55.0	55.0	55.0
DII	12.8	12.1	8.8
FII	9.7	10.3	14.3
Others	22.5	22.5	21.9

FII Includes depository receipts

Margins beat estimates, led by an improved mix

EV portfolio generates double digit margins for the first time

CMP: INR8,722

Bajaj Auto's (BJAUT) 2QFY26 earnings at INR24.8b were broadly in line with our estimate. While margins were 50bp ahead of expectations at 20.5%, led by an improved mix and favorable currency, lower other income limited earnings upside.

TP: INR9,070 (+4%)

While a recovery in exports and a healthy ramp-up of Chetak and 3Ws are key positives, market share losses in domestic motorcycles, particularly in its crucial 125cc+ segment, remains the key concern. While BJAUT has acquired a controlling stake in KTM under a lucrative deal, its effectiveness depends on how quickly it is able to turn around its operations, which will remain the key monitorable going forward. At ~25.7x/23.5x FY26E/27E EPS, BJAUT appears fairly valued. We reiterate our Neutral rating with a TP of INR9,070, based on 24x Sep27E core EPS.

Margin ahead of estimates on favorable currency and product mix

- Revenue in 2Q grew 14% to INR149b (in line), on account of volume growth of 6% and realization growth of 7%.
- The strong ASP increase was on account of a richer product mix and the highest-ever spare sales in 2QFY26.
- EBITDA margin expanded 30bp YoY to 20.5% (50bp ahead of our estimates)
 due to favorable currency and improved mix.
- EBITDA grew 15% YoY to INR30b (4% ahead of our estimates).
- Lower-than-anticipated other income limited PAT growth, which rose 12% YoY to INR24.8b vs est. of INR24.1b.
- CFO for 1H stood at INR48b and generated FCF of INR45b in 1H, while cash surplus at the end of Sep'25 stood at a healthy INR142b.

Highlights from the management commentary

- BJAUT's focus areas include: 1) competitive growth in the 125 cc plus segment; 2) target to sustain export growth at 15-20%; 3) regain momentum in the EV segment by unlocking supply chain constraints; 4) focus on reviving
- Post GST rate cuts, management expects the motorcycle industry to post a 6-8% growth in 2HFY26.
- The export momentum is likely to continue in the coming quarters, backed by strong demand from Latin American and Asian markets and stabilization in regions like Africa.
- EVs (2W + 3W) contributed 18% to domestic revenues, generating INR17b with double-digit EBITDA margins.
- BAL is currently producing at peak capacity in 3Ws, with further capacity being added to meet export demand.
- The company expects further commodity inflation in the coming quarters, though currency tailwinds should help offset the impact of the same.



Valuation and view

■ While a recovery in exports and a healthy ramp-up of Chetak and 3Ws are key positives, market share losses in domestic motorcycles, particularly in its crucial 125cc+ segment, remains the key concern. While BJAUT has acquired a controlling stake in KTM under a lucrative deal, its effectiveness depends on how quickly it is able to turn around its operations, which will remain a key monitorable moving forward. At ~25.7x/23.5x FY26E/27E EPS, BJAUT appears fairly valued. We reiterate a Neutral rating with a TP of INR9,070, based on 24x Sep27E core EPS.

Quarterly Performance (INR n										(INR m)	
		FY	25			FY2	6E		FY25	FY26E	
	1Q	2 Q	3Q	4Q	1Q	2 Q	3QE	4QE			2QE
Volumes ('000 units)	1,102	1,222	1,224	1,103	1,111	1,294	1,335	1,225	4,651	4,965	1,294
Growth YoY (%)	7.3	15.9	2.0	3.2	0.8	5.9	9.0	11.0	6.9	6.7	5.9
Realization (INR/unit)	108,234	107,470	104,591	110,142	113,247	115,307	112,958	113,779	107,527	113,837	113,381
Growth YoY (%)	7.9	5.1	3.7	2.5	4.6	7.3	8.0	3.3	4.7	5.9	5.5
Net Sales	119,280	131,275	128,069	121,480	125,845	149,221	150,762	139,329	500,103	565,156	146,728
Change (%)	15.7	21.8	5.7	5.8	5.5	13.7	17.7	14.7	11.9	13.0	11.8
EBITDA	24,154	26,522	25,807	24,505	24,818	30,517	30,901	28,563	100,988	114,798	29,351
EBITDA Margins (%)	20.2	20.2	20.2	20.2	19.7	20.5	20.5	20.5	20.2	20.3	20.0
Other Income	3,209	3,845	3,347	3,808	4,308	3,692	3,900	4,221	14,209	16,120	4,000
Interest	207	159	143	168	141	144	146	149	677	580	130
Depreciation	937	956	997	1,111	1,109	1,117	1,130	1,129	4,001	4,485	1,120
PBT after EO	26,219	27,139	28,015	27,033	27,875	32,948	33,525	31,506	108,406	125,854	32,101
Effective Tax Rate (%)	24.2	26.1	24.7	24.2	24.8	24.7	24.8	24.8	24.8	16.0	24.8
Adj. PAT	19,884	22,160	21,087	20,492	20,960	24,797	25,212	23,678	83,103	94,648	24,148
Change (%)	19.4	20.7	3.3	5.8	5.4	11.9	19.6	15.5	11.1	13.9	9.0

E: MOFSL Estimates



Divi's Laboratories

Estimate change	1
TP change	1
Rating change	—

Bloomberg	DIVI IN
Equity Shares (m)	265
M.Cap.(INRb)/(USDb)	1767.1 / 19.9
52-Week Range (INR)	7078 / 4942
1, 6, 12 Rel. Per (%)	8/4/6
12M Avg Val (INR M)	2885

Financials & Valuations (INR b)

Tillaticials & Valuation	5113 (11 4 11	,	
Y/E MARCH	FY26E	FY27E	FY28E
Sales	107.7	129.9	150.7
EBITDA	34.2	41.7	50.2
Adj. PAT	24.6	30.5	36.4
EBIT Margin (%)	27.5	28.5	29.8
Cons. Adj. EPS (INR)	92.6	114.7	137.1
EPS Gr. (%)	14.0	23.9	19.5
BV/Sh. (INR)	630.7	710.4	805.8
Ratios			
Net D:E	-0.2	-0.2	-0.2
RoE (%)	15.5	17.1	18.1
RoCE (%)	15.6	17.1	18.1
Payout (%)	30.1	30.5	30.4
Valuations			
P/E (x)	71.9	58.0	48.6
EV/EBITDA (x)	50.7	41.5	34.4
Div. Yield (%)	0.4	0.4	0.5
FCF Yield (%)	0.4	0.4	1.1
EV/Sales (x)	16.1	13.3	11.5

Shareholding pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	51.9	51.9	51.9
DII	19.8	19.1	21.1
FII	19.4	19.7	17.3
Others	9.0	9.3	9.8

FII includes depository receipts

CMP: INR6,657 TP: INR6,925 (+4%) Neutra

Operating leverage and CS strength support margins

Growth visibility intact, but upside priced in

- Divi's Laboratories (DIVI) delivered better-than-expected performance in 2Q with a 4%/10%/10% beat on revenue/EBITDA/PAT. While gross margin has been steady for the past eight quarters, DIVI has delivered improved EBITDA margin YoY as well as QoQ, led by better operating leverage.
- Based on the generics and custom synthesis (CS) composition highlighted by the management, DIVI has achieved an all-time high quarterly revenue in the CS segment in 2QFY26.
- The generics business remained on a moderate YoY growth path. While pricing pressure persisted in this segment, DIVI was able to offset this impact through backward integration and higher volume offtake.
- The nutraceutical business has seen a notable uptick for the past two quarters.
- We broadly retain our FY26/FY27/FY28 estimates. We value DIVI at 55x 12M forward earnings to arrive at our TP of INR6,925. DIVI continues to strengthen its position as a reliable CDMO company for global pharma players, aided by 1) differentiated skill sets such as peptide and contrast media manufacturing, 2) enhanced reliability for supply despite geopolitical turmoil, and 3) a built capacity that would cater to future requirements.
- Further, it continues to focus on improving operating efficiency in manufacturing generics and adding new molecules in this segment.
 However, the current valuation adequately factors in the earnings upside.
 Reiterate Neutral.

Revenue growth led by operating leverage drives EBITDA growth YoY

- DIVI's revenue grew 16.1% YoY to INR27.1b (our est: INR26.1b) for 2QFY26.
- Gross margin expanded 190bp YoY to 60.6%.
- EBITDA margin expanded 200bp YoY to 32.7% (our est: 31%), majorly driven by growth in gross margin.
- As a result, EBITDA grew 24% YoY to INR8.9b (our est: INR8.1b) for 2QFY26.
- Adjusted for INR630m in forex gain, PAT grew 31% YoY to INR6.4b (our est: INR5.8b).

Highlights from the management commentary

- DIVI had a CC growth of 10.7% in 1HFY26.
- The generics: CS share in sales for 2QFY26 stood at 44:56.
- This implies the generics segment grew 4% YoY, while the CS business grew 27.5% YoY for the quarter.
- DIVI has inaugurated the Peptide Center of Excellence. DIVI has engaged with several big pharma companies at different stages of clinical trials in peptide products.
- DIVI continues to invest in the lab and the manufacturing stage for peptides.



- DIVI manufactures its own protected amino acids. Hence, DIVI is in a superior position from the impurity standpoint.
- On a YoY basis, the volume gain in existing products as well as new products is getting offset by the pricing pressure.
- Capex stood at INR15.5b for 1HFY26. There is a scope of capex of more than INR20b in FY26.
- The US and EU formed 74% of sales for 2QFY26.
- The nutraceutical business was INR2.4b in 2QFY26
- DIVI has capitalized assets worth INR4.5b
- DIVI has progressed well on iodine-based contrast media products. DIVI is undergoing a validation process and will be qualified soon. DIVI is working with multiple global pharma companies for gadolinium-based contrast media products. This would take at least a year for commercial success.
- DIVI has witnessed stability in raw material prices over the recent past in the generics segment.
- Considering geopolitical turmoil, DIVI has maintained sufficient inventory levels to ensure the timely availability of required products to its customers.

Quarterly Performance

Y/E March		FY	25			FY2	6E		FY25	FY26E	FY26E	Var.
(INRm)	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	(%)
Net Sales	21,180	23,380	23,190	25,850	24,100	27,150	27,403	29,043	93,600	1,07,695	26,090	4.1
YoY Change (%)	19.1	22.5	25.0	12.2	13.8	16.1	18.2	12.4	19.3	15.1	11.6	
Total Expenditure	14,960	16,220	15,760	16,990	16,810	18,270	18,771	19,691	63,930	73,542	18,002	
EBITDA	6,220	7,160	7,430	8,860	7,290	8,880	8,632	9,352	29,670	34,154	8,088	9.8
YoY Change (%)	23.4	43.5	51.9	21.2	17.2	24.0	16.2	5.6	33.5	15.1	13.0	
Margins (%)	29.4	30.6	32.0	34.3	30.2	32.7	31.5	32.2	31.7	31.7	31.0	
Depreciation	970	990	990	1,070	1,120	1,130	1,135	1,192	4,020	4,577	1,143	
EBIT	5,250	6,170	6,440	7,790	6,170	7,750	7,496	8,160	25,650	29,576	6,944	11.6
YoY Change (%)	27.7	52.7	63.5	22.5	17.5	25.6	16.4	4.7	39.0	15.3	12.6	
Interest	0	0	0	10	30	80	0	0	10	110	0	
Other Income	780	770	720	760	800	820	833	795	3,030	3,249	758	
PBT before EO Income	6,030	6,940	7,160	8,540	6,940	8,490	8,330	8,955	28,670	32,715	7,702	10.2
Forex gain /(Loss)	10	290	100	100	390	630	0	0	500	1,020	0	
PBT	6,040	7,230	7,260	8,640	7,330	9,120	8,330	8,955	29,170	33,735	7,702	18.4
Tax	1,740	2,120	1,370	2,020	1,880	2,230	2,041	2,239	7,250	8,390	1,848	
Rate (%)	28.8	29.3	18.9	23.4	25.6	24.5	24.5	25.0	24.9	24.9	24.0	
PAT	4,300	5,110	5,890	6,620	5,450	6,890	6,289	6,716	21,920	25,345	5,853	17.7
Adj. PAT	4,293	4,905	5,809	6,543	5,160	6,414	6,289	6,716	21,550	24,579	5,853	9.6
YoY Change (%)	20.3	38.3	68.5	22.0	20.2	30.8	8.3	2.6	35.3	14.1	19.3	
Margins (%)	20.3	21.9	25.4	25.6	22.6	25.4	22.9	23.1	23.4	23.5	22.4	
Adj. EPS	16.2	18.5	21.9	24.7	19.4	24.2	23.7	25.3	81.2	92.6	22.1	

Hindalco





Estimate change	\longleftrightarrow
TP change	↓
Rating change	—

Bloomberg	HNDL IN
Equity Shares (m)	2247
M.Cap.(INRb)/(USDb)	1776.2 / 20
52-Week Range (INR)	864 / 546
1, 6, 12 Rel. Per (%)	1/20/17
12M Avg Val (INR M)	3800
Free float (%)	65.4

Financials & Valuations (INR h)

rilialiciais & valuacions (livit b)							
Y/E MARCH	2026E	2027E	2028E				
Sales	2,597	2,703	2,825				
EBITDA	329	340	358				
Adj. PAT	165	166	176				
EBITDA Margin (%)	13	13	13				
Cons. Adj. EPS (INR)	74	75	79				
EPS Gr. (%)	-1	1	6				
BV/Sh. (INR)	504	572	643				
Ratios							
Net D:E	0.3	0.3	0.2				
RoE (%)	15.8	13.9	13.0				
RoCE (%)	13.4	12.9	12.6				
Payout (%)	9.4	9.3	10.1				
Valuations							
P/E (x)	10.7	10.5	10.0				
P/BV (x)	1.6	1.4	1.2				
EV/EBITDA(x)	6.5	6.1	5.6				
Div. Yield (%)	0.9	0.9	1.0				
FCF Yield (%)	2.3	5.2	5.8				
·							

Shareholding Pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	34.6	34.6	34.6
DII	24.5	25.3	24.6
FII	32.6	31.9	32.8
Others	8.3	8.2	8.0

FII includes depository receipts

CMP: INR790 TP: INR920 (+16%) Buy

Earnings beat led by favorable pricing; Novelis to see muted performance in near term

Consolidated performance

- Consolidated net sales stood at INR660.6b (+14% YoY and +3% QoQ) against our est. of INR637.4b, driven by favorable pricing and a better product mix.
- Consolidated EBITDA stood at INR89.7b (+14% YoY and +13% QoQ) against our est. of INR74.6b, driven by higher aluminum prices, a better product mix and benefits from a cost mitigation plan.
- Adj. PAT came in at INR48.7b (+14% YoY and +22% QoQ) against our est. of INR36.4b. The beat was primarily led by a better operating profit from both India and Novelis businesses.
- Consol. net debt-to-EBITDA ratio stood at 1.23x as of 2QFY26 vs. 1.02x as of 1QFY26.

Aluminum business

- Upstream revenue stood at INR100.8b in 2QFY26 (+10% YoY), led by higher average aluminum prices. Aluminum upstream EBITDA stood at INR45.2b (+22% YoY; USD1,521/t), driven by higher volume and favorable pricing.
- Downstream revenue stood at INR38.1b (+20% YoY) on account of higher shipment and favorable pricing. Downstream EBITDA stood at INR2.6b (+69% YoY) led by better product-mix. This translates into EBITDA/t of USD265 (+49% YoY) in 2QFY26 (flat QoQ).
- Upstream aluminum sales stood at 341kt (+4% YoY) and downstream aluminum sales stood at 113KT (+10% YoY) in 1QFY26.
- HNDL has announced Phase-II of Aditya Aluminum expansion (193KT), with a project cost of INR102.25b and expected commissioning in FY29.

Copper business

- Copper business revenue stood at INR145.6b (+11% YoY), aided by higher average copper prices.
- EBITDA for copper business came in at INR6.3b in 2QFY26, down 24% YoY, led by a sharp decline in TCs/RCs, offset by higher sulphuric acid prices.
- Copper metal sales were at 113KT (-3% YoY) and CCR sales were at 97KT (+8% YoY).

Novelis' 2QFY26 performance

- Shipment volume stood at 941kt (flat YoY and -2% QoQ) and was in line with our estimate. Higher automotive and aerospace shipments were offset by lower beverage packaging and specialty shipments.
- Revenue stood at USD4.7b (+10% YoY and flat QoQ) against our estimate of USD4.4b. The beat was due to higher ASP for the quarter at USD5,041/t (+11% YoY and +3% QoQ), driven by favorable aluminum prices.
- Adjusted EBITDA stood at USD422m (vs. our estimate of USD374m), declining 9% YoY (+1% QoQ), primarily due to net negative tariff impacts and higher aluminum scrap prices, partially offset by higher product pricing and cost efficiencies. Adj. EBITDA/t for the quarter stood at USD449 (against our estimate of USD395), declining 8% YoY but rising 4% QoQ.

10 November 2025 9



 APAT stood at USD141m in 2QFY26 (-30% YoY and -10% QoQ) against our estimate of USD105m.

Highlights from the management commentary

- In 2Q, aluminium CoP was 3-4% higher QoQ, due to monsoon-related coal logistics challenges and higher alumina input costs. Management expects CoP in 3QFY26 to remain broadly flat, with easing coal prices offset by a slight rise in CPC and coke costs.
- The company expects aluminium production and shipments to remain steady or slightly higher in 2HFY26, supported by the ramp-up of downstream capacity and stable operations across smelters.
- The specialty alumina business, with ~0.5mt capacity at Belgaum and Muri, continued to perform well, though realizations were temporarily impacted by a sharp fall in alumina index prices from USD700/t to USD350/t.
- Management emphasized that consol. net leverage to remain below 2x throughout the announced investment phase.
- It guided alumina sales to moderate in 3QFY26 due to a planned maintenance shutdown at Utkal Alumina. For FY26, alumina sales volumes would be ~700-800kt.
- The company reiterated its capex plan of USD10b over FY26-29, covering both India and Novelis projects. Annual Capex guidance stands at INR85b for FY26 and a peak capex of ~INR110b for FY27 due to the execution of large upstream and recycling projects.

Valuation and view

- HNDL posted a strong consolidated performance in 2QFY26. Earnings growth was primarily driven by favorable pricing. Going forward, the strong earnings outlook for Indian business remains intact. However, the overall Hindalco business outlook has weakened owing to the Bay Minette project cost escalation to USD5b from USD4.1b (revised from USD2.6b earlier) and muted earning in 2H, led by Oswego fire incident.
- Novelis volumes are expected to decline with FCF impact of USD550-650m, (incl. EBITDA impact of USD100-150m in FY26), which erodes near-term earnings visibility and stretches the working capital. Management expects to recover ~70-80% via insurance in FY27.
- We increase our consolidated FY26 EBITDA and PAT estimates by 4%/7% incorporating the strong domestic business outlook, offsetting the muted Novelis profitability for FY26. We largely maintain our FY27 estimate, assuming Novelis to recover and India business to remain strong.
- At CMP, the stock trades at 6.1x EV/EBITDA and 1.4x P/B on FY27E. We reiterate our BUY rating on HNDL with an SoTP-based TP of INR920.

10 November 2025



Consolidated quarterly performance											(INR	b)
Y/E March		FY25			FY26 FY29			FY25	FY26E	FY26	vs Est	
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	(%)
Net Sales	570.1	582.0	583.9	648.9	642.3	660.6	628.9	665.4	2,385.0	2,597.2	637.4	3.6
Change (YoY %)	7.6	7.4	10.6	15.9	12.7	13.5	7.7	2.5	10.4	8.9		
Change (QoQ %)	1.8	2.1	0.3	11.1	(1.0)	2.8	(4.8)	5.8		-		
Total Expenditure	495.1	503.2	508.1	560.5	563.3	570.9	551.6	582.3	2,066.9	2,268.1		
EBITDA	75.0	78.8	75.8	88.4	79.1	89.7	77.3	83.0	318.1	329.0	74.6	20.1
Change (YoY %)	31.3	40.5	29.3	32.3	5.4	13.7	1.9	(6.1)	33.2	3.5		
Change (QoQ %)	12.3	5.1	(3.8)	16.5	(10.5)	13.4	(13.8)	7.4	-	-		
As % of Net Sales	13.2	13.5	13.0	13.6	12.3	13.6	12.3	12.5	13.3	12.7		
Interest	8.6	8.7	8.2	8.7	7.5	8.0	10.7	11.1	34.2	37.3		
Depreciation	18.9	19.3	19.4	21.2	20.8	21.6	21.7	22.7	78.8	86.7		
Other Income	4.2	10.8	5.1	7.0	6.0	7.1	7.1	7.2	27.1	27.5		
PBT (before EO item)	51.8	61.6	53.4	65.4	56.7	67.2	52.1	56.4	232.1	232.5		
Extra-ordinary Income	(3.3)	(5.1)	(0.4)	0.1	-	(1.8)	-	-	(8.8)	-		
PBT (after EO item)	48.5	56.4	53.0	65.5	56.7	65.4	52.1	56.4	223.3	232.5		
Total Tax	17.7	17.3	15.6	12.7	16.7	18.0	16.0	17.2	63.4	67.9		
% Tax	36.6	30.7	29.5	19.3	29.5	27.5	30.7	30.5	28.4	29.2		
PAT before MI and Associate	30.7	39.1	37.3	52.8	40.0	47.4	36.1	39.2	160.0	164.6		
Adjusted PAT	33.1	42.7	37.6	52.8	40.0	48.7	36.1	39.2	166.2	164.6	36.4	33.9
Change (YoY %)	34.0	97.3	61.5	66.3	21.1	14.0	(4.1)	(25.7)	63.9	(0.9)		
Change (QoQ %)	4.1	29.2	(11.8)	40.2	(24.1)	21.6	(25.8)	8.6				

Source: MOFSL, Company





Trent

Estimate change	\leftarrow
TP change	
Rating change	←→

Bloomberg	TRENT IN
Equity Shares (m)	355
M.Cap.(INRb)/(USDb)	1644.9 / 18.6
52-Week Range (INR)	7493 / 4488
1, 6, 12 Rel. Per (%)	-3/-16/-34
12M Avg Val (INR M)	6706

Financials & Valuations Consol (INR b)

mancials & valuations consol (new b)								
FY26E	FY27E	FY28E						
203.1	234.6	270.5						
35.9	41.6	47.9						
18.6	20.9	23.9						
17.7	17.7	17.7						
52.4	58.9	67.2						
21.3	12.4	14.1						
214.5	271.1	336.0						
0.0	-0.1	-0.2						
29.6	25.9	23.7						
19.4	16.8	15.4						
10.5	10.2	9.7						
88.4	78.6	68.9						
45.9	39.3	33.8						
8.2	7.0	6.0						
0.1	0.1	0.1						
	203.1 35.9 18.6 17.7 52.4 21.3 214.5 0.0 29.6 19.4 10.5 88.4 45.9 8.2	FY26E FY27E 203.1 234.6 35.9 41.6 18.6 20.9 17.7 17.7 52.4 58.9 21.3 12.4 214.5 271.1 0.0 -0.1 29.6 25.9 19.4 16.8 10.5 10.2 88.4 78.6 45.9 39.3 8.2 7.0						

Shareholding Pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	37.0	37.0	37.0
DII	20.0	18.5	13.4
FII	16.8	18.4	26.6
Others	26.2	26.1	23.0

FII includes depository receipts

CMP: INR4,627 TP: INR6,000 (+30%) Buy

Robust cost controls cushion margins; growth pickup vital

- Trent's revenue growth continued to decelerate in 2QFY26 (+17% YoY), as ~43% YoY area addition growth was offset by sharp ~17% YoY decline in revenue per square foot, indicating store-level sales cannibalization.
- However, despite revenue growth deceleration and ~90bp YoY gross margin contraction (mix impact), Trent delivered ~16% growth in 2QFY26 pre-INDAS EBITDA (with modest ~10bp YoY margin dip), aided by robust cost controls (employee cost flat YoY, despite 33% YoY store additions).
- Star business continued to underperform as revenue declined ~2% YoY (vs. 7% YoY growth in 1Q) as multiple stores underwent upgrades during 2Q. Store count remained stable at 77, while revenue per sqft declined 14% YoY to INR26.9k (vs. 1.5% YoY uptick on much larger base for DMart).
- We raise our FY26-28 reported EBITDA estimates by ~4-5%, driven by costsaving measures. However, we cut our FY27-28E earnings by 4-5% due to higher depreciation.
- We build in a CAGR of 17%/20%/14% in standalone revenue/EBITDA/PAT over FY25-28E, driven mainly by store expansions and robust cost controls.
- We continue to like Trent for its robust footprint additions, strong double-digit growth, long runway for growth in Star (presence in just 10 cities), and potential scale-up of emerging categories (Beauty, Innerwear, Footwear, and LGDs). However, revenue growth acceleration remains a key trigger.
- Reiterate BUY on Trent with a revised TP of INR6,000, premised on 44x Dec'27E EV/EBITDA for the standalone (Westside and Zudio) business, ~3x EV/sales for Star JV, and ~1.5x EV/EBITDA for Zara JV (sharp cut from ~6x EV/EBITDA due to tendering of shares by Trent at low valuations).
- After recent correction, the stock currently trades at ~70x Dec'27E EPS, excluding the contribution from Star and Zara JV.

Strong margin performance drives beat; 1H pre-INDAS EBITDA up 26% YoY

- Standalone revenue at INR47b grew 17% YoY (disclosed earlier), driven by
 ~33% YoY net store additions as revenue per store declined ~9% YoY.
- Trent reported low-single-digit LFL growth for its fashion portfolio.
- Gross profit grew 15% YoY to INR20.5b (vs. our est. INR20.9b) as gross margin contracted ~90bp YoY to 43.3% (~70bp miss).
- Despite 33% YoY net store additions, employee costs remained flat YoY
 (13% below), driven by savings from RFID implementation.
- SG&A and other costs increased ~11% YoY (2% lower than our est.).
- As a result, reported EBITDA grew 27% YoY to INR8.1b (6% beat) as lower gross margin was offset by superior control on costs.
 - Reported EBITDA margins **expanded 135bp YoY to 17.2%** (~110bp ahead), driven by robust cost controls.
 - ➤ As per company, standalone pre-INDAS EBITDA grew 16% YoY in 2Q to INR5.75b (23% YoY in 1H), with pre-INDAS EBITDA margin of 12.2% (vs. ~13% in 1QFY26). Standalone pre-Ind AS EBIT margin declined 80bp YoY to 10.2%.



- Trent's occupancy cost (rentals above EBITDA) remained flat YoY; however, depreciation and interest costs jumped.
- For 1HFY26, pre-INDAS EBITDA grew 26% YoY (vs. 32% YoY growth in reported EBITDA) to INR11.9b, driven by ~70bp margin expansion to 12.5% (vs. ~180bp expansion in reported EBITDA).
- Adjusted PAT grew 7% YoY to INR4.5b (~5% beat) as higher EBITDA and lower tax rate were partly offset by higher depreciation (+65% YoY), finance cost (+28% YoY) and lower other income (-14% YoY).
- For 1HFY26, revenue/reported EBITDA/adj. PAT grew 18%/32%/14%.
- Based on our estimates, 2H revenue/EBITDA/adj. PAT growth would be 20%/29%/23%.

Pickup in store addition in 2QFY26, especially for Westside

- After subdued store expansion activity in 1QFY26, store expansion picked up pace, with store count across fashion formats rising to 1,101 (up 33% YoY).
- In 2Q, Westside added the highest number of quarterly net stores in several quarters, with 13 net store additions (19 openings, 6 closures), taking the total store count to 261 (+15% YoY) and area rising ~28% YoY. Westside entered two new cities to expand its presence to 88 cities.
- **Zudio** added 40 net store openings (44 openings, 4 closures) in 2QFY26 (41 in 1HFY26 vs. 32 in 1HFY25) to reach 806 stores (+40% YoY), with retail area rising 56% YoY. Zudio entered nine new cities to expand its presence to 244 cities.
- Trent launched a new format, Burnt Toast, during the quarter, which helped to increase the other fashion format's store count by 5 QoQ to 34 (+21% YoY).
- We note that store additions typically pick up pace in 2H and all eyes would be on further scale-up of Trent's fashion footprint as it remains the biggest driver of growth amid weakening SSSG.

Working capital steady; FCF improves despite jump in cash capex

- WC days were steady at 37 (flat YoY) as moderation in inventory days to 43 (from 45 YoY) was offset by lower payable days.
- OCF (after interest and leases) surged 1.5x YoY to INR10b, driven by 26% YoY increase in pre-INDAS EBITDA and favorable WC movement (release of INR1.7b vs. build-up of INR2.7b YoY).
- However, Trent's net capex jumped to INR8.4b (vs. INR3.8b YoY and INR8.2b in FY25), which resulted in FCF of INR2.3b (vs. ~INR500m YoY).
- Trent's net cash stood at ~INR1.9b in FY25 (vs ~INR3.4b at end-FY25).

Star business: Muted performance with dip in revenue

- Revenue declined 2% YoY (vs. 7% YoY in 1Q) as multiple stores underwent upgrades in 2Q and 1HFY26.
- Store count remained flat in 2QFY26 at 77 stores (1 opening offset by 1 closure).
- Calc. annualized revenue per sqft declined ~14% YoY to INR26.9k (vs. +1.5% YoY for DMart at INR36.6k) and annualized revenue per store declined ~7% YoY to INR457m (vs. +1% YoY for DMart at INR1.51b).
- The share of own-brand offerings now contributes ~73% to Star's revenue (stable YoY).



Highlights from the management commentary

- Consumer sentiment in 2Q was relatively muted and was further affected by unseasonal rains.
- With GST rationalization, customers initially prioritized purchases of big-ticket products with greater GST cut benefits. Management expects demand traction to pick up over the medium term for discretionary lifestyle categories as well.
- Emerging categories, including beauty and personal care, innerwear, and footwear, contributed to 21% of standalone revenue.
- Online revenue grew 56% YoY, contributing 6%+ of Westside sales.
- Investments in technology and automation have aided in delivery of stable operating economics. Especially, the RFID implementation has led to material optimization in manpower requirements across Trent's portfolio.
- Variable structure of costs, including store rentals and fees to business associates, has helped Trent gain operating leverage.
- A change in the maturity profile of new stores has led to increased depreciation relative to revenue.

Consolidated performance

- Consolidated revenues grew 16% YoY to INR48b.
- Reported EBITDA grew 27% YoY to INR8.2b. Margin rose 150bp YoY to 17%.
- Pre-IND AS EBITDA for 1HFY26 stood at INR11.9b (up 27% YoY), with margins expanding ~90bp YoY to 12.3%.
- Adjusted PAT stood at INR3.7b (up 11% YoY), driven by higher EBITDA and lower tax rate, partly offset by higher D&A and finance costs.

Zara India: Trent to tender ~15% stake for INR1.5b

- Trent has decided to tender 94,900 shares in Inditex Trent Retail (Zara India) for ~INR15,422/share in buyback.
- This transaction will fetch modest ~INR1.5b to Trent and lower its stake to 20%.
- The implied valuation for Zara India is modest at ~INR7.8b (vs. our earlier ascribed value of ~INR13b for Trent's 35% stake).

Valuation and view

- TRENT's growth rate has decelerated sharply in the last few quarters due to weak LFL amid a subdued demand environment. However, the company continues to display strong cost controls to report healthy EBITDA growth.
- We continue to like Trent for its robust footprint additions, strong double-digit growth, long runway for growth in Star (presence in just 10 cities), and potential scale-up of emerging categories (Beauty, Innerwear, Footwear, and LGDs). However, revenue growth acceleration remains a key trigger.
- We raise our FY26-28E reported EBITDA by 4-5%, led by cost-saving measures. However, we cut our FY27-28E earnings by 4-5% due to higher depreciation.
- We build in a CAGR of 17%/20%/14% in standalone revenue/EBITDA/PAT over FY25-28E, driven mainly by store expansions and robust cost controls.
- Reiterate BUY on Trent with a revised TP of INR6,000, premised on 44x Dec'27E EV/EBITDA for the standalone (Westside and Zudio) business, ~3x EV/sales for Star JV, and ~1.5x EV/EBITDA for Zara JV.
- After recent correction, the stock currently trades at ~70x Dec'27E P/E, excluding the contribution from Star and Zara JV.



Standalone - Quarterly Earnings Summary

(INR m)

Y/E March		FY	25			FY2	26E		FY25	FY26E	FY26E	Est. Var
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	=		2QE	(%)
Revenue	39,917	40,356	45,347	41,061	47,813	47,241	54,417	49,187	1,66,681	1,98,657	47,620	-0.8
YoY Change (%)	57.4	39.6	36.9	28.8	19.8	17.1	20.0	19.8	39.8	19.2	22.7	
Total Expenditure	33,812	33,949	36,971	34,497	39,435	39,108	43,316	41,040	1,39,229	1,62,899	39,953	-2.1
EBITDA	6,106	6,407	8,376	6,564	8,377	8,132	11,101	8,148	27,452	35,758	7,667	6.1
EBITDA Margin (%)	15.3	15.9	18.5	16.0	17.5	17.2	20.4	16.6	16.5	18.0	16.1	6.9
Depreciation	1,759	1,915	2,393	2,631	2,839	3,153	3,216	3,227	8,699	12,435	2,952	6.8
Interest	312	324	363	371	395	413	454	624	1,369	1,886	423	-2.4
Other Income	461	1,387	564	970	409	1,192	592	937	3,381	3,129	1,387	-14.0
PBT before EO expense	4,496	5,554	6,184	4,532	5,552	5,759	8,023	5,233	20,766	24,567	5,678	1.4
Extra-Ord expense	-	-	-	-	-	-	-	-	-	-	-	
PBT	4,496	5,554	6,184	4,532	5,552	5,759	8,023	5,233	20,766	24,567	5,678	1.4
Tax	1,074	1,320	1,490	1,033	1,326	1,251	1,885	1,311	4,918	5,773	1,363	-8.2
Reported PAT	3,422	4,234	4,693	3,499	4,226	4,508	6,137	3,922	15,848	18,793	4,315	4.5
YoY Change (%)	130.8	46.2	36.6	41.3	23.5	6.5	30.8	12.1	54.0	18.6	1.9	

E: MOFSL Estimates



Cholamandalam Inv. & Finance

Estimate change	←→
TP change	←→
Rating change	\leftarrow

Bloomberg	CIFC IN
Equity Shares (m)	841
M.Cap.(INRb)/(USDb)	1433.7 / 16.2
52-Week Range (INR)	1782 / 1168
1, 6, 12 Rel. Per (%)	3/4/27
12M Avg Val (INR M)	2752

Financials & Valuations (INR b)

		<u> </u>	
Y/E March	FY25	FY26E	FY27E
Total Income	135.7	169.9	204.8
PPP	82.3	103.9	126.0
PAT	42.6	51.3	67.1
EPS (INR)	50.6	59.8	78.2
EPS Gr. (%)	24	18	31
BV (INR)	281	356	432
Valuations			
NIM (%)	6.9	7.0	7.2
C/I ratio (%)	39.3	38.8	38.5
RoAA (%)	2.4	2.4	2.6
RoE (%)	19.7	18.9	19.8
Payout (%)	4.0	3.3	3.2
Ratios			
P/E (x)	33.6	28.4	21.7
P/BV (x)	6.1	4.8	3.9
Div. Yield (%)	0.1	0.1	0.1

Shareholding pattern (%)

As of	Sep-25	Jun-25	Sep-24
Promoter	49.9	49.9	50.2
DII	17.3	16.1	16.6
FII	26.9	28.0	27.2
Others	6.0	6.1	6.0

FII Includes depository receipts

CMP: INR1,704 TP: INR1,935 (+14%) Buy

Soft quarter; business volumes and asset quality to improve in 2H

Asset quality deteriorates; AUM growth at the lower end of guidance

- Cholamandalam Inv. & Finance (CIFC)'s 2QFY26 PAT grew ~20% YoY to INR11.5b (in line). PAT grew ~20% YoY in 1HFY26, and we expect its PAT to grow ~21% YoY in 2H.
- CIFC's NII grew ~25% YoY to ~INR33.8b in 2QFY26 (in line). Other income grew ~33% YoY to ~INR7b (~5% below est.), driven by higher fee income and assignment income of ~INR764m (PQ: INR1.5b).
- CIFC's opex rose ~23% YoY to ~INR16.2b (in line), and the cost-income ratio declined ~1pp QoQ to ~40% (PQ: 38% and PY: 41%). The sequential increase in opex was due to variable compensation/incentives and investments in building the gold and CD business. PPoP grew ~28% YoY to INR24.6b.
- Yields (calc.) rose ~5bp QoQ to ~14.45%, and CoF (calc.) declined ~15bp QoQ to ~7.65%. NIM rose ~15bp QoQ to ~6.9%. Management guided for a further ~10-15bp NIM expansion in H2FY26, aided by benefits in CoF. We expect the NIM to expand to ~7%/7.2% in FY26/FY27 (vs. ~6.9% in FY25).
- Management reiterated that the 20%+ AUM growth target remains intact, and it does not appear to be at risk. The company shared that business momentum was very healthy in Oct'25, and it expects disbursements and sequential AUM growth to accelerate in 2HFY26.
- The company also guided for overall credit costs to decline, supported by a reduction in slippages and a gradual improvement in vehicle utilization levels in 2H, which should enhance borrower repayment capacity. It is targeting to maintain credit costs at around 1.6% for the full year. We model credit costs of 1.6%/1.4% for FY26/FY27E.
- We cut our FY26E EPS by 2-3% to factor in slightly lower loan growth and higher credit costs. We model a CAGR of 14%/20%/25% in disbursement /AUM/PAT over FY25-28E. CIFC will have to utilize its levers on NIM (and fee income) to offset the impact of moderation in AUM growth and elevated credit costs. We estimate RoA/RoE of ~2.7%/20% in FY28. We reiterate our BUY rating with a TP of INR1,935 (premised on 4x Sep'27E BVPS).
- **Key risks:** 1) weak macros translating into weaker vehicle demand and sustained lower capacity utilization; 2) higher business volumes, following the festive season and GST cuts, rebounding to previous normalized levels, and 3) deterioration in asset quality, particularly in the new businesses and vehicle finance, which could keep the credit costs high for longer than estimated.

AUM rises ~21% YoY; disbursements flat both YoY and QoQ

- Business AUM grew 21% YoY/3.4% QoQ to INR1.99t, with newer businesses now forming ~12% of the AUM mix.
- Total disbursements in 2QFY26 were flat YoY and QoQ at ~INR244b. New lines of businesses contributed ~19% to the disbursement mix (PQ: ~17% and PY: ~24%), and VF disbursements in 2QFY26 grew ~10% YoY.
- Gold loan disbursements in 2QFY26 stood at ~INR5.5b and are expected to pick up in 2HFY26, which should support overall gold loan growth.
- We model a total AUM CAGR of ~20% over FY25-28E.



Asset quality deteriorates across segments; GS3 up ~20bp QoQ

- GS3/NS3 deteriorated ~20bp/12bp QoQ to 3.35%/1.9%, while PCR on S3 declined ~50bp QoQ to ~43.2%. ECL/EAD rose ~7bp QoQ to 2.05% (PQ: ~1.97%). GS3 in newer businesses rose ~20bp QoQ to ~2.8% (PQ: 2.6% and PY: 1.6%).
- Stage 2 + Stage 3 (30+ dpd) rose ~25bp QoQ to ~6.45%.
- CIFC's 2Q credit costs stood at ~INR9b (~vs. est. of INR9.2b). This translated into annualized credit costs of ~1.85% (PY: ~1.55% and PQ: ~1.9%). GNPA/NNPA (RBI IRAC) rose ~30bp/20bp QoQ to ~4.6%/3.1%. In 2QFY26, write-offs (calc.) stood at ~INR6.4b, translating into ~1.6% of TTM AUM (PY: ~1.1% and PQ: 1.3%).
- CRAR stood at ~20% (Tier 1: ~14.6%) as of Sep'25.
- Management guided credit costs of ~1.6% in FY26 (vs. ~1.4% in FY25). We estimate credit costs (as a % of avg. assets) of ~1.6%/1.4% in FY26/FY27.

Key highlights from the management commentary

- Management indicated that origination yields in gold loans remained healthy, and the company does not intend to price below industry peers to chase growth.
- Credit cost losses in the CSEL portfolio have already peaked and are expected to moderate progressively in the subsequent quarters.
- While the benefits of all the actions taken by the government (personal income tax cut, GST cuts, reduction in interest rates) were not fully visible in 2QFY26, the medium-term outlook remains strong.

Valuation and View

- CIFC delivered a soft quarter, with disbursements remaining largely flat YoY/QoQ and credit costs staying elevated. Asset quality weakened across product segments. A key positive was NIM expansion of ~15bp QoQ.
- The stock trades at 3.9x FY27E P/BV. In order to sustain this premium valuation multiple, CIFC will have to give higher confidence in its ability to deliver on its AUM growth and credit costs guidance for FY26. Further, it might have to fully leverage its diversified product suite to deliver its medium-term AUM growth guidance of 20-25%. We estimate a CAGR of ~20%/25% in AUM/PAT over FY25-28 for an RoA/RoE of 2.7%/20% in FY28E. We reiterate our BUY rating with a TP of INR1,935 (premised on 4x Sep'27E BVPS).



Quarterly Performance												(INR M)
Y/E March		FY	25			FY2	26E		FY25	EV26	2QFY26E	v/s Est.
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q		1120	2Q1120L	V/3 L3t.
Interest Income	53,695	57,680	61,587	64,180	66,501	68,942	71,631	75,055	2,37,200	2,82,129	68,496	1
Interest Expenses	27,957	30,551	32,718	33,623	34,663	35,155	35,858	36,727	1,24,849	1,42,403	35,182	0
Net Interest Income	25,738	27,128	28,869	30,557	31,838	33,787	35,773	38,328	1,12,351	1,39,726	33,313	1
YoY Growth (%)	39.7	34.6	33.0	29.8	23.7	24.55	23.9	25.4	34.0	24.4	22.8	
Other Income	4,595	5,248	6,537	7,027	6,807	6,959	7,754	8,610	23,348	30,130	7,329	-5
Total Income	30,333	32,376	35,406	37,584	38,645	40,746	43,526	46,938	1,35,699	1,69,856	40,643	0
YoY Growth (%)	42.6	36.8	37.2	29.0	27.4	25.9	22.9	24.9	35.9	25.2	25.5	
Operating Expenses	11,834	13,155	14,130	14,269	14,528	16,169	17,168	18,088	53,388	65,952	16,181	0
Operating Profit	18,499	19,221	21,276	23,315	24,117	24,578	26,359	28,850	82,311	1,03,903	24,462	0
YoY Growth (%)	38.1	35.3	40.4	43.2	30.4	27.9	23.9	23.7	39.4	26.2	27.3	
Provisions & Loan Losses	5,814	6,235	6,640	6,253	8,821	8,970	8,700	8,247	24,943	34,738	9,200	-2
Profit before Tax	12,685	12,986	14,636	17,062	15,296	15,608	17,659	20,603	57,369	69,165	15,262	2
Tax Provisions	3,263	3,355	3,771	4,395	3,937	4,054	4,556	5,276	14,783	17,823	3,938	3
Net Profit	9,422	9,631	10,865	12,667	11,359	11,553	13,103	15,327	42,585	51,342	11,324	2
YoY Growth (%)	29.8	26.3	24.0	19.7	20.6	20.0	20.6	21.0	24.4	20.6	17.6	
Key Parameters (Calc., %)												
Yield on loans	14.4	14.51	14.6	14.5	14.4	14.45	14.4	14.3	14.5	14.2		
Cost of funds	7.86	7.94	8.06	7.86	7.78	7.63	7.56	7.52	8.1	7.6		
Spread	6.5	6.6	6.6	6.6	6.6	6.8	6.8	6.8	6.5	6.6		
NIM	6.84	6.78	6.81	6.80	6.76	6.91	7.00	7.11	6.9	7.0		
C/I ratio	39.0	40.6	39.9	38.0	37.6	39.7	39.4	38.5	39.3	38.8		
Credit cost	1.55	1.56	1.57	1.39	1.87	1.83	1.70	1.53	1.5	1.7		
Tax rate	25.7	25.8	25.8	25.8	25.7	26.0	25.8	25.6	25.8	25.8		
Balance Sheet Parameters												
Disbursements (INR b)	243	243	258	264	243	244	286	303	1,009	1,076		
Growth (%)	21.6	12.9	15.3	6.6	0.0	0.5	10.8	14.5	13.7	6.7		
AUM (INR b)	1,554	1,646	1,746	1,847	1,921	1,992	2,098	2,215	1,847	2,215		
Growth (%)	35.4	32.5	30.5	26.9	23.6	21.0	20.2	19.9	26.9	19.9		
AUM mix (%)												
Vehicle finance	57.0	55.9	55.4	54.8	54.5	54.0	54.0	52.9	54.8	52.9		
Home Equity	20.7	21.2	21.5	22.4	22.9	23.2	23.5	24.6	22.4	24.6		
Home loans & Others	22.3	23.0	23.1	22.8	22.6	22.7	22.5	22.5	12.8	12.0		
Borrowings (INR b)	1,499	1,578	1,671	1,749	1,813	1,875	1,920	1,988	1,749	1,988		
Growth (%)	38.6	32.1	35.7	30.1	20.9	18.8	14.9	13.6	30.1	13.6		
Asset Quality Parameters												
GS 3 (INR B)	41.2	47.1	51.3	52.1	60.4	66.3			52.1	66.5		
GS 3 (%)	2.6	2.83	2.9	2.8	3.2	3.35			2.8	3.0		
NS 3 (INR B)	22.5	26.1	28.7	28.5	34.0	37.6			28.5	37.3		
NS 3 (%)	1.5	1.60	1.7	1.6	1.8	1.94			1.5	1.7		
PCR (%)	45.5	44.5	44.1	45.3	43.7	43.2			45.3	44.0		
Vehicle finance AUM mix (%)												
LCV	19.8	19.8	19.2	19.0	19.2	19.3			19.8	19.8		
Cars & MUV	22.8	23.1	23.7	24.1	24.5	24.8			22.8	23.1		
3W & SCV	3.6	3.6	3.6	3.5	3.5	3.5			3.6	3.6		
Used CV	27.4	27.6	27.6	27.7	27.6	27.6			27.4	27.6		
Tractor	6.5	6.2	6.0	5.6	5.3	5.1			6.5	6.2		
HCV	6.7	6.6	6.6	6.8	6.7	6.7			6.7	6.6		
CE	6.5	6.3	6.4	6.4	6.3	6.1			6.5	6.3		
Two wheeler	6.8	6.7	6.8	6.8	6.8	6.9			6.8	6.7		
E: MOEST estimates	0.0	0.7	0.0	0.0	0.0	0.3			0.0	0.7		

E: MOFSL estimates

Buy



Power Finance Corporation

Estimate change	\leftarrow
TP change	\leftarrow
Rating change	\leftarrow
-	

CMP: INR380

Bloomberg	POWF IN
Equity Shares (m)	3300
M.Cap.(INRb)/(USDb)	1254.9 / 14.2
52-Week Range (INR)	524 / 357
1, 6, 12 Rel. Per (%)	-9/-10/-23
12M Avg Val (INR M)	3254

Financials & Valuations (INR b)

Y/E March	FY25	FY26E	FY27E
NII	193	216	240
PPP	216	228	264
PAT	174	191	203
EPS (INR)	52.6	57.9	61.4
EPS Gr. (%)	21	10	6
BV/Sh. (INR)	276	316	359
ABV/Sh. (INR)	232	272	315
RoAA (%)	3.2	3.2	3.1
RoAE (%)	20.4	19.6	18.2
Div Payout (%)	30.0	30.1	30.0
Valuations			
P/E (x)	7.2	6.6	6.2
P/BV (x)	1.4	1.2	1.1
Core P/E (x)	5.1	4.6	4.3
Core P/BV (x)	1.1	0.9	0.8
Div. Yld (%)	4.2	4.6	4.8

Shareholding pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	56.0	56.0	56.0
DII	16.0	16.1	17.5
FII	18.8	18.7	17.7
Others	9.1	9.2	8.8

FII includes depository receipts

Earnings below est.; muted loan growth from higher repayments
Asset quality broadly stable; reported NIM dips ~5bp QoQ

TP: INR485 (+28%)

- Power Finance Corporation (PFC)'s 2QFY26 PAT grew ~2% YoY to INR44.6b (~17% miss). PAT in 1HFY26 grew 11% YoY, and we expect PAT in 2HFY26 to grow by 10% YoY. NII grew ~20% YoY to ~INR52.9b in 2QFY26 (inline).
- Other operating income declined ~19% YoY to ~INR11.8b (PY: INR14.7b), which included dividend income of INR11b (PY: INR12.5b). The company reported exchange losses of INR5b (PQ: exchange losses of INR6.5b). The EUR/INR movement is one of the major reasons for the foreign exchange translation loss in 2QFY26.
- Opex declined ~18% YoY to ~INR1.9b (inline), and the cost-income ratio rose ~25bp QoQ to ~3.65%. PPoP grew ~9% YoY to INR57.8b (~9% miss).
- PFC shared that ~95% of its foreign currency borrowings are hedged, with the small unhedged portion majorly linked to Euro-denominated bonds. The EUR appreciated by ~8% against the USD in 1HFY26, which led to mark-to-market losses. However, the company also shared that since these foreign borrowings are long-term, any favorable movement in exchange rates could help reverse these exchange losses. The company noted that the EUR/USD exchange rate has moved more favorably in recent days.
- The reported yield dipped ~3bp QoQ to ~9.98%, while the reported CoB rose ~3bp QoQ to ~7.43%. This led to ~5bp QoQ dip in spreads to 2.55% in 1HFY26. Reported NIM for 2QFY26 contracted 5bp QoQ to ~3.62% (PQ: 3.68%).
- GS3 declined ~5bp QoQ to ~1.87%, while NS3 was broadly stable QoQ at 0.37%. PCR on Stage 3 was stable QoQ at ~80.2%. Provisions for the quarter stood at INR2.4b (PQ: -INR6.8b and PY: -INR1.2b). This translated into annualized credit costs of 4bp (PY: -3bp and PQ: -12bp).
- PFC highlighted that the resolution plan for the Sinnar Thermal Power project (with an exposure of ~INR10b) has been submitted for NCLT approval. The company has ~80% provision cover on this account.
- We estimate a disbursement/advances/PAT CAGR of 11%/12%/10% over FY25-FY28E, an RoA/RoE of 3.1%/18%, and a dividend yield of ~5.5% in FY28E. We reiterate our BUY rating with an SoTP (Sep'27E)-based TP of INR485 (premised on 1x target multiple for the PFC standalone business and INR151/share for PFC's stake in REC after a hold-co discount of 20%).

Disbursements rise ~7% YoY; loan book grows ~2% QoQ

- Loan book stood at INR5.61t and grew 14% YoY/2% QoQ. Disbursements during the quarter rose ~7% YoY to ~INR498b. Repayments during the quarter stood at ~28% (PQ: 22% and PY: ~24%).
- The renewables segment in the loan mix was stable at 15% (PQ: 15%). Disbursements to the infrastructure sector formed ~4% of the total disbursements in 2QFY26.
- PFC maintained its loan growth guidance to ~10-11% in FY26. We model a loan book CAGR of ~12% over FY25-FY28E.



Asset quality broadly stable; PCR also stable QoQ

- GS3 declined ~5bp QoQ to ~1.87%, while NS3 was broadly stable QoQ at 0.37%.
 PCR on Stage 3 was broadly stable QoQ at ~80.2%. Standard assets (Stage 1 + 2)
 PCR was broadly stable QoQ at ~1%.
- PFC has ~22 projects (PQ: 22 projects) that are classified as NPA. Resolutions in ~11 NPA projects (PQ: 11) are being pursued under NCLT, and the remaining ~11 NPA projects (PQ: 11) are being pursued outside NCLT.
- CRAR stood at ~21.6% as of Sep'25.

Key highlights from the management commentary

- Management noted that there have been no prepayment requests for the Kaleshwaram project (exposure of ~INR260b), and repayments are happening in their normal course. Given that this project is backed by a state guarantee and has budgetary support, PFC does not see any prepayment or credit risk associated with this exposure.
- The company closed its first cross-border project financing transaction in Bhutan, providing INR48b of funding for a 600MW hydropower project. The loan has been denominated in INR, and the transaction was undertaken with a special approval from the RBI.

Valuation and view

- PFC delivered a muted performance for the quarter, with loan growth remaining soft and earnings coming in below expectations due to elevated forex losses on the unhedged portion of its foreign currency borrowings. NIM and spreads moderated during the quarter, reflecting some pressure on yields in a declining interest rate environment. Asset quality, however, remained broadly stable, and credit costs continued to remain benign.
- PFC (standalone) trades at 0.8x FY27E P/BV and ~4x FY27 P/E, and we believe that the risk-reward is attractive considering decent visibility on loan growth, further stressed asset resolutions, and healthy RoE of 18-20% over FY26-27E.

 Reiterate our BUY rating with an SoTP (Sep'27E)-based TP of INR485 (premised on 1x target multiple for the PFC standalone business and INR151/share for PFC's stake in REC after a hold-co discount of 20%).
- **Key risks:** 1) weaker loan growth driven by higher prepayments; 2) increase in exposure to power projects without PPAs; 3) compression in spreads and margins due to an aggressive competitive landscape; and 4) any slowdown in the offtake of renewable energy projects.

PFC: SoTP - Sep'27

	Stake	Target Multiple	Value (INR B)	INR per share	% To Total		Rationale
PFC Standalone	100	1.0	1,097	334	69	*	1.0x Sep'27 PBV
REC Stake (Pre-HoldCo)	53	1.1	624	189		*	1.1x Sep'27 PBV
Hold Co Discount (20%)			125				
REC Stake (Post-Holdco)			499	151	31		
Target Value			1,596	485	100		



Quarterly Performance											(INR m)
Y/E March		FY	/25			F	Y26E		FY25	FY26E	2Q	v/s
Particulars	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			FY26E	Est.
Interest Income	1,18,270	1,19,090	1,24,172	1,37,215	1,37,389	1,34,728	1,36,345	1,40,591	4,98,747	5,49,052	1,35,465	-1
Interest Expenses	74,990	75,007	77,231	78,109	82,697	81,835	82,981	85,235	3,05,380	3,32,748	83,276	-2
Net Interest Income	43,280	44,083	46,942	59,106	54,692	52,893	53,364	55,356	1,93,367	2,16,304	52,189	1
YoY Gr %	23.5	18.2	12.9	39.5	26.4	20.0	13.7	-6.3	23.7	11.9	18.4	
Other Income	3,160	14,655	5,971	11,309	2,016	11,829	6,763	12,812	35,096	33,420	15,095	-22
Net Operational Income	46,440	58,738	52,913	70,415	56,708	64,722	60,127	68,167	2,28,463	2,49,724	67,284	-4
YoY Gr %	41.1	19.4	11.5	42.1	22.1	10.2	13.6	-3.2	27.6	9.3	14.5	
Exchange gain/(loss)	589	-3,100	457	-2,614	-6,546	-4,972	-1,300	-682	-4,668	-13,500	-2,000	149
Total Net Income	47,029	55,639	53,370	67,801	50,162	59,750	58,827	67,486	2,23,795	2,36,224	65,284	-8
YoY Gr %	24.6	15.9	18.0	34.9	6.7	7.4	10.2	-0.5	23.5	5.6	17.3	
Operating Expenses	1,016	2,355	1,832	2,341	1,848	1,932	2,071	2,390	7,500	8,241	2,025	-5
Operating Profit	46,013	53,284	51,538	65,460	48,313	57,819	56,756	65,095	2,16,295	2,27,983	63,259	-9
YoY Gr %	25.3	13.7	16.8	39.8	5.0	8.5	10.1	-0.6	23.9	5.4	18.7	
Provisions	620	-1,241	745	4,447	-6,818	2,420	-3,000	1,722	4,571	-5,677	-2,000	-221
PBT	45,393	54,525	50,793	61,013	55,132	55,399	59,756	63,374	2,11,724	2,33,660	65,259	-15
Tax	8,214	10,821	9,244	9,924	10,117	10,780	10,756	10,874	38,202	42,526	11,747	-8
Tax Rate %	18.1	19.8	18.2	16.3	18.3	19.5	18.0	17.2	18.0	18.2	18.0	
PAT	37,179	43,704	41,549	51,090	45,015	44,619	49,000	52,500	1,73,522	1,91,134	53,512	-17
YoY Gr %	23.6	13.6	23.0	23.5	21.1	2.1	17.9	2.8	20.6	10.2	22.4	
Key Parameters (Calc., %)												
Yield on loans	9.9	9.8	10.0	10.7	10.3	9.9						
Cost of funds	7.4	7.3	7.4	7.0	7.1	7.0						
Spread	2.5	2.5	2.6	3.7	3.1	2.9						
NIM	3.56	3.57	3.76	4.51	3.93	3.73						
C/I ratio	2.3	5.3	3.9	4.0	3.38	3.65						
Credit cost	0.01	(0.03)	0.01	0.08	(0.12)	0.04						
Balance Sheet Parameters												
Disbursements (INR b)	195	467	342	680	362	498						
Growth YoY (%)	(15)	42	45	40	86	7						
AUM (INR b)	4,750	4,934	5,038	5,431	5,498	5,612						
Growth YoY (%)	10	10	10	13	16	14						
Asset Quality Parameters			2									
GS 3 (INR B)	161	134	135	105	105	105						
GS 3 (%)	3.4	2.7	2.7	1.9	1.92	1.87						
NS 3 (INR B)	41.1	35.3	35.9	20.9	20.8	20.8						
NS 3 (%)	0.9	0.7	0.7	0.4	0.4	0.4						
PCR (%)	74.4	73.6	73.4	80.1	80.3	80.2						

PCR (%)
E: MOFSL Estimates



Torrent Pharma

Estimate change	\leftarrow
TP change	←→
Rating change	←

Bloomberg	TRP IN
Equity Shares (m)	338
M.Cap.(INRb)/(USDb)	1211.6 / 13.7
52-Week Range (INR)	3790 / 2886
1, 6, 12 Rel. Per (%)	0/4/8
12M Avg Val (INR M)	1203

Financials & Valuations (INRb)

	1	- /	
Y/E March	FY26E	FY27E	FY28E
Sales	130.3	143.4	166.4
EBITDA	42.6	49.2	58.1
Adjusted PAT	23.7	28.6	35.3
EBIT Margin (%)	26.3	28.0	29.3
Cons. Adj EPS (INR)	70.0	84.6	104.2
EPS Gr. (%)	21.2	20.8	23.1
BV/Sh. (INR)	538.1	646.2	779.2
Ratios			
Net D-E	0.3	0.2	0.1
RoE (%)	28.4	28.6	29.2
RoCE (%)	22.7	24.5	26.6
Payout (%)	36.4	36.1	36.1
Valuation			
P/E (x)	51.1	42.3	34.4
EV/EBITDA (x)	28.6	24.3	20.2
Div. Yield (%)	0.6	0.7	0.9
FCF Yield (%)	2.3	2.8	3.3
EV/Sales (x)	9.4	8.3	7.0
-			

Shareholding Pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	68.3	68.3	71.3
DII	9.3	8.7	7.1
FII	15.9	16.1	14.5
Others	6.5	6.9	7.2

FII includes depository receipts

CMP: INR3,580 TP: INR3,770 (+5%) Neutral

Execution gains in DF/LATAM/US

Softness in EU persists in 2Q; valuation limits upside

- Torrent Pharma (TRP) delivered in-line financial performance for the quarter. YoY growth improved in the US generics and LATAM markets, led by new product launches and steady market share gains in the base portfolio.
- After a slowdown in the LATAM business in FY25, TRP has revived growth in this segment, outperforming the market over the past two quarters. Product approvals and enhanced marketing efforts have driven higher YoY growth. The company has already submitted the application for Semaglutide and is well-positioned to benefit from this opportunity, given its strong brand franchise in this market.
- In the Domestic Formulation (DF) segment, TRP faced minimal impact from the GST transition and outperformed the industry. Notably, it recorded a higher YoY volume growth of 3.7% vs the industry (0.5%) in 2QFY26.
- Following the receipt of a voluntary action indicated (VAI) at its US site in Aug'24, the business has recorded healthy growth over the past two quarters, driven largely by new product launches.
- We largely maintain our estimates for FY26/FY27/FY28. We value TRP at 40x 12M forward earnings to arrive at a TP of INR3,770. TRP remains well-positioned to deliver industry-leading growth in DF/LATAM. While current product launches have enabled a pick-up in the US growth, the pace of filings is expected to accelerate from FY27 onwards. Temporary disruptions continue to impact the EU business in the near term. Considering all these factors, we expect a 13%/16%/23% revenue/EBITDA/PAT CAGR over FY25-28. Integration and synergy benefits from the JB acquisition are expected to materialize following the completion of the acquisition process. Considering the limited upside from current levels, we reiterate Neutral on the stock.

Sales/EBITDA rise 14%/15% YoY; PAT grows at a high rate of 33% due to lower tax rate

- Sales grew 14.3% YoY to INR33b.
- DF revenue grew 11.5% YoY to INR18.2b (55% of sales). US generics grew 25.7% YoY to INR3.4b (10% of sales). LATAM business grew 21% YoY to INR3.2b (10% of sales). ROW+CDMO sales grew 19.6% YoY at INR5.2b (16% of sales). Germany sales rose 5.2% YoY to INR3b (9% of sales).
- Gross margin contracted 75bp at 75.8% for 2QFY26.
- EBITDA margin expanded 30bps YoY to 32.8%, as the increase in RM costs (up 75bps YoY as a % of sales)/employee costs (up 20bps YoY as a % of sales) was offset by lower other expenses (down 125bps YoY as a % of sales).
- Accordingly, EBITDA grew 15.3% YoY to INR10.8b (vs our Est: INR10.7b).
- Adj. PAT grew 32.6% YoY to INR6b. Exceptional item pertains to regulatory/statutory fees.
- For 1HFY26, Revenue/EBITDA/PAT grew 13%/14%/17% YoY



Highlights from the management commentary

- TRP delivered volume/new launches/price YoY growth of 3.7%/3%/5.5% in the DF segment for the quarter.
- The company delivered 13% YoY growth in the chronic segment vs industry YoY growth of 11%. The outperformance was driven by a superior show in therapies like cardiac and gastro.
- TRP's DF segment faced minimal impact from the GST transition during the quarter.
- TRP delivered 13% YoY CC growth in the Brazilian market vs the industry YoY growth of 7% in 2QFY26.
- The company has filed for Semaglutide in the Brazilian market. Given the product's relevance for the patient population, the Brazilian regulatory agency may prioritize Semaglutide submissions across companies.

Quarterly performance	(Consolid	ated)										(INRm)
Y/E March		FY	25			FY2	6E		FY25	FY26	FY26E	Var.
INR m	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	vs Est
Net Revenues	28,590	28,890	28,090	29,590	31,780	33,020	32,498	33,030	115,160	130,328	32,165	2.7
YoY Change (%)	10.3	8.6	2.8	7.8	11.2	14.3	15.7	11.6	7.3	13.2	11.3	
EBITDA	9,240	9,390	9,140	9,810	10,470	10,830	10,497	10,768	37,580	42,565	10,679	1.4
YoY Change (%)	16.8	13.8	5.2	11.1	13.3	15.3	14.8	9.8	11.6	13.3	13.7	
Margins (%)	32.3	32.5	32.5	33.2	32.9	32.8	32.3	32.6	32.6	32.7	33.2	
Depreciation	1,970	1,980	1,990	2,010	2,010	2,040	2,107	2,142	7,950	8,299	2,210	
EBIT	7,270	7,410	7,150	7,800	8,460	8,790	8,389	8,626	29,630	34,265	8,469	3.8
YoY Change (%)	21.2	18.8	9.0	14.7	16.4	18.6	17.3	10.6	15.7	15.6	14.3	
Margins (%)	25.4	25.6	25.5	26.4	26.6	26.6	25.8	26.1	25.7	26.3	26.3	
Interest	750	640	570	560	560	480	520	510	2,520	2,070	540	
Other Income	240	-160	330	-180	-370	-270	182	171	230	-287	175	
PBT before EO Expense	6,760	6,610	6,910	7,060	7,530	8,040	8,051	8,287	27,340	31,908	8,104	-0.8
One-off expenses	200	0	0	410	150	130	0	0	610	280	0	
PBT after EO Expense	6,560	6,610	6,910	6,650	7,380	7,910	8,051	8,287	26,730	31,628	8,104	
Tax	1,990	2,080	1,880	1,670	1,900	2,000	2,069	2,163	7,620	8,132	2,123	
Rate (%)	29.4	31.5	27.2	23.7	25.2	24.9	25.7	26.1	27.9	25.5	26.2	
Reported PAT	4,570	4,530	5,030	4,980	5,480	5,910	5,982	6,124	19,110	23,496	5,980	-1.2
Minority Interest	0	0	0	0	0	0	0	0	0	0	0	
Adj PAT	4,709	4,530	5,030	5,287	5,591	6,007	5,982	6,124	19,556	23,705	5,980	0.4
YoY Change (%)	24.6	17.4	31.9	17.8	18.7	32.6	18.9	15.8	22.7	21.2	32.0	
Margins (%)	16.5	15.7	17.9	17.9	17.6	18.2	18.4	18.5	17.0	18.2	18.6	

Buy



Cummins India

Estimate change

TP change

Rating change

Bloomberg	KKC IN
Equity Shares (m)	277
M.Cap.(INRb)/(USDb)	1189.7 / 13.4
52-Week Range (INR)	4495 / 2580
1, 6, 12 Rel. Per (%)	7/47/15
12M Avg Val (INR M)	1969

Financials Snapshot (INR b)

- manage			
Y/E MARCH	FY26E	FY27E	FY28E
Net Sales	119.5	139.6	162.1
EBITDA	25.3	27.9	32.5
PAT	24.3	27.3	31.9
EPS (INR)	87.6	98.5	114.9
GR. (%)	22.2	12.5	16.7
BV/Sh (INR)	289.1	327.7	373.0
Ratios			
ROE (%)	32.3	31.9	32.8
RoCE (%)	30.8	30.4	31.3
Valuations			
P/E (X)	49.0	43.6	37.4
P/BV (X)	14.9	13.1	11.5
EV/EBITDA (X)	45.9	41.4	35.4
Div Yield (%)	1.1	1.3	1.5
·			

Shareholding Pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	51.0	51.0	51.0
DII	21.8	22.6	22.6
FII	18.4	17.5	17.5
Others	8.8	8.9	8.9

FII includes depository receipts

Strong broad-based performance

CMP: INR4,292

Cummins India (KKC) once again reported a strong set of results with a beat on all parameters. Revenue growth was led by sharp growth in powergen and healthy growth in distribution and exports. The industrial segment was impacted by slow construction activity. KKC has grown its CPCB 4+-related portfolio by 20% YoY, which indicates a healthy YoY volume improvement. We expect KKC to continue to benefit from 1) demand improvement in the powergen segment as industry volumes have now improved back to pre-emission levels, 2) a fairly strong outlook for data centers, 3) improved penetration for the distribution segment, and 4) a gradual recovery in exports. KKC stands far ahead of the competition in terms of overall product offering and distribution reach. We tweak our estimates and roll forward our valuations to 42x Mar'28E earnings. We reiterate our BUY rating with a revised TP of INR4,950.

TP: INR4,950 (+15%)

A strong set of results with an all-round beat

KKC reported a strong set of results with a beat across all parameters. Revenue was up 27% YoY to INR31.7b, beating our estimate by 10%. Domestic sales increased 28% YoY/10% QoQ to INR25.8b (9% above our estimates), whereas export sales increased 24% YoY/4% QoQ to INR5.5b (13% above our estimates). Exports have been continuously increasing since 4QFY24. Gross margin at 37.0% saw a 100bp YoY expansion. This led to an EBITDA margin expansion of 260bp YoY/50bp QoQ to 21.9%. This was higher than our expectation of 20.0%. Absolute EBITDA increased 44% YoY/11% QoQ to INR6.9b, a 21% beat to our estimate. Adj. PAT was up 42% YoY to INR6.4b (21% above our estimates). For 1HFY26, revenue/EBITDA/PAT grew 27%/39%/37%. For 1HFY26, OCF/FCF grew 7%/6% YoY to INR7.4b/INR6.3b.

Powergen segment benefiting from strong demand

The powergen segment delivered a strong performance with revenue rising 50% YoY and 27% QoQ to INR13.4b, driven by broad-based demand across low, medium, and high horsepower gensets and the lumpy execution of data center orders. Data centers contributed around 40% of overall powergen sales in Q2FY26, supported by lumpy project execution. Excluding data centers, core powergen sales grew ~20% YoY, led by healthy demand from hospitals, real estate, and commercial buildings. Pricing has largely stabilized post the CPCB IV+ transition, though competitive intensity remains across all horsepower categories. Overall, we expect powergen demand to remain strong, while the data center contribution is likely to normalize over the next few quarters as project execution schedules even out. We expect the powergen segment revenue to clock a 17% CAGR over FY25-28.



Industrial segment hurt by monsoons

Industrial segment revenue stood at INR3.9b, down 5% YoY and 7% QoQ, hit by extended monsoons slowing down construction activity and limited mining tenders. Railways performed well with strong execution, while construction and mining remained soft. Within the portfolio, marine activity picked up on the back of government procurement interest, though it remains a small contributor. The company is also broadening its product portfolio, with the Hotel Load Converter in railways approved for serial production, and sales expected to commence over the next few quarters. We marginally cut our growth assumptions for the industrial segment and expect the segment revenue to clock a 12% CAGR over FY25-28.

Distribution segment benefiting from strong aftermarket performance

The distribution segment reported revenue of INR8.0b, up 21% YoY and 2% QoQ, reflecting strong aftermarket performance driven by healthy demand across service and parts categories. The company continues to enhance its service capabilities and readiness to support CPCB IV+ compliant engines, which are expected to expand the addressable aftermarket base over time. We expect the distribution segment to record a CAGR of 19% over FY25-28.

Exports continuously improving on a sequential basis

Exports grew 24% YoY and 4% QoQ to INR5.5b, supported by strong demand from Europe and the Middle East across both high- and low-horsepower product lines. High-horsepower exports rose 40% YoY to INR2.8b, while low horsepower increased 11% YoY to INR2.2b. Exports during the quarter benefited from improved order execution and product placement, though channel inventory correction and muted order inflows could weigh on near-term performance. Data center-related exports remain limited, as production for such projects is concentrated near end markets such as the US and Europe. The company remains cautiously optimistic, focusing on regional diversification and operational efficiency to mitigate short-term volatility in global demand. We expect export revenue to clock a 17% CAGR over FY25-28.

Financial outlook

We raise our estimates for FY26 and largely maintain our estimates for FY27/28. We expect KKC's revenue/EBITDA/PAT CAGR of 16%/16%/17% over FY25-28 and build in an EBITDA margin of 21.2%/20.0%/20.1% for FY26/27/28. Our estimates factor in a gross margin of 36% in FY26 and 35% in FY27/28 vs. 36% in FY25, since we expect some gross margin contraction as price levels for CPCB 4+ normalize.

Valuation and view

The stock is currently trading at 49.0x/43.6x/37.4x on FY26/27/28E EPS. We **reiterate BUY** on the stock with a revised TP of INR4,950 based on 42x Mar'28E earnings.

Key risks and concerns

Key risks to our recommendation would come from lower-than-expected demand for key segments, higher commodity prices, increased competitive intensity, and lower-than-expected recovery in exports.



Standalone - Quarterly Earnings Model

(IN	R r	n)

Y/E March		FY	25			FY2	26E		FY25	FY26E	FY26E	Est
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE	_		2QE	Var (%)
Net Sales	23,042	24,923	30,860	24,569	29,068	31,703	29,546	29,154	1,03,394	1,19,471	28,779	10
YoY Change (%)	4.3	31.2	21.8	6.1	26.2	27.2	-4.3	18.7	15.4	15.5	15.5	
Gross profit	8,701	8,917	10,729	9,131	10,752	11,579	10,636	10,161	37,478	43,129	10,216	
Total Expenditure	18,369	20,113	24,860	19,372	22,833	24,755	23,518	23,057	82,714	94,163	23,023	
EBITDA	4,673	4,810	6,000	5,197	6,235	6,948	6,027	6,098	20,680	25,308	5,756	21
YoY Change (%)	37.2	42.1	11.5	-4.5	33.4	44.4	0.5	17.3	17.4	22.4	19.7	
Margins (%)	20.3	19.3	19.4	21.2	21.4	21.9	20.4	20.9	20.0	21.2	20.0	
Depreciation	439	452	481	457	479	492	492	492	1,829	1,955	483	2
Interest	48	26	27	52	27	26	54	60	151	166	42	(40)
Other Income	1,322	1,611	1,209	2,119	1,529	1,964	1,816	1,816	6,261	7,124	1,695	16
PBT before EO expense	5,509	5,944	6,702	6,807	7,258	8,394	7,296	7,361	24,961	30,310	6,926	21
Extra-Ord expense					-442	-	-	-	-	-442	-	
PBT	5,509	5,944	6,702	6,807	7,700	8,394	7,296	7,361	24,961	30,751	6,926	21
Tax	1,311	1,438	1,562	1,593	1,807	2,017	1,824	1,641	5,904	7,289	1,662	
Rate (%)	23.8	24.2	23.3	23.4	23.5	24.0	25.0	22.3	23.7	23.7	24.0	
Reported PAT	4,198	4,506	5,140	5,214	5,893	6,377	5,472	5,721	19,058	23,463	5,264	21
Adj PAT	4,198	4,506	5,140	5,214	5,555	6,377	5,472	5,722	19,058	23,126	5,264	21
YoY Change (%)	33.0	37.2	12.7	-7.2	32.3	41.5	6.5	9.7	14.7	21.3	16.8	
Margins (%)	18.2	18.1	16.7	21.2	19.1	20.1	18.5	19.6	18.4	19.4	18.3	

E: MOFSL Estimates

		FY25					FY26E				FY26E	Est
INR m	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	Var (%)
Segmental revenue												
Powergen	8,030	8,960	12,710	8,740	10,560	13,400	10,999	10,844	13,400	45,803	10,564	27
Industrial	3,720	4,060	5,110	3,790	4,180	3,870	4,599	5,356	3,870	18,005	4,791	(19)
Distribution	6,510	6,580	7,460	6,310	7,770	7,960	7,982	7,983	7,960	31,695	7,830	2
Exports	3,890	4,400	4,640	4,790	5,230	5,450	5,197	4,886	5,450	20,763	4,840	13
Total	22,620	24,484	30,414	24,144	28,587	31,216	29,149	28,914	31,216	1,17,865	28,397	10



Apollo Hospitals

Estimate change	←
TP change	()
Rating change	—

Bloomberg	APHS IN
Equity Shares (m)	144
M.Cap.(INRb)/(USDb)	1098.8 / 12.4
52-Week Range (INR)	8100 / 6001
1, 6, 12 Rel. Per (%)	-2/5/-2
12M Avg Val (INR M)	2949

Financials & Valuations (INR b)

		/	
Y/E March	FY26E	FY27E	FY28E
Sales	246.6	284.3	324.3
EBITDA	36.3	41.8	48.6
Adj. PAT	18.7	22.4	27.8
EBIT Margin (%)	14.7	14.7	15.0
Cons. Adj. EPS (INR)	130.1	155.6	193.1
EPS Gr. (%)	29.4	19.6	24.1
BV/Sh. (INR)	718.8	873.5	1,067.0
Ratios			
Net D:E	-0.1	-0.3	-0.4
RoE (%)	20.5	20.2	20.6
RoCE (%)	15.7	16.4	17.6
Payout (%)	4.5	3.8	3.0
Valuations			
P/E (x)	58.7	49.1	39.5
EV/EBITDA (x)	30.7	26.1	21.7
Div. Yield (%)	0.1	0.1	0.1
FCF Yield (%)	2.3	2.6	3.0
EV/Sales (x)	4.5	3.8	3.3
·			

Shareholding Pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	28.0	29.3	29.3
DII	21.4	21.6	20.2
FII	44.2	43.5	45.4
Others	6.4	5.6	5.1

FII includes depository receipts

Improved case mix/Healthco drives earnings

CMP: INR7,642

Calibrated approach to improve GMV prospects; bed additions on track

TP: INR9,015 (+18%)

- Apollo Hospitals Enterprises (APHS) delivered largely in-line revenue for the quarter. It delivered better-than-expected EBITDA/PAT, led by improved profitability in the hospitals/Healthco business.
- APHS is focused on optimizing the CONGO/payor mix to ensure profitable growth at existing hospitals. Patient volume growth was soft for the quarter due to a higher base of medical admissions in the past year. Notably, CONGO specialties' revenue grew 14% YoY.
- Further, bed additions are expected to start from 3QFY26 onwards, aimed at supporting expansions into new locations and strengthening the Apollo group's brand franchise.
- Offline pharmacy's revenue grew 16% YoY, led by improved same-store sales growth as well as store additions. Platform GMV grew 16% YoY, led by healthy growth in pharma transactions as well as transacting users.
- We raise our FY26 earnings estimate by 5%, factoring in better Healthco performance. However, we reduce our FY27 estimates by 5%, factoring in higher operational costs related to the launch of new hospitals. We value APHS on an SoTP basis (30x EV/EBITDA for the hospital business, 20x EV/EBITDA for retained pharmacy, 25x EV/EBITDA for AHLL, 23x EV/EBITDA for front-end pharmacy, and 2x EV/sales for Apollo 24/7) to arrive at our TP of INR9,015.
- We remain positive on APHS, supported by: a) the optimization of case mix/addition of beds in healthcare services, and b) continued improvements in the pharma/diagnostics/insurance segments for better GMV growth prospects. Reiterate BUY.

Sustained momentum in revenue growth

- APHS's 2QFY26 revenue grew 13% YoY to INR63.0b (our est: INR61.4b).
- Healthcare services' revenue grew 9% YoY to INR31.7b, driven by growth in both inpatient volume (+2%) and the price and case mix (+7%). Healthco's revenue grew 17% YoY to INR26.6b. AHLL's revenue grew 17% YoY to INR4.7b, primarily driven by growth in diagnostics.
- EBITDA margin expanded 30bp YoY to 14.9% (our est 14.5%). EBITDA grew 15.4% YoY to INR9.4b (our est: INR8.9b).
- Adj. PAT grew 26% YoY to INR4.8b (our est: INR4.4b).
- Revenue/EBITDA/PAT grew 14%/20%/33% YoY in 1HFY26 to INR121.5/17.9/9.1b.



Highlights from the management commentary

- The hospital business recorded limited IP/OP volume YoY growth due to a high season-related base in 2QFY25. Lower patient flow from Bangladesh further impacted growth on a YoY basis.
- APHS achieved a 14% YoY revenue growth in CONGO specialties, helping offset the high base impact from last year in the hospital business.
- The company has pushed its target of achieving cash break-even in Healthco (excluding ESOP) by a quarter.
- APHS has commenced the commissioning of hospitals at Defence Colony, Delhi, and Royal Mudhol, Pune, in 3QFY26. The Sarjapur and Bengaluru hospitals are expected to be commissioned in 4QFY26, while the Hyderabad and Gurugram hospitals are scheduled for 1QFY27. Overall opex related to these hospitals is expected to be INR1.5b on an annualized basis.
- The company aims for cost savings of INR1.2b, of which INR600m has already been achieved through improved material management and supplier consolidation. Further optimization is expected from HR efficiencies and reduced IT spend.

Consolidated - Quarterly Earning Model

Consolidated - Quarterly Earning IV	ouei											
Y/E March		FY				FY2			FY25	FY26E	FY26E	
(INRm)	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	(%)
Gross Sales	50,856	55,893	55,269	55,922	58,421	63,035	61,520	63,578	2,17,940	2,46,555	61,369	2.7%
YoY Change (%)	15.1	15.3	13.9	13.1	14.9	12.8	11.3	13.7	14.3	13.1	9.8	
Total Expenditure	44,105	47,738	47,654	48,225	49,902	53,624	52,477	54,359	1,87,722	2,10,362	52,470	
EBITDA	6,751	8,155	7,615	7,697	8,519	9,411	9,043	9,219	30,218	36,192	8,898	5.8%
YoY Change (%)	32.6	30.0	24.1	20.2	26.2	15.4	18.8	19.8	26.4	19.8	9.1	
Margins (%)	13.3	14.6	13.8	13.8	14.6	14.9	14.7	14.5	13.9	14.7	14.5	
Depreciation	1,774	1,845	1,846	2,110	2,147	2,178	2,170	2,243	7,575	8,738	3	
Interest	1,164	1,175	1,098	1,148	1,083	1,096	1,120	1,167	4,585	4,466	1,130	
Other Income	372	382	638	611	402	547	560	758	2,003	2,267	530	
PBT before EO expense	4,185	5,517	5,309	5,050	5,691	6,684	6,313	6,566	20,061	25,255	6,091	9.7%
Extra-Ord expense/(Income)	0	0	0	0	0	0	0	0	0	0	0	
PBT	4,185	5,517	5,309	5,050	5,691	6,684	6,313	6,566	20,061	25,255	6,091	9.7%
Tax	1,145	1,617	1,568	1,010	1,417	1,807	1,736	1,825	5,340	6,425	1,645	
Rate (%)	27.4	29.3	29.5	20.0	24.9	27.0	27.5	27.8	26.6	25.4	27.0	
Minority Interest & Profit/Loss of Asso.	-12	112	18	144	-54	105	82	71	262	204	73	
Cos.	-12	112	10	144	-34	105	02	/1	202	204	75	
Reported PAT	3,052	3,788	3,723	3,896	4,328	4,772	4,495	4,670	14,459	18,626	4,373	9.1%
Adj PAT	3,052	3,788	3,723	3,896	4,328	4,772	4,495	4,670	14,459	18,712	4,373	9.1%
YoY Change (%)	83.2	63.5	51.8	53.5	41.8	26.0	20.7	19.9	61.1	29.4	15.5	
Margins (%)	6.0	6.8	6.7	7.0	7.4	7.6	7.3	7.3	6.6	7.6	7.1	
EPS	21.2	26.3	25.9	27.1	30.1	33.2	31.3	32.5	100.6	130.1	30.4	

Key Performance Indicators (Consolidated)

Y/E March		FY	25			FY2	:6E		FY25	FY26E	FY2	6E
INRm	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE	-		2QE	vs Est
Hospital Revenue (INRm)	26,373	29,032	27,850	28,220	29,351	31,690	30,724	33,360	1,11,475	1,25,125	31,439	0.8%
YoY Growth (%)	15.0	14.0	13.0	10.3	11.3	9.2	10.3	18.2	13.0	12.2	8.3	
EBITDA margin (%)	23.6	24.9	24.1	24.3	24.5	24.6	24.2	21.1			25	
Healthco (INRm)	20,821	22,822	23,524	23,763	24,718	26,606	26,465	25,942	90,930	1,03,730	25,447	4.6%
YoY Growth (%)	15.3	17.3	14.8	17.2	18.7	16.6	12.5	9.2	16.2	14.1	11.5	
EBITDA margin (%)	1.1	2.3	2.4	1.5	3.8	4.1	4.3	4.6			4	
AHLL Revenue (INRm)	3,661	4,039	3,895	3,940	4,351	4,739	4,332	4,277	15,535	17,699	4,484	5.7%
YoY Growth (%)	14.9	14.0	15.3	11.1	18.8	17.3	11.2	8.6	13.8	13.9	11.0	
Cost Break-up												
Gross Margin (%)	48.4	48.9	47.5	47.6	47.8	48.5	48.7	49.0	48.1	48.5	48.1	
EBITDA Margin (%)	13.3	14.6	13.8	13.8	14.6	14.9	14.7	14.5	13.9	87.6	14.5	
PAT Margin (%)	6.0	6.8	6.7	7.0	7.4	7.6	7.3	7.3	6.6	78.5	7.1	



ABB India

TP change	
Rating change	

Bloomberg	ABB IN
Equity Shares (m)	212
M.Cap.(INRb)/(USDb)	1063 / 12
52-Week Range (INR)	7960 / 4590
1, 6, 12 Rel. Per (%)	-5/-11/-34
12M Avg Val (INR M)	2110

Financials Snapshot (INR b)

		~,	
Y/E DEC	CY25E	CY26E	CY27E
Net Sales	130.5	146.3	167.1
EBITDA	20.3	22.9	27.1
PAT	16.8	18.9	22.1
EPS (INR)	79.1	89.3	104.4
GR. (%)	-10.6	12.9	16.8
BV/Sh (INR)	366.0	398.9	435.6
Ratios			
ROE (%)	22.6	23.4	25.0
RoCE (%)	22.8	23.5	25.2
Valuations			
P/E (X)	63.4	56.1	48.0
P/BV (X)	13.7	12.6	11.5
EV/EBITDA (X)	51.4	45.3	38.1
Div Yield (%)	0.8	1.0	1.2

Shareholding pattern (%)

Sep-25	Jun-25	Sep-24
75.0	75.0	75.0
8.3	7.7	5.4
8.3	9.3	12.3
8.4	8.1	7.3
	75.0 8.3 8.3	75.0 75.0 8.3 7.7 8.3 9.3

FII Includes depository receipts

CMP: INR5,017 TP: INR5,800 (+16%) In-line performance; recovery still some time away

ABB's 3QCY25 performance was in line with our estimates. The company remains affected by lower ordering as well as margin pressure due to Quality Control Order (QCO) implementation, higher RM costs, and increased competition. Overall order inflows were down 3% YoY, while base ordering has remained strong. ABB continues to benefit from a growing addressable market from data centers, electronics, and renewables, while government and private sector ordering is yet to pick up. Due to lower-than-expected capex from the government and private sectors, we project the current trend of weakness in order inflows will continue for a few more quarters. This can hurt execution growth too for a few more quarters. Along with this, higher costs related to QCO implementation can affect margins too for a few more quarters. However, we expect these adversities to bottom out in 2-3 quarters. We project ABB to benefit from demand improvement across key capex areas. To bake in the 9MCY25 performance, we cut our CY26/27 estimates for ABB by 6%/7% and revise our TP to INR5,800, based on Dec'27 estimates. We reiterate our BUY rating, as we expect the company to benefit in the long run from improved ordering and higher margins.

Results broadly in line

ABB's results came in line across all metrics. Revenue grew 14% YoY to INR33.1b. EBITDA margin came in ahead of our estimates. However, the margin contracted 350bp YoY to 15.1% due to higher material costs and reliance on imports to support delivery commitments in the wake of QCO compliance. Overall, PAT came slightly ahead of our estimates. However, PAT declined 7% YoY to INR4.1b due to margin contraction over the past year. Order inflows dipped 3% YoY to INR32.3b, primarily due to the timing of large orders. Base orders remained strong, rising 13% YoY, which lifted the overall order book to INR99b. For 9MCY25, revenue increased 9% YoY. EBITDA/PAT declined 9%/8% YoY, while EBITDA margin in 9MCY25 contracted 320bp YoY to 15.5%. ABB's cash position continues to remain strong at INR50b at the end of 3QCY25.

Overall ordering momentum remains weak

Base orders grew 13% YoY, reflecting broad-based demand across business divisions, while overall orders declined 3% YoY due to the timing of large orders. The order backlog stood at INR99b, providing healthy revenue visibility, with about 30% of the order book comprising large, long-cycle system orders and the balance being shorter-cycle product and service orders. Growth in base orders was supported by strong activity in Motion and Robotics and Discrete Automation, driven by demand from renewables, buildings and infrastructure, data centers, and process industries. Ordering was impacted by the deferment of large project decisions, and private capex activity remained selective.



Margin performance can remain weak in the near term vs. last year

EBITDA margin stood at 15.1% for the quarter, improving from 13.0% in 2QCY25 but lower than 18.6% in 3QCY24. The sequential improvement was driven by stronger execution, higher service contribution, and operating leverage, while the YoY moderation reflected an unfavorable product mix, pricing pressure, and cost impact from QCO-related imports and forex fluctuations. ABB quantified these headwinds as roughly 1% from mix, 1.0–1.5% from pricing, 0.75–0.8% from QCO, and 0.6% from forex, together resulting in about a 3% YoY impact. We expect near-term margin performance to remain affected by these negatives, as QCO implementation timelines are still not over yet, especially for the motion and electrification segments. We thus expect an EBITDA margin of 15.5%/15.7%/16.2% for CY25/CY26/CY27.

Electrification segment: QCO and forex weigh on profitability

The electrification segment witnessed 19% YoY revenue growth in 3QCY25, while PBIT margin contracted 120bp YoY to 19.6% due to higher reliance on imports to comply with QCO guidelines, material cost impact, and forex volatility during the quarter. Order inflow for the segment declined 2% YoY owing to a high base of large orders last year. Demand remains strong across key industries such as renewables, data centers, smart buildings, and infrastructure. Weakness in inflows can weigh on execution growth, and QCO compliance continues to weigh on margins for this segment. We thus expect the segment's revenue/orders to clock a CAGR of 17%/ 18% over CY25-27, with PBIT margin to be in the range of 19-20%.

Motion & Robotics: Performance led by an uptick in demand for drives and automation

Motion and Robotics segments grew 14% YoY, supported by healthy execution in motors, drives, and automation systems. PBIT margin declined 780bp YoY to 14.5% due to an unfavorable product mix, pricing pressure, and higher import and forex costs arising from QCO-related sourcing. Order inflows increased across Motion and Robotics, aided by a large Motion order of about INR1.5b and total Robotics orders of INR2b, primarily from automotive and electronics customers. **Demand remained strong** in select segments such as **cement**, **steel**, **and oil & gas** in Motion and **automotive and electronics** in Robotics, with growing participation in **EV-related and process automation applications.** We expect both these segments together to clock a revenue and order inflows CAGR of 13% each over CY25-27 on stronger execution, with PBIT margin ranging around 16-18%.

Process Automation: Sequential recovery amid delayed project decisions

Process automation segment revenue stood at INR6b, flat YoY but improving QoQ (up 22%), supported by execution of existing orders and stronger service contributions. PBIT margins improved 50bp QoQ, mainly due to a higher share of service and retrofit execution. Order inflows declined 4% YoY but increased 2% QoQ, as large project decisions were delayed, while service and base orders provided stability. Demand was led by metals, energy, and marine industries, while customers in process sectors deferred major greenfield expansions amid macro uncertainty. We expect the segment's revenue/orders to clock a CAGR of 6%/15% over CY25-27, with PBIT margins to be in the range of 17.0-18.5%.



Financial outlook

We broadly maintain our estimates for CY25 and cut our estimates by 6%/7% for CY26/27 to bake in lower margins for the Electrification and Motion segments, which are currently affected by QCO implementation as well as competitive pricing. We thus expect revenue/EBITDA/PAT CAGR of 13%/16%/15% over CY25-27.

Valuation and recommendation

We believe that in the near term, ABB can underperform due to pressure on margins as well as sluggish ordering activity across the private and government sectors. However, in the long run, we expect ABB to improve upon margins once QCO implementation is over in the next few quarters and revenues once ordering activity starts ramping up. We thus reiterate our BUY rating with a revised DCF-based TP of INR5,800, implying a target multiple of 55x Dec'27 earnings. Scope of rerating back to higher multiples, as seen earlier for ABB, will emerge once inflows and margins start showing an improving trend.

Key risks and concerns

Slowdown in order inflows, pricing pressure across segments, increased competition, supply chain issues, and geopolitical risks could affect our estimates and valuations.

Standalone - Quarterly Earn	ings Model											(INR m)
Y/E December		CY	24			CY	25E		CY24	CY25E	CY25E	Est
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE	_		3QE	Var (%)
Net Sales	30,804	28,309	29,122	33,649	31,596	31,754	33,107	38,276	1,21,883	1,34,733	33,412	-1
YoY Change (%)	27.8	12.8	5.2	22.0	2.6	12.2	13.7	13.7	16.7	10.5	14.7	
Total Expenditure	25,152	22,884	23,719	27,076	25,773	27,614	28,103	32,724	98,831	1,14,214	28,634	
EBITDA	5,652	5,425	5,402	6,573	5,823	4,141	5,004	5,552	23,052	20,519	4,778	5
YoY Change (%)	98.1	55.6	23.2	57.6	3.0	-23.7	-7.4	-15.5	54.7	-11.0	-11.6	
Margins (%)	18.3	19.2	18.6	19.5	18.4	13.0	15.1	14.5	18.9	15.2	14.3	
Depreciation	314	310	328	337	338	355	366	306	1,289	1,365	336	
Interest	38	45	30	51	47	42	56	-0	165	145	36	
Other Income	871	868	929	866	923	998	840	908	3,534	3,668	874	
PBT before EO expense	6,171	5,938	5,973	7,051	6,361	4,741	5,421	6,154	25,133	22,677	5,279	3
PBT	6,171	5,938	5,973	7,051	6,361	4,741	5,421	6,154	25,133	22,677	5,279	3
Tax	1,575	1,511	1,568	1,732	1,620	1,220	1,332	1,542	6,387	5,715	1,330	
Rate (%)	25.5	25.5	26.3	24.6	25.5	25.7	24.6	25.1	25.4	25.2	25.2	
Reported PAT	4,596	4,426	4,405	5,319	4,741	3,521	4,089	4,612	18,746	16,962	3,949	4
Adj PAT	4,596	4,426	4,405	5,319	4,741	3,521	4,089	4,612	18,746	16,962	3,949	4
YoY Change (%)	87.4	49.6	21.7	54.1	3.2	-20.5	-7.2	-13.3	50.2	-9.5	-10.3	
Margins (%)	14.9	15.6	15.1	15.8	15.0	11.1	12.4	12.0	15.4	12.6	11.8	

Sell



Hitachi Energy

Estimate changes	1
TP change	1
Rating change	←→

Bloomberg	POWERIND IN
Equity Shares (m)	45
M.Cap.(INRb)/(USDb)	929.9 / 10.5
52-Week Range (INR)	21800 / 8738
1, 6, 12 Rel. Per (%)	17/38/40
12M Avg Val (INR M)	2128

Financials Snapshot (INR b)

		~ /	
Y/E MARCH	FY26E	FY27E	FY28E
Net Sales	80.5	109.4	138.5
EBITDA	11.6	16.4	20.8
PAT	9.1	11.9	14.9
EPS (INR)	203.2	266.4	334.5
GR. (%)	162.4	31.1	25.5
BV/Sh (INR)	1,203.4	1,479.4	1,826.8
Ratios			
ROE (%)	17.8	18.9	19.3
RoCE (%)	18.3	19.4	19.6
Valuations			
P/E (X)	102.7	78.4	62.4
P/BV (X)	17.3	14.1	11.4
EV/EBITDA (X)	76.7	54.1	42.2
Div Yield (%)	0.0	0.0	0.0

Shareholding pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	71.3	71.3	75.0
DII	7.9	10.3	9.0
FII	9.7	7.2	5.1
Others	11.1	11.2	10.9

FII Includes depository receipts

Strong margins result in sharp PAT beat

CMP: INR20,863

Hitachi Energy's 2QFY26 results beat our estimates on the back of a sharp recovery in EBITDA margins and higher other income. Order inflow was healthy for the quarter, and the bid pipeline also remains strong for the company. Over the last few quarters, we note that the company's order book cycle is turning longer but margin improvement is now visible. The company's capacity expansion too will help meet the upcoming demand across segments. We increase our estimates by 12%/5% for FY27/28 to bake in increased margin, capex and other income and roll forward our TP to INR18,000. The stock is currently trading at 103x/78x/62x P/E on FY26E/27E/28E earnings. We reiterate our Sell rating on the stock on account of pricey valuations. Our estimates bake in 29% revenue CAGR and 63% PAT CAGR over FY25-28 and an implied target multiple of 60x on two-year forward earnings.

TP: INR18,000 (-14%)

PAT boosted by better-than-expected EBITDA margin and other income

2Q revenue was 12% lower than our estimate as execution remained weaker than our expectations. However, with a better-than-expected EBITDA margin of 16.3%, higher other income, and a lower tax rate, reported PAT came in 42% ahead of our estimate. Revenue grew 18% YoY to INR18.3b (12% below our estimate). EBITDA at INR3.0b (vs. our estimate of INR2.5b) grew 172% YoY. EBITDA margin at 16.3% was 430bp above our expectation of 12%, driven by lower-than-expected operating expenses. PAT increased 406% YoY to INR2.6b, 42% above our estimate. Order inflows grew 14% YoY to INR22.2b, taking the order book to INR294b. Growth in inflows was led by the large orders for GIS and AIS stations, and locomotive transformers. Among segments, industries and renewables were the key contributors to the order book, followed by transmission and transport. For 1HFY26, revenue/EBITDA/PAT growth stood at 15%/188%/531% YoY. OCF came in at INR8.7b vs. an outflow of INR0.8b in 1HFY25. FCF stood at INR807m in 1HFY26 vs. an outflow of INR118.1m in 1HFY25.

Prospect pipeline building up well for the sector

HVDC continues to be a major growth engine for Hitachi Energy across both domestic and international markets. Of the total order book of INR294b, ~INR100b comes from base orders, with the rest linked to HVDC projects. The domestic pipeline remains strong, with one HVDC project tariff-based bidding already completed and another 6GW LCC project expected to be tendered out soon. Management expects two to three HVDC projects to come up for bidding each year over the next few years in India. The company also expects to benefit from demand in India's DC market, where Hitachi Energy's addressable opportunity stands at ~15-20%. With India's rapid renewable expansion, rising industrial and transmission investments, and ongoing metro and rail modernization, the company's focus on capacity expansion, services, digital solutions, and new areas like energy storage places it on a future-ready growth



Exports continue to be one of the key growth levers

Exports continued to play a meaningful role in Hitachi Energy's inflows in 2Q, contributing nearly 30% (excluding HVDC). Inflows in 2Q increased 59% YoY, driven by a well-diversified customer base across utilities, renewables, data centers, and industrial segments spread over multiple geographies. The export order book remains healthy and continues to benefit from Hitachi Energy's global supply network and localization initiatives.

Key export orders received by the company in 2QFY26 are:

- 114 Nos IMB 800kV CTs to Canadian utilities
- 12 Nos 800 kV Breakers to Ukrainian utilities
- 17 Nos. 245kV PASS and 8 Nos. 145kV PASS to Thailand
- 132 KV AIS package to Babek, Azerbaijan
- Power Quality Products to Transco in Dubai

Margin resilience to sustain going forward

Hitachi Energy delivered a strong margin of 16.3% during the quarter. This was mainly led by 1) operating leverage, as higher execution volumes helped spread fixed costs more efficiently, 2) an improved product mix, with a larger share of high-margin products contributing to revenue, 3) increasing share of exports in the total order book, which are usually short-cycle orders with high margins, 4) increasing share of service orders, with current levels at high single-digits, and 5) lower royalty cost during the quarter due to the timing effect of revenue recognition. We expect the increasing share of exports and services and a better product mix to support the company's target of sustaining double-digit margins over the long term. We have factored in margin of 14.5%/15%/15% for FY26/27/28E in our estimates.

Financial outlook

For FY27/FY28, we raise our estimates by 12%/5% to factor in higher margins and slightly lower revenue to bake in the longer-gestation order book. We thus expect revenue/EBITDA/PAT CAGR of 29%/52%/63% over FY25-28E. Our estimates currently bake in nearly one HVDC win for the company every year and consistent expansion in margins. This results in EBITDA margin expansion to 14.5%/15%/15% for FY26/27/28.

Valuation and view

The stock is currently trading at 102.7x/78.4x/62.4x P/E on FY26E/27E/28E earnings. **We reiterate our Sell rating** with a revised TP of INR18,000 (vs. INR16,500 earlier) based on 60x two-year forward earnings.



Quarterly performance (Stand	dalone)											(INR m)
		FY	FY25 FY26E						FY25	FY26E	FY26E	Est
Y/E March	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE	•		2QE	Var (%)
Net Sales	13,272	15,537	16,203	18,837	14,789	18,326	20,419	26,930	63,849	80,463	20,931	(12)
Change (%)	27.6	26.5	27.2	11.1	11.4	17.9	26.0	43.0	21.9	26.0	34.7	
EBITDA	479	1,097	1,669	2,713	1,549	2,990	3,063	4,036	5,958	11,638	2,512	19
Change (%)	42.3	68.0	145.5	49.1	223.4	172.5	83.5	48.8	70.7	95.3	128.9	
As % of Sales	3.6	7.1	10.3	14.4	10.5	16.3	15.0	15.0	9.3	14.5	12.0	
Depreciation	221	228	230	235	250	258	331	483	914	1,322	282	(8)
Interest	109	164	120	60	40	29	39	45	452	152	113	(75)
Other Income	1	1	2	182	509	826	600	439	186	2,374	450	84
PBT	150	706	1,322	2,600	1,769	3,529	3,293	3,946	4,778	12,537	2,567	37
Tax	46	183	467	628	453	886	912	1,224	1,324	3,474	711	
Effective Tax Rate (%)	30.8	25.9	35.3	24.1	25.6	25.1	27.7	31.0	27.7	27.7	27.7	
Extra-ordinary Items			519	(134)					386			
Reported PAT	104	523	1,374	1,839	1,316	2,644	2,381	2,722	3,840	9,063	1,856	42
Change (%)	332.4	111.4	498.1	61.8	1,163.0	405.6	73.3	48.0	110.9	162.4	254.9	
Adj PAT	104	523	855	1,973	1,316	2,644	2,381	2,722	3,454	9,063	1,856	42
Change (%)	332.4	111.4	272.1	73.5	1,163.0	405.6	178.6	38.0	110.9	162.4	254.9	
As % of Sales	2.5	0.7	1.7	0.4	7.9	2.2	0.9	0.1	0.2	0.2	1.2	



Lupin

Estimate change TP change Rating change

Bloomberg	LPC IN
Equity Shares (m)	457
M.Cap.(INRb)/(USDb)	900.6 / 10.2
52-Week Range (INR)	2403 / 1774
1, 6, 12 Rel. Per (%)	1/-9/-12
12M Avg Val (INR M)	2053

Financials & Valuations (INR b)

- Individuo di Valuationo (IIIII D)										
Y/E MARCH	FY26E	FY27E	FY28E							
Sales	261.2	285.2	309.9							
EBITDA	72.4	69.9	71.6							
Adj. PAT	46.1	45.0	46.1							
EBIT Margin (%)	22.9	20.0	18.8							
Cons. Adj. EPS (INR)	101.3	98.9	101.4							
EPS Gr. (%)	40.8	NA	2.5							
BV/Sh. (INR)	498.1	594.1	692.6							
Ratios										
Net D:E	-0.1	-0.3	-0.4							
RoE (%)	23.1	18.1	15.8							
RoCE (%)	19.4	16.2	14.6							
Payout (%)	2.8	3.0	2.9							
Valuations										
P/E (x)	19.5	19.9	19.4							
EV/EBITDA (x)	12.1	12.0	11.1							
Div. Yield (%)	0.1	0.1	0.1							
FCF Yield (%)	5.3	4.9	5.1							
EV/Sales (x)	3.4	2.9	2.6							
•										

Shareholding pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	46.9	46.9	47.0
DII	26.6	25.6	25.1
FII	20.5	21.3	21.5
Others	6.1	6.3	6.4

FII Includes depository receipts

CMP: INR1,972 TP: INR2,100 (+7%) Neutral Record US sales/emerging market recovery boosts earnings

Work-in-progress to build a pipeline in the inhalers/injectable space

- Lupin (LPC) delivered better-than-expected performance for the quarter, with a 9%/30%/28% beat on revenue/EBITDA/PAT. Strong traction in the US and emerging markets, supported by production-linked income (PLI), led to a positive surprise in both revenue and profitability.
- LPC achieved an all-time high quarterly sales run rate of USD315m in the US, led by strong traction in limited-competition products and minimal price erosion in the base portfolio.
- LPC's efforts to revive business in Brazil/SA have strengthened its Emerging Markets performance, with upcoming launches to support growth in Brazil.
- While YoY growth in the domestic formulation (DF) segment may appear muted, excluding in-licensed products, the DF business grew 10.7% YoY in 1HFY26, outperforming IPM. With a rising chronic share and increased sales force, LPC is well-positioned to sustain this industry-leading growth in the DF segment
- We raise our earnings estimate by 13.5%/4%/2% for FY26/FY27/FY28, factoring in: a) the strong off-take of products (g-Tolvaptan/Mirabegron/Spiriva) in the US market, b) improved business prospects in emerging markets, and c) product pipeline in DF markets. We value LPC 21x 12M forward earnings to arrive at a TP of INR2,100.
- After a strong revival from earnings decline (FY22-23) to robust growth in FY24-25, the growth trajectory is expected to continue in FY26. However, intense competition in current high-value products in the US is likely to constrain YoY growth in FY27/FY28. Accordingly, we reiterate a Neutral stance on the stock.

Product mix/operating leverage drives strong margin expansion YoY

- LPC's 2QFY26 revenue grew 27%YoY to INR70.5b. (our est. INR64.5b).
- US sales grew 47.3% YoY to INR27.6b (up 41% YoY in CC to USD315m; 39% of sales). Emerging market sales grew 45.3% YoY to INR 9.2b (13% of sales).
 Other developed market sales grew 18.9% YoY to INR8b (12% of sales).
 Domestic formulation (DF) sales grew 3.4% YoY to INR20.7b (29% of sales).
- API sales decreased 12.8% YoY to INR2.5b (4% of sales).
- Gross Margin (GM) expanded 460bp YoY to 74.1% due to a reduction in raw material costs.
- EBITDA margin expanded 800bp YoY to 30.3% (our est: 25.5%, largely due to improved GM. The benefit was partly offset by higher employee costs (+250bp YoY as % of sales).
- As a result, EBITDA grew 72.8% YoY to INR21.4b (vs our est: INR16.5b).
- Adj. PAT grew 72.8% YoY INR13.3b (our est: INR10.3b).
- For H1FY26, revenue/EBITDA/PAT grew 19%/45%/48% YoY.



Highlights from the management commentary

- LPC revised its EBITDA margin guidance upwards to 25-26% for FY26 vs the earlier guidance of 24-25%. However, EBITDA margin for 2HFY26 will be lower compared to 1HFY26 due to increased R&D spending and a decline in PLI income.
- LPC expects the USD1b US sales run rate to sustain in FY27.
- It also indicated EBITDA margin to sustain at 24-25% in FY27.
- LPC guided for R&D spend to range between 7.5% and 8.5% of sales for FY26. ~70 % of the R&D spend is allocated towards complex products.
- US growth remained strong, led by exclusivity of Tolvaptan /continued traction in Mirabegron and g-Spiriva, offsetting mild price erosion.
- The Biosimilar portfolio will start contributing to revenue from FY27 onwards and intends to have five products commercialized by FY30. Specifically, LPC targets b-Pegfilgrastim by the end of the month, while Ranvizumab is expected around mid-CY26.
- LPC plans to invest USD250m over the next five years to build a manufacturing facility in Coral Springs, Florida, designed to produce over 25 critical respiratory medicines, including albuterol inhalers.

Quarterly	Performance ((Consoli	dated)
-----------	---------------	----------	-------	---

(INR m)

Y/E March	FY25 FY26E						FY25	FY26E	FY26E	% Var		
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	•		2QE	
Net Sales	56,003	55,427	56,927	56,671	62,684	70,475	65,574	62,432	225,028	261,165	64,498	9.3
YoY Change (%)	21.5	10.0	9.5	14.2	11.9	27.1	15.2	10.2	13.6	16.1	16.4	
Total Expenditure	42,389	43,059	43,162	43,750	46,269	49,099	47,476	45,950	172,361	188,794	48,051	
EBITDA	13,614	12,368	13,765	12,921	16,415	21,376	18,098	16,482	52,668	72,372	16,447	30.0
YoY Change (%)	109.0	34.0	34.7	29.6	20.6	72.8	31.5	27.6	46.6	37.4	33.0	
Margins (%)	24.3	22.3	24.2	22.8	26.2	30.3	27.6	26.4	23.4	27.7	25.5	
Depreciation	2,477	2,569	2,715	3,932	2,990	3,168	3,330	3,171	11,693	12,658	3,275	
EBIT	11,137	9,799	11,050	8,989	13,425	18,208	14,768	13,312	40,975	59,714	13,172	
YoY Change (%)	167.3	45.1	44.5	21.3	20.5	85.8	33.6	48.1	57.7	45.7	34.4	
Margins (%)	19.9	17.7	19.4	15.9	21.4	25.8	22.5	21.3	18.2	22.9	20.4	
Interest	680	709	669	891	918	1,076	820	554	2,949	3,367	880	
Other Income	678	423	537	570	790	900	620	140	2,207	2,450	590	
EO Exp/(Inc)	1,204	-1,036	956	-291	-859	-2,037	0	0	834	-2,896	0	
PBT	9,930	10,549	9,963	8,958	14,156	20,070	14,568	12,898	39,401	61,694	12,882	
Tax	1,875	1,954	2,124	1,135	1,941	5,221	3,132	2,863	7,087	13,158	2,460	
Rate (%)	18.9	18.5	21.3	12.7	13.7	26.0	21.5	22.2	18.0	21.3	19.1	
Minority Interest	-42	-69	-37	-99	-24	-69	-70	-72	-246	-235	-75	
Reported PAT	8,013	8,526	7,802	7,726	12,191	14,779	11,366	9,963	32,067	48,299	10,346	
Adj PAT	8,990	7,682	8,554	7,472	11,450	13,272	11,366	9,963	32,698	46,051	10,346	28.3
YoY Change (%)	214.9	55.5	42.6	47.0	27.4	72.8	32.9	33.3	73.2	40.8	34.7	
Margins (%)	16.1	13.9	15.0	13.2	18.3	18.8	17.3	16.0	14.5	17.6	16.0	
EPS	20	17	19	16	25	29	25	22	72	101	23	28.3

E: MOFSL estimates





Kalyan Jewellers

Estimate change TP change Rating change

Bloomberg	KALYANKJ IN
Equity Shares (m)	1033
M.Cap.(INRb)/(USDb)	529.5 / 6
52-Week Range (INR)	795 / 399
1, 6, 12 Rel. Per (%)	4/-6/-33
12M Avg Val (INR M)	4821

Financials & Valuations (INR b)

Y/E March	FY26E	FY27E	FY28E
Sales	329.4	411.3	489.8
EBITDA	21.3	25.7	29.9
Margins (%)	6.5	6.2	6.1
Adj. PAT	11.6	14.8	17.6
Adj. EPS (INR)	11.2	14.3	17.0
EPS Growth (%)	43.4	27.6	18.9
BV/Sh.(INR)	54.8	64.1	74.1
Ratios			
RoE (%)	22.1	24.1	24.6
RoIC (%)	15.7	17.3	18.9
Valuations			
P/E (x)	45.7	35.8	30.1
P/BV (x)	9.4	8.0	6.9
EV/Sales (x)	1.6	1.3	1.0
EV/EBITDA(x)	24.6	20.1	16.9

Shareholding Pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	62.8	62.8	62.9
DII	14.6	13.3	13.7
FII	14.1	16.8	15.8
Others	8.5	7.0	7.6

FII includes depository receipts

CMP: INR513 TP: INR675 (+32%) Buy

Growth trajectory sustains; healthy festive season fuels growth further

- Kalyan Jewellers (KALYANKJ)'s consolidated revenue grew 30% YoY to INR78.6b (in line). India business achieved 31% YoY revenue growth, driven by store additions (added a net of 13 Kalyan Indian stores and 15 Candere stores) and 16% SSSG (14% in the South, 17% in the non-South).
- Management said that demand momentum on the ground remained healthy, with Navratri witnessing robust offtakes. During the 30 days leading up to Diwali, KALYANKJ reported LFL growth of over 30%, indicating sustained festive momentum.
- KALYANKJ's studded share remained stable at 31% in 2QFY26 vs 30% in 2QFY25. Studded revenue surged 36% YoY.
- Gross margin for the Indian business contracted 100bp YoY to 12.5%. The margin contraction was largely due to the rising mix from franchised stores (~49% revenue mix in 2QFY26). EBITDA margin for the India business remained flat YoY to 6.3%. Lower advertising costs were offset by higher employee and other expenses. PBT margin expanded 60bp YoY to 5.1%, while PBT jumped 49% YoY, fueled by interest savings on debt reduction.
- KALYANKJ repaid INR1.3b of non-GML debt during the quarter, reducing debt to INR5.5b. It further plans to lower non-GML debt by ¬INR1.5b in 2HFY26, targeting INR4b by Mar'26, with the aim to become debt-free by FY27.
- The Middle East business delivered 8% revenue growth driven by 7% SSSG. Studded share was 18%. There were two new store additions in 2QFY26.
- KALYANKJ plans to launch a new regional jewelry brand in 4QFY26 with an initial investment of INR3b, primarily towards inventory. It will begin with five pilot COCO stores and further expansion to be franchisee-led. We look forward to more clarity on this initiative and remain watchful of its progress.
- With the successful scale-up of its new franchise businesses (>45% revenue contribution) and stable success in non-Southern markets, the company has established itself as a leading brand in the industry. KALYANKJ is further establishing a region-specific store format to combat increasing competition from the unorganized players. We model a 25%/22%/30% revenue/EBITDA/PAT CAGR during FY25-28E. We reiterate our BUY rating with a TP of INR675 (based on 45x Sep'27 P/E).

India outperformance sustains; store roll-outs remain healthy India business

- YoY to INR68.4b (est. of INR66.7b), and same-store sales increased 16% YoY. SSSG was 14% in the South regions and 17% in the non-South regions. South revenue growth was 19%, and non-South was 44% YoY. Non-South markets showed promising growth, with revenue contribution increasing to 54%. Studded share remained stable at 30.9% in 2QFY26 vs 29.7% in 2QFY25. Studded revenue grew 37% YoY.
- Stellar growth in profitability: EBITDA grew 30% YoY to INR4.3b. PBT grew by 49% YoY to INR3.5b, and APAT jumped 52% YoY to 2.6b.



- Rapid store expansion: The company added a net of 13 Kalyan stores in India, reaching a total of 300 stores. Candere added 15 stores, reaching a total of 96 stores. Total stores in India stood at 396. 'My Kalyan' grassroots stores reached 1,092 in 2QFY26, contributing ~13% to revenue from operations in India and over 28% to enrolment in advance purchase schemes in India.
- In 1HFY26, its revenue/EBITDA/PAT grew 31%/34%/54%.

Middle East

- Sales grew 8% YoY to INR8.7b, driven by SSSG of 7%.
- Gross margin contracted 60bp YoY to 13.7%, and EBITDA margin contracted 30bp YoY to 7.1%. EBITDA grew 4% YoY to INR613m. PAT grew 9% YoY to INR151m.
- There were two new store additions during the quarter. The studded share stood at 18% vs 19%.
- In 1HFY26, its revenue/EBITDA/PAT grew 18%/11%/15%.

Consolidated performance

- KALYANKJ's consolidated revenue grew 30% YoY to INR78.6b (est. INR76.4).
- Gross margin contracted ~80bp YoY to 12.9% (est. 13.3%).
- EBITDA margin contracted 20bp YoY to 6.3%. (est. 6.7%). EBITDA grew 25% YoY to INR5.0b (est. INR5.1b). PBT rose 42% YoY to INR3.5b, and APAT grew 43% YoY to INR2.6b.

Key takeaways from the management commentary

- Momentum on the ground remained healthy, with Navratri witnessing robust offtakes, and the strong demand trend continued into the festive period. During the 30 days leading up to Diwali, KALYANKJ reported LFL growth of over 30%, indicating sustained festive momentum.
- The company will launch a new regional jewelry brand store in 4QFY26, with an initial investment of INR3b (primarily in inventory). It will open five pilot COCO stores, after which expansion will follow a FOCO.
- Of the planned 84 Kalyan India stores, 40 have already opened; internationally, six stores are planned (three already operational two in the Middle East and one in the US). For Candere, 30 stores are open out of the 80 planned for FY26.
- The company has restarted debt repayment after getting approval from its lead bank to release real estate kept as collateral. It repaid INR1,300m during the quarter, bringing non-GML debt down to INR5,500m as of Sep'25. KALYANKJ plans to further reduce its non-GML debt by about INR1,500m in 2HFY26 to reach INR4,000m by Mar'26 and aims to be debt-free by FY27.


Valuation and view

- We raise our EPS estimates by 5% for FY26 and FY27.
- With the successful scale-up of its new franchise businesses (>45% revenue contribution) and continued success in non-Southern markets, the company has established itself as a leading brand in the industry. Its non-South expansion has improved the studded jewelry mix, while the asset-light expansion supports healthy cash flow generation for debt repayment and enhances profitability by reducing interest costs. It is also gaining momentum in the Middle East and the US.
- We model 25%/22%/30% revenue/EBITDA/PAT CAGR during FY25-28E. We reiterate our BUY rating with a TP of INR675 (based on 45x Sep'27 P/E).



rmance											(INR m
	FY	25			FY2	26E		FY25	FY26E	FY26E	Var.
1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2Q	(%)
277	303	349	388	406	436	480	560	388	560	452	
55,355	60,655	72,869	61,815	72,685	78,560	98,655	79,487	2,50,451	3,29,387	76,401	2.8%
26.5	37.4	39.5	36.6	31.3	29.5	35.4	28.6	35.0	31.5	26.0	
47,419	52,313	63,323	53,314	62,603	68,395	86,589	69,349	2,16,370	2,86,936	66,275	
7,935	8,342	9,546	8,501	10,081	10,166	12,066	10,138	34,081	42,451	10,127	0.4%
14.3	13.8	13.1	13.8	13.9	12.9	12.2	12.8	13.6	12.9	13.3	
4,175	4,379	4,609	4,507	5,001	5,196	5,629	5,346	17,671	21,172	5,021	
7.5	7.2	6.3	7.3	6.9	6.6	5.7	6.7	7.1	6.4	6.6	
3,760	3,962	4,936	3,994	5,080	4,970	6,437	4,792	16,410	21,279	5,106	-2.7%
6.8	6.5	6.8	6.5	7.0	6.3	6.5	6.0	6.6	6.5	6.7	
16.4	26.3	33.5	34.8	35.1	25.4	30.4	20.0	25.0	29.7	28.9	
852	903	876	962	1,036	949	876	810	3,595	3,671	903	
755	850	890	933	977	1,032	1,042	977	3,427	4,028	997	
222	260	313	408	463	514	454	521	1,446	1,952	377	
2,375	2,469	3,484	2,507	3,530	3,503	4,972	3,526	10,834	15,531	3,583	-2.2%
599	649	886	630	889	898	1,268	908	2,764	3,962	914	
25.2	26.3	25.4	25.1	25.2	25.6	25.5	25.7	25.5	25.5	25.5	
1,776	1,821	2,598	1,877	2,641	2,605	3,704	2,618	8,070	11,569	2,669	-2.4%
23.4	34.6	43.8	36.4	48.7	43.1	42.6	39.5	35.1	43.4	46.6	
1,776	1,303	2,187	1,877	2,641	2,605	3,704	2,618	7,142	11,569	2,669	
	1Q 277 55,355 26.5 47,419 7,935 14.3 4,175 7.5 3,760 6.8 16.4 852 755 222 2,375 599 25.2 1,776 23.4	FY 1Q 2Q 277 303 55,355 60,655 26.5 37.4 47,419 52,313 7,935 8,342 14.3 13.8 4,175 4,379 7.5 7.2 3,760 3,962 6.8 6.5 16.4 26.3 852 903 755 850 222 260 2,375 2,469 599 649 25.2 26.3 1,776 1,821 23.4 34.6	FY25 1Q 2Q 3Q 277 303 349 55,355 60,655 72,869 26.5 37.4 39.5 47,419 52,313 63,323 7,935 8,342 9,546 14.3 13.8 13.1 4,175 4,379 4,609 7.5 7.2 6.3 3,760 3,962 4,936 6.8 6.5 6.8 16.4 26.3 33.5 852 903 876 755 850 890 222 260 313 2,375 2,469 3,484 599 649 886 25.2 26.3 25.4 1,776 1,821 2,598 23.4 34.6 43.8	FY25 1Q 2Q 3Q 4Q 277 303 349 388 55,355 60,655 72,869 61,815 26.5 37.4 39.5 36.6 47,419 52,313 63,323 53,314 7,935 8,342 9,546 8,501 14.3 13.8 13.1 13.8 4,175 4,379 4,609 4,507 7.5 7.2 6.3 7.3 3,760 3,962 4,936 3,994 6.8 6.5 6.8 6.5 16.4 26.3 33.5 34.8 852 903 876 962 755 850 890 933 222 260 313 408 2,375 2,469 3,484 2,507 599 649 886 630 25.2 26.3 25.4 25.1 1,776 1,821 2,	FY25 1Q 2Q 3Q 4Q 1Q 277 303 349 388 406 55,355 60,655 72,869 61,815 72,685 26.5 37.4 39.5 36.6 31.3 47,419 52,313 63,323 53,314 62,603 7,935 8,342 9,546 8,501 10,081 14.3 13.8 13.1 13.8 13.9 4,175 4,379 4,609 4,507 5,001 7.5 7.2 6.3 7.3 6.9 3,760 3,962 4,936 3,994 5,080 6.8 6.5 6.8 6.5 7.0 16.4 26.3 33.5 34.8 35.1 852 903 876 962 1,036 755 850 890 933 977 222 260 313 408 463 2,375 2,469	FY25 FY2 1Q 2Q 3Q 4Q 1Q 2Q 277 303 349 388 406 436 55,355 60,655 72,869 61,815 72,685 78,560 26.5 37.4 39.5 36.6 31.3 29.5 47,419 52,313 63,323 53,314 62,603 68,395 7,935 8,342 9,546 8,501 10,081 10,166 14.3 13.8 13.1 13.8 13.9 12.9 4,175 4,379 4,609 4,507 5,001 5,196 7.5 7.2 6.3 7.3 6.9 6.6 3,760 3,962 4,936 3,994 5,080 4,970 6.8 6.5 6.8 6.5 7.0 6.3 852 903 876 962 1,036 949 755 850 890 933 977 1,032	FY25 FY26E 1Q 2Q 3Q 4Q 1Q 2Q 3QE 277 303 349 388 406 436 480 55,355 60,655 72,869 61,815 72,685 78,560 98,655 26.5 37.4 39.5 36.6 31.3 29.5 35.4 47,419 52,313 63,323 53,314 62,603 68,395 86,589 7,935 8,342 9,546 8,501 10,081 10,166 12,066 14.3 13.8 13.1 13.8 13.9 12.9 12.2 4,175 4,379 4,609 4,507 5,001 5,196 5,629 7.5 7.2 6.3 7.3 6.9 6.6 5.7 3,760 3,962 4,936 3,994 5,080 4,970 6,437 6.8 6.5 6.8 6.5 7.0 6.3 6.5 755	FY25 FY26E 1Q 2Q 3Q 4Q 1Q 2Q 3QE 4QE 277 303 349 388 406 436 480 560 55,355 60,655 72,869 61,815 72,685 78,560 98,655 79,487 26.5 37.4 39.5 36.6 31.3 29.5 35.4 28.6 47,419 52,313 63,323 53,314 62,603 68,395 86,589 69,349 7,935 8,342 9,546 8,501 10,081 10,166 12,066 10,138 14.3 13.8 13.1 13.8 13.9 12.9 12.2 12.8 4,175 4,379 4,609 4,507 5,001 5,196 5,629 5,346 7.5 7.2 6.3 7.3 6.9 6.6 5.7 6.7 3,760 3,962 4,936 3,994 5,080 4,970 6,437 <	FY25 FY26E FY25E FY25E FY25E FY25E FY25E FY25E TY25E TY25E TY25E 14QE 24QE 24QE 24QE 277 303 349 388 406 436 480 560 388 406 436 480 550 388 406 435 406 436 480 550 35.4 28.6 35.0 35.0 47,419 52,313 63,323 53,314 62,603 68,395 86,589 69,349 2,16,370 4,936 8,501 10,081 10,166 12,066 10,138 34,081 4,175 4,379 4,609 4,507 5,001	FY25 FY26E FY26E FY26E FY26E FY26E FY26E FY26E FY26E PY26E FY26E FY26E FY26E 140E 20 3QE 3QE 3QE 3QE 3QE 3AE 560 3AE 560 3AE 560 3AE 58AE 3AE 3AE 3AE 3AE 5AE 5AE<	FY25 FY26E 2Q 277 303 349 388 406 436 480 560 388 560 452 55,355 60,655 72,869 61,815 72,685 78,560 98,655 79,487 2,50451 3,29,387 76,401 26.5 37.4 39.5 36.6 31.3 29.5 35.4 28.6 35.0 31.5 26.0 47,419 52,313 63,323 53,314 62,603 68,395 86,589 69,349 2,16,370 2,86,936 66,275 7,935 8,342 9,546 8,501 10,081 10,166 12,066 10,138

E: MOFSL Estimates







Estimate change	1
TP change	1
Rating change	

Bloomberg	MCX IN
Equity Shares (m)	51
M.Cap.(INRb)/(USDb)	480.9 / 5.4
52-Week Range (INR)	9627 / 4408
1, 6, 12 Rel. Per (%)	13/51/41
12M Avg Val (INR M)	3908
Free float (%)	100.0

Financials & Valuations (INR b)

Y/E Mar	2026E	2027E	2028E
Sales	18.7	23.1	25.0
EBIT Margin (%)	65.3	67.2	66.2
PAT	10.5	13.1	14.1
EPS (INR)	206.0	257.7	277.0
EPS Gr. (%)	87.1	25.1	7.5
BV/Sh. (INR)	411.6	463.2	518.5
Ratios			
RoE (%)	52.7	58.9	56.4
Valuations			
P/E (x)	45.8	36.6	34.0
P/BV (x)	22.9	20.4	18.2
Div Yield (%)	0.4	0.4	0.4

Shareholding Pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	0.0	0.0	0.0
DII	60.5	59.1	57.5
FII	19.2	21.9	22.3
Others	20.3	19.0	20.3

FII includes depository receipts

CMP: INR9,430 TP: INR10,700 (+13%) Neutral Healthy participation and product launches driving growth

- MCX's operating revenue came in at INR3.7b in 2QFY26, up 31% YoY (in line). For 1HFY26, revenue rose 44%, to INR7.5b.
- Total expenses jumped 23% YoY to INR1.3b, with staff costs up 37% YoY and other expenses up 17% YoY. EBITDA stood at INR2.4b, up 36% YoY in 2Q (in line). For 1H, EBITDA rose 56% to INR4.9b.
- 2Q PAT of ~INR2b was up 29% YoY (in line). 1H PAT rose 51%, to INR4b.
- MCX introduced several new products, including Silver (30kg) and Silver Mini (5kg) monthly expiry contracts, Cardamom Futures, and Nickel Futures, and Options on the MCX iCOMDEX Bullion Index (MCX BULLDEX), covering both Gold and Silver. These launches have witnessed healthy traction, and management indicated that the product pipeline remains robust with necessary regulatory approvals already in place.
- We have raised our EPS estimates for FY26/FY27/FY28 by 21%/27%/18%, factoring in strong volume growth in Sep-Oct'25. We reiterate a Neutral rating on the stock with a one-year TP of INR10,700 (premised on 40x Sep'27E EPS).

Volumes at all-time high

- Transaction fee for 2Q stood at ~INR3.2b, up 27% YoY, comprising options and futures in the ratio of 68:32 (vs. 2QFY25 at INR2.5b in the ratio of 70:30).
- Overall ADT was up 87% YoY at INR4.1t, largely driven by 91%/55% YoY growth in Options Notional ADT/Futures ADT to INR3.7t/INR417.6b.
- Options notional ADT surged 91% YoY to INR3.7t, largely supported by 700%/95% YoY growth in bullion/base metal contracts, while energy contracts remained flat YoY. Options premium ADT rose 25% YoY to ~INR41b, with 356%/3% YoY rise in bullion and energy contracts.
- Futures ADT rose 55% YoY to INR417.6b, fueled by 82%/21% YoY growth in bullion/energy contracts, while base metal futures volumes declined 32% YoY.
- MCX continues to dominate the commodity futures market with 98.9% share as of 1HFY26, with 100%/99.4%/100%/100%/1.3% share in precious metals/energy/base metals/index futures/agri commodities.
- Other income at INR266m grew 5% YoY but dipped 19% QoQ.
- Total expenses jumped 23% YoY to INR1.3b, with CIR at 34.9% vs. 37.2% in 2QFY25 and 35.2% in 1QFY26. Staff costs rose 37% YoY to INR448m, while other expenses were up 17% YoY at INR858m, including mainly software charges/computer tech costs/contribution to SGF, which rose 10%/8%/56% YoY to INR231m/INR188m/INR268m.
- Client participation increased 16% YoY, with traded clients at 0.79m-0.64m in options and 0.27m in futures—reflecting growth across all participant categories (participation mix being futures: options at 54.84%:42%)
- The number of UCCs at the end of 2QFY26 stood at 36.7m compared to 28.9m in 2QFY25 and 34.7m in 1QFY26.

10 November 2025 40



Key takeaways from the management commentary

- Domestic mutual funds and AIFs exhibited strong participation, while PMS participation is yet to gain similar momentum. The exchange added 17 new members during the year and maintains a healthy pipeline of prospective members currently under engagement.
- Weekly options remain under evaluation, with no confirmed launch timeline. The exchange continues to assess feasibility, regulatory considerations, and market dynamics for potential offerings across both equity and commodity derivatives. Co-location facilities remain restricted by regulators, with no visibility on approval in the near term.
- On Oct'25, a technical issue led to a temporary shift of operations to the disaster recovery (DR) site. Disruption was caused by a predefined parameter limit within gateway services, which has since been rectified. Normal operations have resumed at the primary site. Exchange continues to engage with SEBI, though no penal action has been taken to date.

Valuation and view

- Sep-Oct'25 saw record volumes for bullion contracts given the surge in process. We expect normalization in bullion contract volumes and have factored in a decline of ~30% in Nov'25, followed by a modest recovery with ~1% MoM growth. For other commodities we factor in 1% MoM growth until Mar'28. We have not built any major contribution from electricity or index contracts. Our monthly transaction revenue forecast for Mar'28 still is lower than Oct'25.
- We have raised our EPS estimates for FY26/FY27/FY28 by 21%/27%/18%, given stronger volume growth observed in Sep-Oct'25. We reiterate a Neutral rating on the stock with a one-year TP of INR10,700 (premised on 40x Sep'27E EPS).

Quarterly Performance	INR m													
		FY	25			FY	26		FY25	FY26E	Est.	Var.	YoY	QoQ
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QFY26	(%/bp)	(%)	(%)
Sales	2,344	2,856	3,014	2,913	3,732	3,742	5,956	5,310	11,127	18,741	3,760	(0.5)	31.0	0.3
YoY Gr. (%)	60.8	73.0	57.4	60.9	59.2	31.0	97.6	82.3	62.8	68.4	31.7			
Staff Costs	321	327	332	463	448	448	465	485	1,443	1,846	457	(2.0)	37.1	(0.1)
Other expenses	697	735	750	849	867	858	1,071	1,075	3,031	3,871	919	(6.7)	16.8	(1.0)
EBITDA	1,326	1,794	1,931	1,602	2,417	2,436	4,420	3,750	6,653	13,024	2,383	2.2	35.8	0.8
Margins (%)	56.6	62.8	64.1	55.0	64.8	65.1	74.2	70.6	59.8	69.5	63.4			
Depreciation	134	140	146	217	173	198	203	209	638	783	176	11.9	40.8	14.2
EBIT	1,191	1,654	1,785	1,385	2,244	2,239	4,217	3,542	6,016	12,241	2,207	1.5	35.3	(0.2)
Interest Costs	1	1	2	1	1	1	1	2	5	5	1	(40.0)	(40.0)	-
Other Income	188	252	230	292	326	266	274	282	962	1,147	310	(14.3)	5.2	(18.6)
PBT bef. Exceptional items	1,379	1,906	2,013	1,675	2,569	2,504	4,490	3,821	6,973	13,384	2,515	(0.5)	31.4	(2.5)
Tax	273	374	418	328	532	514	988	870	1,394	2,904	553	(7.1)	37.6	(3.4)
Rate (%)	19.8	19.6	20.8	19.6	20.7	20.5	22.0	22.8	20.0	21.7	22.0			
Profit from associate	4	4	5	8	-5	-15	0	20	21	0	0.0			
PAT	1,109	1,536	1,600	1,355	2,032	1,975	3,502	2,971	5,600	10,479	1,962	0.6	28.5	(2.8)
Y-o-Y Gr. (%)	NA	NA	NA											
EPS (INR)	21.8	30.2	31.5	26.6	39.9	38.8	68.8	58.4	109.8	205.5	38.6	0.6	28.5	(2.8)
Total volumes (INR t)	112.3	143.2	148.4	160.2	198.9	267.3	396.9	366.4	564.0	1,239.3	268.2	(0.3)	86.7	34.4
Y-o-Y Gr. (%)	116.8	113.8	101.7	93.8	77.1	86.7	167.5	128.7	105.1	119.7	87.4			



Estimate change TP change Rating change

HEXT IN
609
409.5 / 4.6
900 / 590
-5/-6/-
928
25.5

Financials & Valuations (INR b)

rillaliciais & valu	rilialiciais & valuations (livin b)					
Y/E Mar	CY25E	CY26E	CY27E			
Sales	134.0	146.8	163.2			
EBIT Margin (%)	13.3	14.8	15.2			
PAT	14.4	16.6	19.2			
EPS (INR)	23.3	26.9	31.1			
EPS Gr. (%)	20.8	15.5	15.6			
BV/Sh. (INR)	99.9	113.6	129.4			
Ratios						
RoE (%)	25.2	25.6	26.0			
RoCE (%)	20.1	24.1	27.9			
Payout (%)	50.0	50.0	50.0			
Valuations						
P/E (x)	28.9	25.0	21.6			
P/BV (x)	6.7	5.9	5.2			
EV/EBITDA (x)	18.2	14.8	12.6			
Div Yield (%)	1.7	2.0	2.3			

Shareholding pattern (%)

•		
As On	Sep-25	Jun-25
Promoter	74.6	74.6
DII	11.1	9.9
FII	8.3	9.9
Others	6.0	5.6

FII Includes depository receipts

Hexaware Technologies

CMP: INR672 TP: INR850(+26%) Buy

Not out of the woods yet

Incremental headwinds to weigh on 4QCY25 performance

- Hexaware Technologies (HEXT) reported revenue of USD395m in 3QCY25, up 3.4% QoQ in CC terms vs. our estimate of 3.3% QoQ CC. Growth was led by Manufacturing and Consumer (up 16.5% QoQ), followed by Healthcare and Insurance (up 11.3% QoQ). Hi-Tech and PS & Travel verticals declined by 8.6%/9.8% QoQ. The reported EBIT margin stood at 14.7%, broadly in line with our estimate of 14.9%. PAT was down 2.6% QoQ/up 23.4% YoY at INR3.7b (our est. of INR3.8b).
- In INR terms, 3Q revenue/EBIT/PAT grew 11.1%/22.8%/23.4% YoY. In 4Q, we expect its revenue/EBIT/PAT to grow 9.2%/18.1%/13.1% YoY. We expect near-term softness from incremental headwinds in 4Q, though HEXT's USD3b deal pipeline and margin discipline highlight steady execution. Visibility into CY26 should improve as client budgets are finalized by Jan'26. We reiterate our BUY rating with a TP of INR850 (based on 28x Jun'27E EPS, 30x earlier), implying a 26% potential upside.

Our view: Continued pressure in near term

- Headwinds to weigh on 4Q growth: HEXT reported 3.4% QoQ CC growth (1.7% organic) in 3QCY25, broadly in line with expectations, aided by higher license-linked revenues. We believe the demand environment is largely unchanged, and short-term challenges persist.
- US government shutdown has temporarily restricted H1-B visa transfers between employers, which we think could constrain onsite growth in the near term; this is an additional headwind and was not baked into our estimates.
- Incremental furloughs and budget constraints in select Professional Services accounts may also weigh on 4Q performance. That said, we expect visibility to improve into CY26 as client budgets close out over Dec'25-Jan'26. We expect YoY CC growth of 7.1%/7.9% in CY25E/CY26E, with organic YoY CC growth of 5.7% for each.
- Vertical momentum mixed; BFSI remains key driver: Financial Services will remain the primary growth driver, aided by new logos and deal ramp-ups. Healthcare & Insurance benefitted from license-linked revenue, while HiTech & Professional Services remained under pressure due to client-level budget cuts and slower project ramp-ups; we expect a gradual recovery over the next couple of quarters.
- Short-cycle deals returning, but yet to make a dent: We note a sequential improvement in deal activity, led by some traction in short-cycle, GCC-led, and renewal-based engagements. Two large consolidation deals were won in BFSI and Insurance. We believe the record USD3b pipeline could offer momentum in CY26, though some moderation in 4Q is likely as decisions close.



■ Marginal revision to EBITDA guidance: EBITDA margin expanded 30bp QoQ to 17.5%, supported by operational efficiency and forex gains, partly offset by higher license and travel costs. Offshore mix improved to ~49%, providing structural leverage. SMC integration helped to tilt the mix to offshore, which helped in margin gains. We expect margins to stay within the revised guidance of 17.1-17.2% as the company continues to reinvest operational savings in growth. We expect EBITDA margin of 17.1%/17.9% in CY25E/CY26E.

Valuation and view

Amid a cautious demand environment, HEXT's execution remains steady, supported by traction in short-cycle and consolidation deals. The company is navigating transient challenges, such as furlough impact in 4Q, visa transfer restrictions and selective client budget constraints, while maintaining margin discipline within the guided band. Our estimates are broadly unchanged. We expect a PAT CAGR of 15.5% over CY25-27E. We reiterate our BUY rating with a TP of INR850 (based on 28x Jun'27E EPS), implying a 26% potential upside.

Revenue and margins in line with our estimate; Manufacturing and Healthcare led growth

- USD revenue came in at USD394.8m, up 3.4% QoQ in CC terms vs. our estimate of an increase of 3.3% QoQ CC.
- Growth was led by Manufacturing and Consumer (up 16.5% QoQ), followed by Healthcare and Insurance (up 11.3% QoQ). Hi-Tech and Professional Services & Travel and Transportation verticals declined by 8.6%/9.8% QoQ.
- In terms of geographies, Americas was up 3.7% QoQ, and Europe grew 2.4% QoQ in USD terms.
- EBITDA margin stood at 17.3% (est. 17.3%). The company revised its EBITDA guidance to 17.1-17.2% (from 17.1-17.4% earlier) after wage hikes in CY25.
- Reported EBIT margin stood at 14.7%, broadly in line with our estimate of 14.9%.
- PAT was down 2.6% QoQ/up 23.4% YoY at INR3.7b (our est. of INR3.8b).
- The headcount rose to 33,590 (up 3.6% QoQ) in 3QCY25. Attrition (LTM) increased by 30bp QoQ to 11.4%. Utilization was up 10bp QoQ at 83.8%.
- The company announced the acquisition of a 100% stake in Cybersolve to enhance its capabilities in identity access and management solutions. The company will pay USD34.5m upfront, while the remaining payment of USD31.5m is contingent on financial performance, taking the total consideration to USD66m.

Key highlights from the management commentary

- The demand environment has stabilized, with improving trends across verticals and early signs of recovery in the Manufacturing & Consumer (M&C) sector the key drag in earlier quarters.
- Short-term headwinds emerged from the US government shutdown, restricting visa transfers (for employees moving between US employers), which could constrain onsite growth temporarily.
- Management expects CY26 to be better than CY25, supported by improved demand visibility and ongoing client budget discussions for next year. Further clarity on client spending plans is expected in 4QCY25.
- This quarter benefited from higher license revenue, which offset headwinds from a higher offshore mix and moderation in the BPO segment.




- Management guided for a flat 4QCY25, factoring in regular furloughs (~2.5-3% impact) and temporary government shutdown-related disruptions.
- Two major consolidation deals were won one with a **Canadian bank** and another with a **Germany-based global insurer**.
- Deal momentum remains healthy across categories short-cycle, GCC-led, and renewal-based engagements.
- Manufacturing & Consumer: Early recovery signs are visible, aided by SMC contribution. Excluding SMC, the segment still delivered positive growth. New logos were added, and the decline has largely bottomed out.

Quarterly Performa	nce										(IN	R Million)
Y/E March		CY	24			CYZ	25E		CY24	CY25E	Est.	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE			3QCY25	(% / bp)
Revenue (USD m)	331	352	374	372	372	382	395	391	1,429	1,539	397	-0.6
QoQ (%)	5.3	6.4	6.4	-0.5	-0.2	2.9	3.3	-1.0			3.9	-66bp
Revenue (INR m)	27,488	29,355	31,357	31,544	32,079	32,607	34,836	34,448	1,19,744	1,33,970	34,659	0.5
YoY (%)	9.6	12.7	18.3	20.6	16.7	11.1	11.1	9.2		11.9	10.5	56bp
GPM (%)	41.4	41.2	42.3	42.3	41.9	41.5	43.1	42.4	41.8	42.2	42.8	26bp
Other (%)	26.2	26.6	26.6	26.8	25.5	29.1	25.8	25.8	26.6	26.5	25.5	30bp
EBITDA	4,176	4,311	4,911	4,904	5,278	4,044	6,013	5,718	18,302	21,053	5,996	0.3
EBITDA Margin (%)	15.2	14.7	15.7	15.5	16.5	12.4	17.3	16.6	15.3	15.7	17.3	-4bp
EBIT	3,576	3,624	4,173	4,141	4,543	3,292	5,124	4,892	15,514	17,851	5,164	-0.8
EBIT Margin (%)	13.0	12.3	13.3	13.1	14.2	10.1	14.7	14.2	13.0	13.3	14.9	-19bp
Other income	2	172	-114	29	-180	1,391	-157	-69	89	985	-104	51.0
PBT	3,578	3,796	4,059	4,170	4,363	4,683	4,967	4,823	15,603	18,836	5,060	
ETR (%)	22.0	27.7	26.2	23.1	25.0	18.9	25.5	24.8	24.8	23.6	25.0	53bp
Minority Interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			0.0	
Reported PAT	2,790	2,746	2,997	3,207	3,271	3,797	3,699	3,627	11,740	14,394	3,795	-2.5
QoQ (%)	45.8	-1.6	9.1	7.0	2.0	16.1	-2.6	-2.0			0.0	
YoY (%)	NA	NA	NA	67.6	17.2	38.3	23.4	13.1	17.7	22.6	26.6	
Extra-ordinary items	0	0	0	0	0	0	0	0	0	0	0	
Adj. PAT	2,790	2,746	2,997	3,207	3,271	3,797	3,699	3,627	11,740	14,394	3,795	
EPS (INR)	4.6	4.5	5.0	5.2	5.3	6.2	6.0	5.9	19.3	23.3	6.1	-2.6



NALCO

Neutral



NACL IN
1837
431.1 / 4.9
263 / 138
7/44/-7
2557

Financials & Valuations (INR b)

Y/E MARCH	FY26E	FY27E	FY28E
Sales	168	173	182
EBITDA	68	67	69
Adj. PAT	47	44	45
EBITDA Margin (%)	41	39	38
Cons. Adj. EPS (INR)	25.6	24.2	24.5
EPS Gr. (%)	-11	-6	1
BV/Sh. (INR)	119	140	161
Ratios			
Net D:E	-0.4	-0.4	-0.5
RoE (%)	24	19	16
RoCE (%)	32	25	22
Payout (%)	16	17	16
Valuations			
P/E (x)	9.1	9.7	9.5
P/BV (x)	2.0	1.7	1.5
EV/EBITDA(x)	5.1	4.7	4.2
Div. Yield (%)	1.7	1.7	1.7
FCF Yield (%)	7.5	8.0	8.2

Shareholding Pattern (%)

	•	•	
As On	Sep-25	Jun-25	Sep-24
Promoter	51.3	51.3	51.3
DII	15.4	15.8	19.3
FII	16.2	15.1	12.1
Others	17.1	17.9	17.4

FII includes depository receipts

Strong alumina valumos with favorable aluminum

TP: INR250 (+7%)

Strong alumina volumes with favorable aluminum prices drive earnings beat; estimates raised

- NALCO (NACL)'s revenue stood at INR42.9b (+7% YoY and +13% QoQ) vs. our est. of INR37.1b. The growth was driven by favorable aluminum prices.
- Consol. EBITDA stood at INR19.3b (+24% YoY and +29% QoQ) against our est. of INR11.5b during the quarter.
- EBITDA margin stood at 44.9% in 2QFY26 against 39.2% in 1QFY26 and 38.7% in 2QFY25.
- Adj. PAT for the quarter stood at INR14.3b (+37% YoY and +36% QoQ) against our est. of INR7.8b, supported by strong operating performance.
- In 1HFY26, NACL's revenue stood at INR81b (+18% YoY), primarily led by a strong increase in aluminum prices and alumina volume, which largely offset the adverse impact of muted alumina prices.
- Alumina sales volume stood at 700kt, up +82% YoY, while aluminum sales volume saw a marginal contraction of 2% YoY to 226kt in 1HFY26.
- NACL's EBITDA and adj. PAT stood at INR34.1b (+38% YoY) and INR24.8b (+52% YoY), respectively, for 1HFY26.
- The Board approved the first interim dividend of INR4 per share (~80% of FV) for FY26.

Aluminum business

CMP: INR235

- Revenue from the aluminum business stood at INR28.9b, up by 7% YoY and
 6% QoQ during the quarter.
- Metal production stood at 119kt, up by +3% YoY and QoQ both, while sales volume was at 112kt (-7% YoY and -1% QoQ) during the quarter.
- NACL's EBIT stood at INR11.9b, up by 39% YoY and 32% QoQ in 2QFY26.

Chemical (Alumina) business

- In 2QFY26, the revenue from the chemical business stood at INR18.3b, up +13% YoY and 8% QoQ, primarily driven by strong volume growth, which offset the impact of muted alumina prices.
- Alumina hydrate production stood at 576kt, increased by 13% YoY and flat QoQ, while sales volume grew by 33% YoY and 30% QoQ to 396kt.
- NACL's EBIT came in at INR6.2b, up by 5% YoY and 24% QoQ in 2QFY26.

Key highlights from the management commentary

- Management guided alumina volume of ~1,200-1,280kt and aluminum sales of 470kt in FY26.
- ~50% of alumina production is used internally for aluminum smelting, and the balance is sold, mainly exported. NALCO has a limited storage capacity of ~75kt at Vizag silos and 36kt at Damanjodi; therefore, the alumina sales are closely aligned with production.
- The average alumina prices are ~USD320-340 currently. The aluminum prices stood at USD2,800-2,900.
- It has a 4mt coal production target for FY26. Out of the 7.2mt requirement, 3mt would be met from CIL (under FSA), not from the e-auction.



Valuation and view

- NACL posted a strong performance during 2Q, led by favorable aluminum prices and strong alumina volume, which helped to offset the muted alumina price impact during the quarter. With limited production room at the smelter, the LME prices become a vital factor for near-term operating performance.
- In the long run, NACL plans an expansion with a total capex of INR300b, which could significantly enhance production capacity. However, with the completion timeline of FY30, execution risks and cost escalations remain key concerns.
- Despite strong fundamentals, zero debt, and a robust demand outlook for aluminum in India, the near-term upside is capped by limited production headroom, US trade tension, on-time execution challenges, and regulatory risks. We raise our FY26 revenue/EBITDA/PAT estimates by 8/32/34%, while our FY27 estimates are flat/+21%/+25%, incorporating the strong alumina volume growth and favorable LME prices.
- At CMP, NACL trades at 4.7x on EV/EBITDA and 1.7x on P/B. We reiterate our Neutral rating on the stock with a revised TP of INR250, valuing the stock at 5x EV/EBITDA on Sep'27 estimates.

Consolidated Quarterly Performance (INR m)

Y/E March		FY	25			FY	26		FY25	FY26E	FY26	Vs
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	Est %
Net Sales	28,561	40,015	46,622	52,678	38,069	42,923	43,166	43,661	1,67,876	1,67,820	37,113	15.7
Change (YoY %)	(10.1)	31.5	39.3	47.2	33.3	7.3	(7.4)	(17.1)	27.7	(0.0)		
Change (QoQ %)	(20.2)	40.1	16.5	13.0	(27.7)	12.8	0.6	1.1				
Total Expenditure	19,219	24,525	23,347	25,140	23,148	23,665	25,608	23,980	92,230	99,791		
EBITDA	9,342	15,490	23,275	27,539	14,921	19,259	17,558	19,681	75,646	68,028	11,537	66.9
Change (YoY %)	57.2	290.7	201.1	148.7	59.7	24.3	(24.6)	(28.5)	163.4	(10.1)		
Change (QoQ %)	(15.6)	65.8	50.3	18.3	(45.8)	29.1	(8.8)	12.1				
Interest	34	44	191	321	80	84	109	162	590	435		
Depreciation	1,743	1,798	2,857	878	1,783	1,738	1,802	1,886	7,276	7,209		
Other Income	605	718	991	1,256	1,235	1,515	1,188	813	3,570	4,750		
PBT (after EO)	8,170	14,366	21,219	27,596	14,293	18,952	16,835	18,446	71,351	65,135		
Total Tax	2,158	3,744	5,390	6,813	3,654	4,621	4,461	4,525	18,104	17,261		
% Tax	26.4	26.1	25.4	24.7	25.6	24.4	26.5	24.5	25.4	26.5		
PAT before MI and Asso.	6,012	10,622	15,829	20,784	10,639	14,332	12,374	13,921	53,247	47,874		
Sh. of Associate	(128)	(162)	(166)	(111)	(144)	(32)	(210)	(453)	(567)	(839)		
Reported PAT after MI/Asso.	5,884	10,460	15,663	20,672	10,495	14,299	12,164	13,468	52,679	47,035		
Adjusted PAT	5,884	10,460	15,663	20,672	10,495	14,299	12,164	13,468	52,679	47,035	7,758	84.3
Change (YoY %)	76.3	458.3	232.8	205.5	78.4	36.7	(22.3)	(34.9)	164.9	(10.7)		
Change (QoQ %)	(13.0)	77.8	49.7	32.0	(49.2)	36.3	(14.9)	10.7				

E: MOFSL Estimates



Amber Enterprises

Estimate changes	↓
TP change	
Rating change	(

Bloomberg	AMBER IN
Equity Shares (m)	35
M.Cap.(INRb)/(USDb)	254 / 2.9
52-Week Range (INR)	8626 / 5235
1, 6, 12 Rel. Per (%)	-16/16/11
12M Avg Val (INR M)	3634

Financials Snapshot (INR b)

i manciais snapsnot (nitro)								
Y/E MARCH	FY26E	FY27E	FY28E					
Sales	117.9	146.0	179.8					
EBITDA	9.0	12.4	16.5					
EBITDA Margin (%)	7.6	8.5	9.2					
PAT	3.2	5.5	7.9					
EPS (INR)	90.4	158.0	224.9					
EPS Growth (%)	25.6	74.7	42.3					
BV/Share (INR)	1,027	1,185	1,410					
Ratios								
Net D/E	0.1	0.1	-0.0					
RoE (%)	10.8	14.3	17.3					
RoCE (%)	11.3	14.9	18.1					
Valuations								
P/E (x)	80.0	45.8	32.2					
P/BV (x)	7.0	6.1	5.1					
EV/EBITDA (x)	28.8	20.8	15.5					
EV/EBITDA (x)	28.8	20.8	15.					

Shareholding pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	38.2	39.7	39.8
DII	20.2	17.8	17.8
FII	30.6	28.6	26.4
Others	11.0	13.9	16.0

FII Includes depository receipts

CMP: INR7,227 TP: INR8,400 (+16%)

Buy

Weak demand impacts performance

Amber Enterprises (AMBER) posted a weak performance in 2QFY26. Weakness was driven by the consumer durable segment, which was impacted by lower demand and delayed purchases owing to GST 2.0. The company has still outperformed the RAC industry in 2QFY26, with a decline of 18% YoY vs the industry decline of 30-33% YoY for the quarter. The electronics division was also impacted by weak demand in the consumer durable segment. We expect this demand to revive in 2HFY26, and the company to outperform the RAC industry for FY26. We expect the electronics division's performance to be driven by growth in both PCBA and PCB segments, along with recent acquisitions of Powerone and Unitronics despite a slight delay in the commissioning of the Ascent facility. This momentum is expected to be further supported by the commissioning of the company's capacity in JV with Korea Circuit, which we expect to commence from FY28. We expect the railway segment's performance to remain subdued in the near term. We cut our PAT estimates by 19%/10%/11% each for FY26/27/28 to factor in 2QFY26 performance and also incorporate the recent fund raise of INR10b. Reiterate BUY with a revised TP of INR8,400 (INR9,000 earlier).

Weaker-than-expected results

AMBER reported a weak set of numbers. 2Q is usually the weakest quarter for AMBER, mainly due to monsoons. Consolidated revenue growth was broadly flat YoY at INR16.5b vs our expectation of 20% growth, mainly due to lower-than-expected demand in the consumer durables segment impacted by the monsoon and delayed purchases following GST 2.0. Gross margin expanded 40bp YoY to 20.5% vs our estimate of 18.0%. Absolute EBITDA declined 20% YoY to INR913m, indicating a miss to our estimates by 37%, while margins contracted 130bp YoY to 5.5% vs our estimate of 7.2%, mainly due to weakness in the consumer durables segment. The company reported a net loss of INR329m vs our estimate of a net profit of INR264m. For 1HFY26, revenue/EBITDA increased 25%/12% YoY, while PAT declined 23% YoY and EBITDA margin contracted 80bp YoY. For 1HF26, the company reported a net operating cash outflow of INR7.7b vs an outflow of INR2b last year, mainly due to an increase in working capital.

Consumer durables segment revival expected in coming quarters

The segment's revenue declined 18% YoY to INR8.7b in 2QFY26 (outperforming the industry's 30-35% volume drop), driven by unfavorable weather and deferred purchases ahead of the GST rate cut implementation. Management remains confident of 13-15% growth in FY26, aided by a likely rebound in 4Q and an expanded product portfolio that now includes a full CAC range up to 17.5 tons. The company's continued focus on scaling its component business, deepening OEM partnerships, and launching new CAC models in Nov-Dec'25 should help it gain share as demand normalizes. Inventory build-up from the weak summer is expected to normalize by 4QFY26, improving working capital and utilization levels. Margins contracted 160bps YoY to 4.3% due to lower plant utilization, though this pressure is purely cyclical, with recovery expected in the seasonally strong 4QFY26. We expect the segment to post a revenue CAGR of 16% over FY25-28, with margins stabilizing at around 8.0%.



Electronics segment scaling towards a full-stack EMS ecosystem

The electronics division continued to deliver strong growth, with revenue up 30% YoY in 2QFY26, driven by strong performance across both PCBA and bare PCB verticals. Margins were temporarily impacted by higher copper-clad laminate and gold prices, but management expects recovery to 8-9% by FY26-end, and anticipates reaching double digits in FY27, as these costs are passed on to customers with a one-quarter lag. **Near-term** growth will be supported by sustained demand from the consumer durables sector and incremental contributions from Power-One Microsystems, which expands AMBER's presence in solar inverters, EV chargers, and battery energy storage systems. Over the medium-to-long term, AMBER is transitioning into a full-stack EMS provider across PCBA, bare PCBs, and complete box-build products for industrial automation and power electronics. The upcoming Ascent Circuits and Korea Circuit JV facilities will enhance its scale, self-reliance, and ability to offer end-to-end solutions. The company targets USD1b revenue in the next three years. We expect a revenue CAGR of 38% over FY25-28, with margins expanding to double digits by FY28, aided by a shift in the mix to higher-margin businesses such as Power-One (15-18%), Unitronics (25-28%), and bare PCBs (17-19%).

Railways segment to revive in FY27

The railways segment recorded 7% YoY growth in revenue in 2QFY26, driven by higher metro project offtake and gradual execution of new orders. Despite the soft quarter, management remains confident of doubling revenue over the next two years, backed by a strong INR26b order book and expected inflows of another INR4b-5b. **Near-term** momentum will come from: 1) Sidwal's greenfield HVAC facility trials beginning in 3QFY26 with commercial operations in 4QFY26, 2) Yujin Machinery JV for pantographs, brakes, and couplers to start production in 1HFY27. While the near-term focus remains on execution ramp-up and cost discipline as new facilities commercialize, the **medium-to-long term** growth will be led by large infrastructure programs such as Vande Bharat, metro rail expansions, and defense cooling systems, which are gaining traction and expected to contribute materially in the coming years. We expect railways division to clock a revenue CAGR of 23% over FY25-28, with margin to sustain around 18.5% for FY27/28.

Building capacities for the next growth cycle

AMBER has planned out a gross capex of INR7b-8.5b in FY26, excluding subsidies. For FY27, ~INR3b will go toward consumer durables, while the bulk of the investment will support the electronics vertical, from the planned INR6.5b for Ascent Circuits and INR12b for the Korea Circuit JV, largely spread over FY26-FY27. Management expects trial production at Ascent to start by Sep'26 and commercial operations in 3QFY27. Korea Circuit's construction will begin by Jan'26, with completion expected in one year and revenue contribution anticipated from FY28 onwards. Additionally, the company expects to receive PLI and other subsidies by FY28-FY29, which should help partially fund expansion and enhance returns on capital employed. We have factored in a capex of INR8b-8.5b each over FY26-28.

Strengthening balance sheet amid acquisitions

The quarter marked significant progress on strategic acquisitions and balance sheet improvement for AMBER. ILJIN completed the acquisition of a 60% stake in Power-One Microsystems, expanding AMBER's footprint into high-growth energy storage and EV charging solutions, and acquired a 40.2% controlling stake in Unitronics (Israel), a leader in industrial automation systems. These acquisitions will not only add to topline growth but also improve blended margins, given their higher margin profiles. The company raised INR10b via QIP and INR17.5b at ILJIN from marquee



investors, strengthening its financial flexibility. Management expects to be net cash positive by FY26-end, with interest costs reducing to INR200m-250m in 2HFY26. The company's capital discipline amid expansion indicates strong balance sheet management, which should support sustainable growth in the coming years.

Financial outlook

We cut our PAT estimates by 19%/10%/11% each for FY26/27/28 to factor in 2QFY26 performance and also incorporate recent fund raise of INR10b. We, thus, expect revenue/EBITDA/PAT CAGR of 22%/29%/48% over FY25-28 for AMBER.

Valuation and recommendation

The stock currently trades at 80.0x/45.8x/32.2x P/E on FY26/27E/28E earnings. We cut our estimates and **reiterate our BUY rating** on the stock with a revised DCF-based TP of INR8,400 (earlier INR9,000).


Key risks and concerns

Key risks and concerns include lower-than-expected demand growth in the RAC industry; change in BEE norms making products costlier; change in announced capex policy; and increased competition across the RAC, mobility, and electronics segments.

Consolidated - Quarterly	Earning Mo	odel										(INR m)
Y/E March		FY	25			FY2	26E		FY25	FY26E	FY26E	Est
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	Var (%)
Gross Sales	24,013	16,847	21,333	37,537	34,491	16,470	26,910	40,069	99,730	1,17,940	20,114	-18
YoY Change (%)	41.1	81.7	64.8	33.8	43.6	-2.2	26.1	6.7	48.2	18.3	19.4	
Total Expenditure	22,051	15,710	19,746	34,590	31,924	15,557	24,946	36,542	92,096	1,08,969	18,672	-17
EBITDA	1,962	1,137	1,587	2,947	2,567	913	1,965	3,527	7,634	8,972	1,442	-37
YoY Change (%)	48.7	90.9	102.2	32.8	30.8	-19.7	23.8	19.7	55.2	17.5	26.8	
Margins (%)	8.2	6.8	7.4	7.9	7.4	5.5	7.3	8.8	7.7	7.6	7.2	
Depreciation	549	566	588	580	618	702	647	620	2,283	2,588	596	18
Interest	518	486	537	546	634	769	250	359	2,087	2,012	586	31
Other Income	207	178	160	191	297	156	189	151	736	792	203	-23
PBT before EO expense	1,101	263	623	2,013	1,612	-403	1,256	2,698	3,999	5,164	463	NM
Extra-Ord expense	0	0	0	0	0	0	0	0	0	0	0	NM
PBT	1,101	263	623	2,013	1,612	-403	1,256	2,698	3,999	5,164	463	NM
Tax	298	26	162	702	484	-156	332	907	1,188	1,567	130	NM
Rate (%)	27.0	10.1	26.1	34.9	30.0	38.8	26.5	33.6	29.7	30.3	28.1	
MI & P/L of Asso. Cos.	79	44	102	151	90	82	104	148	376	425	69	20
Reported PAT	724	192	359	1,160	1,039	-329	820	1,643	2,436	3,173	264	NM
Adj PAT	724	192	359	1,160	1,039	-329	820	1,643	2,436	3,173	264	NM
YoY Change (%)	58.6	NM	NM	22.6	43.5	NM	128.5	41.6	83.3	30.3	37.2	
Margins (%)	3.0	1.1	1.7	3.1	3.0	-2.0	3.0	4.1	2.4	2.7	1.3	
Y/E March			FY25			-	Y26E		FY25	FY26E	FY25E	Est

Y/E March	FY25					FY2	26E		FY25	FY26E	FY25E	Est
INR m	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	Var (%)
Segmental revenue												
Consumer Durables Division	19,180	10,690	15,550	27,870	25,600	8,730	18,660	28,311	73,290	81,301	12,294	-29
Electronics Division	3,880	4,920	4,720	8,420	7,660	6,420	7,080	10,653	21,940	31,813	6,642	-3
Railway Sub-systems & Mobility	950	1,240	1,064	1,250	1,230	1,320	1,170	1,106	4,500	4,826	1,178	12
Total Revenues	24,013	16,847	21,333	37,537	34,491	16,470	26,910	40,069	99,730	1,17,940	20,114	-18
Operating EBITDA												
Consumer Durables Division	1,500	620	1,160	2,340	1,920	370	1,306	2,501	5,620	6,098	762	-51
Margin (%)	7.8	5.8	7.5	8.4	<i>7.5</i>	4.2	7.0	8.8	7.7	7.5	6.2	
Electronics Division	300	370	340	500	490	390	496	1,010	1,510	2,386	531	-27
Margin (%)	7.7	7.5	7.2	5.9	6.4	6.1	7.0	9.5	6.9	7.5	8.0	
Railway Sub-systems & Mobility	200	210	120	300	220	210	207	205	830	842	212	-1
Margin (%)	21.1	16.9	11.2	24.0	17.9	15.9	17.7	18.5	18.4	17.4	18.0	
Total EBITDA (Pre ESOP and	2,000	1,200	1,619	3,140	2,630	970	2,009	3,717	7,960	9,325	1,506	-36
Margin (%)	8.3	7.1	7.6	8.4	7.6	5.9	7.5	9.3	8.0	7.9	7.5	
ESOP/Other op exp	38	63	32	193	63	57	44	189	326	354	64	-10
Total EBITDA	1,962	1,137	1,587	2,947	2,567	913	1,965	3,527	7,634	8,972	1,442	-37
Margin (%)	8.2	6.8	7.4	7.9	7.4	5.5	7.3	8.8	7.7	7.6	7.2	

Neutral





Aegis Logistics

ESTIMATE CHANGE	1
TP change	1
Rating change	\leftarrow

Stock Info	
Bloomberg	AEGISLOG IN
Equity Shares (m)	351
M.Cap.(INRb)/(USDb)	267.2 / 3

52-Week Range (INR) 1037 / 610 1, 6, 12 Rel. Per (%) -9/-8/-10 12M Avg Val (INR M) 1396 Free float (%) 41.9

Financials Snapshot (INR b)

		- 1	
Y/E March	FY26E	FY27E	FY28E
Sales	88.6	89.4	101.1
EBITDA	14.1	15.2	16.5
Adj. PAT	8.2	8.5	9.1
Adj. EPS (INR)	23.3	24.3	26.0
EPS Gr.%	23.2	4.1	7.4
BV/Sh.INR	147.1	162.8	179.8
Ratios			
Net D:E	-0.1	-0.1	-0.2
RoE (%)	16.7	15.7	15.2
RoCE (%)	15.4	15.3	15.0
Payout (%)	35.0	35.0	35.0
Valuation			
P/E (x)	32.7	31.4	29.2
P/BV (x)	5.2	4.7	4.2
EV/EBITDA (x)	17.6	16.3	14.8
Div. Yld (%)	1.1	1.2	1.3
FCF Yld (%)	2.6	1.9	2.9

Shareholding pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	58.1	58.1	58.1
DII	6.3	6.4	6.7
FII	16.9	16.8	17.9
Others	18.8	18.7	17.3

FII Includes depository receipts

Strong gas division performance drives beat

In 2QFY26, Aegis Logistics (AEGIS) reported EBITDA of INR2.9b, beating our estimate by 13%, as the normalized EBITDA of the gas division came in 68% above our estimate, while that of the liquid division stood 15% below estimates. Management has reiterated its PAT guidance of 25% CAGR over the next few years, primarily led by robust upcoming capacities.

TP: INR770 (+1%)

■ We reiterate our Neutral rating on the stock with a TP of INR770, as we now value the company at 30x Dec'27E EPS (earlier 30x FY27E) of INR25.6.

Strong 2Q performance

CMP: INR761

- 2QFY26 revenue came in above our expectations at INR22.9b, while EBITDA came 13% above our estimates at INR2.9b.
 - **EBITDA** margin stood at 12.7% (2QFY25 margins: 12.8%).
- APAT came in at INR1.8b, 40% above our estimate.
- Segmental performance during the quarter:
 - The Liquid division's revenue was INR1.5b (+19% YoY, +7% QoQ), and EBIT was INR0.9b (+31% YoY, +14% QoQ).
 - The Gas division's revenue stood at INR21.4b (+32% YoY, +36%QoQ), and EBIT was INR2b (+52% YoY, 48% QoQ).
- In 2QFY26, standalone revenue stood at INR10.3b (+56% YoY, +22% QoQ).
- Standalone PAT came in at INR1.7b (+131% YoY, +141% QoQ).


Valuation and view: Reiterate Neutral

- AEGIS has reiterated its ambitious capex plan of: 1) commissioning 64,000kl of liquid capacity at Mumbai port by 1QFY27, 2) adding liquid, LPG, and LPG bottling capacity at JNPA (INR16.8b); 3) developing 94kcbm of LPG capacity at Kandla by FY27; 4) commissioning 36,000 mt of ammonia capacity at Pipavav by 1QFY27, and 5) expanding terminal capacity at Haldia, for which 3 acres of land has been acquired.
- While we estimate an 11% CAGR in PAT over FY25-28, we believe that the current valuations at 24.3x FY27E EPS already factor in the strong expansion in capacity and earnings. We value the stock at 30x Dec'27E EPS of INR25.6 to arrive at our TP of INR770. We reiterate our Neutral rating on the stock.



Y/E March		FY:	25			FY	26		FY25	FY26	FY26	Var
•	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE	-		2QE	(%)
Net Sales	16,013	17,504	17,070	17,050	17,194	22,940	22,245	26,195	67,638	88,574	19,141	20%
YoY Change (%)	-23.8	41.8	-8.9	-7.2	7.4	31.1	30.3	53.6	-4.0	31.0	9.4	
EBITDA	2,323	2,239	2,329	4,088	2,399	2,907	3,043	5,706	10,980	14,055	2,581	13%
Margin (%)	14.5	12.8	13.6	24.0	14.0	12.7	13.7	21.8	16.2	15.9	13.5	-0.1
Depreciation	368	374	373	407	417	522	525	535	1,522	1,998	431	
Interest	313	300	514	525	328	243	259	259	1,653	1,090	288	
Other Income	435	395	600	654	625	960	743	949	2,084	3,277	437	
PBT	2,077	1,960	2,041	3,810	2,279	3,102	3,002	5,861	9,888	14,244	2,299	35%
Tax	496	440	446	632	525	662	757	1,646	2,014	3,590	579	
Rate (%)	23.9	22.4	21.8	16.6	23.1	21.3	25.2	28.1	20.4	25.2	25.2	
MI & P/L of Asso. Cos.	266	261	353	361	440	644	644	753	1,240	2,481	440	46%
Reported PAT	1,315	1,260	1,243	2,817	1,313	1,796	1,602	3,463	6,634	8,174	1,279	40%
Adj PAT	1,315	1,260	1,243	2,817	1,313	1,796	1,602	3,463	6,634	8,174	1,279	40%
YoY Change (%)	13.5	-0.8	-4.5	43.5	-0.1	42.6	28.9	22.9	16.5	23.2	1.6	
Margin (%)	8.2	7.2	7.3	16.5	7.6	7.8	7.2	13.2	9.8	9.2	6.7	0.2
Segmental Highlights	-								•		/oY (%) Q	· · · · ·
LPG logistics volumes ('000 MT)	881	1,020	1,097	1,017	1,013	1,064	1,221	1,225	1,161	1,407	32.24	21.19
YoY change (%)	38.3	22.4	11.0	16.1	15.0	4.3	11.3	20.5	14.6	32.2		
LPG distribution volumes ('000 MT)	159	131	144	126	129	129	127	136	145	192	48.84	32.41
YoY change (%)	86.4	12.7	(7.8)	(7.5)	(18.9)	(1.5)	(11.8)	7.9	12.4	48.8		
LPG sourcing volumes ('000 MT)	226	174	179	220	124	194	140	139	119	208	7.22	74.79
YoY change (%)	(1.7)	(23.7)	(10.5)	(7.2)	(45.1)	11.5	(21.8)	(36.8)	(4.0)	7.2		
Gas division EBITDA (INR m)	1,340	1,510	1,470	1,810	1,420	1,440	1,560	2,310	1,500	2,310	60.42	54.00
YoY change (%)	22.9	32.5	(9.8)	24.0	6.0	(4.6)	6.1	27.6	5.6	60.4		
Liquids division EBITDA (INR m)	780	800	850	1,530	1,080	930	950	2,030	1,060	1,160	24.73	9.43
YoY change (%)	41.8	15.9	10.4	118.6	38.5	16.3	11.8	32.7	(1.9)	24.7		

Neutral





Amara Raja **CMP: INR980** TP: INR940 (-4%)

Estimate changes TP change **Rating change**

ARENM IN
183
179.4 / 2
1360 / 805
-4/0/-31
669

Financials & Valuations (INR h)

i ilialiciais & vai	uations (iii	iit bj	
Y/E March	2026E	2027E	2028E
Sales	135.3	148.4	162.8
EBITDA	16.1	18.5	21.2
Adj. PAT	7.8	9.2	10.6
EPS (INR)	42.7	50.1	57.8
EPS Gr. (%)	-11.5	17.4	15.5
BV/Sh. (INR)	438	479	526
Ratios			
RoE (%)	10.1	10.8	11.4
RoCE (%)	10.0	10.6	11.1
Payout (%)	16.9	18.0	18.2
Valuations			
P/E (x)	23.0	19.6	17.0
P/BV (x)	2.2	2.0	1.9
Div. Yield (%)	0.9	1.0	1.1
FCF yield (%)	3.9	5.5	6.7

Shareholding pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	32.9	32.9	32.9
DII	16.2	14.0	15.4
FII	18.0	19.4	22.3
Others	32.9	33.8	29.4

FII Includes depository receipts

Steady quarter

Medium-term margin guidance maintained

- Amara Raja's (ARENM) 2QFY26 PAT at INR2.1b came in line with our estimates. Even at the operating level, EBITDA margin was in line with our estimates at 12% (+50bp QoQ).
- We cut our FY26/FY27 EPS estimates by 6%/8.5% to factor in continued margin pressure in 2Q. While the market is optimistic about ARENM's Li-ion initiative, we are cautious about its potential returns. We believe the stock, trading at around 23.0x FY26E/19.6x FY27E EPS, appears fairly valued. We reiterate a Neutral rating with a TP of INR940, based on 15x standalone EPS and Investment in New Energy business valued at INR 131 per share.

2Q earnings in line with estimates

- ARENM's revenue grew 8% YoY to INR33.9b, in line with our estimate. This growth was primarily driven by the new energy business (+68.9% to INR1.7b), while lead acid and allied products posted modest growth (+4.7% to INR33b).
- EBITDA margin expanded 50bp QoQ (-210bp YoY) to 12% and was in line with our estimate. EBITDA declined ~8% YoY to INR4.1b.
- During the guarter, ARENM received a reimbursement in response to claims against a fire accident at its Chittoor facility. This translated into a one-time extraordinary gain of INR1.2b.
- Hence, reported PAT grew 25.4% YoY to INR4.1b. However, adjusted for this gain, PAT declined 12.1% YoY to INR2.1b (in line with our estimate).
- The Board has approved an interim dividend of INR5.4 per equity share for this quarter.
- At a consolidated level, OCF for 1HFY26 came in at INR5.3b, with INR6.4b spent on capex. AMRJ posted a negative free cash of INR1.1b for 1HFY26.
- 1HFY26 Revenue/EBITDA/PAT grew 7.5%/ -9.0%/ -16.4%, respectively, to INR67b/7.9b/4.1b, respectively. For the remainder of FY26, we expect each of these metrics to grow ~11%/8%/-5%, respectively, to INR68b/INR8.1b/INR3.7b.

Highlights from the management commentary

- OEM volumes across both 4W and 2W grew ~30% YoY, supported by strong festive season demand and pre-buying following GST revisions. Management expects growth to normalize to industry levels in subsequent quarters.
- Management reiterated its confidence in sustaining high single-digit growth in the lead-acid business and scaling the new energy business to contribute 7-8% of total revenue by FY27.
- Management guided for further improvement in the coming quarters, as the tubular battery plant ramps up to full capacity in 3Q and the battery recycling facility commences operations in 4QFY26.

10 November 2025 52



- The company aims to restore consolidated EBITDA margins to **13-14%** over time, driven by operational efficiencies, backward integration through recycling, and cost normalization.
- FY26 outlay of INR13b is planned. Of this, about INR6b is likely to be invested in the lead acid battery business (including tubular plant and battery breaking operations) and another INR7b is likely to be invested in the cell manufacturing facility.
- The company is likely to incur capex of INR3.5-4b for its lead acid business in FY27E, and INR10b for its cell manufacturing facility.

Valuation and view

- ARENM's venture into the lithium-ion business is strategically sound, given the opportunities in the segment and risks facing its core business. However, there are notable challenges: 1) market opportunities are limited by existing OEM partnerships; 2) the low-margin nature of the lithium-ion business is likely to dilute returns; and 3) the long-term viability of the technology remains uncertain despite the large capital investment.
- While the market is optimistic about ARENM's Li-ion initiative, we are cautious about its potential returns. We believe the stock, trading at around 23.0x FY26E/19.6x FY27E EPS, appears fairly valued. Therefore, we reiterate a Neutral rating with a TP of INR940, based on 15x standalone EPS and Investment in New Energy business valued at INR 131 per share.

Quarterly Performance- SA										(INR M)		
Y/E March (INR m)		FY2	25			FY2	6E		FY25	FY26E		VAR
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			2QE	(%)
Net Sales	31,312	31,358	31,640	29,739	33,499	33,882	34,488	33,405	1,24,049	1,35,274	33,553	1.0
YoY Change (%)	13.0	11.6	9.8	6.3	7.0	8.0	9.0	12.3	10.2	9.0	7.0	
RM Cost (% of sales)	68.9	67.6	66.9	67.7	70.5	67.2	69.0	68.9	67.8	68.9	69.5	-230bp
Staff Cost (% of sales)	5.9	6.1	6.0	6.1	5.9	6.6	5.8	5.7	6.0	6.0	6.0	60bp
Other Exp (% of sales)	11.5	12.2	13.9	14.7	12.0	14.2	13.2	13.4	13.1	13.2	12.5	170bp
EBITDA	4,304	4,407	4,158	3,422	3,867	4,059	4,139	4,033	16,291	16,098	4,026	0.8
Margins (%)	13.7	14.1	13.1	11.5	11.5	12.0	12.0	12.1	13.1	11.9	12.0	0bp
Depreciation	1,183	1,220	1,233	1,284	1,292	1,380	1,390	1,399	4,921	5,461	1,298	6.3
Interest	90	131	107	95	104	83	115	149	422	450	110	-24.9
Other Income	256	185	293	200	139	241	180	139	933	700	135	78.4
PBT before EO expense	3,287	3,240	3,111	2,244	2,610	2,838	2,814	2,625	11,881	10,886	2,753	3.1
Extra-Ord expense	0	0	-1,111	0	0	-1,218	0	0	-1,111	-1,218	0	
PBT after EO	3,287	3,240	4,222	2,244	2,610	4,056	2,814	2,625	12,992	12,104	2,753	47.3
Tax	841	833	1,103	576	670	1,032	715	1,009	3,353	3,425	688	
Tax Rate (%)	25.6	25.7	26.1	25.7	25.7	25.4	25.4	38.5	25.8	28.3	25.0	
Adj PAT	2,446	2,407	2,298	1,668	1,940	2,116	2,099	1,615	8,815	7,805	2,065	2.5
YoY Change (%)	23.1	6.3	-9.1	-26.8	-20.7	-12.1	-8.7	-3.2	-2.7	-11.5	-14.2	

E: MOFSL Estimates

Buy



JK Lakshmi Cement

Estimate change	
TP change	()
Rating change	—
•	

Bloomberg	JKLC IN
Equity Shares (m)	124
M.Cap.(INRb)/(USDb)	104.9 / 1.2
52-Week Range (INR)	1021 / 661
1, 6, 12 Rel. Per (%)	-2/4/4
12M Avg Val (INR M)	168

Financial Snapshot (INR b)

Y/E Mar	FY26E	FY27E	FY28E
Sales	69.3	75.7	83.3
EBITDA	11.3	13.4	15.0
Adj. PAT	5.1	6.3	6.4
EBITDA Margin (%)	16.3	17.7	18.0
Adj. EPS (INR)	41.3	51.0	51.3
EPS Gr. (%)	70.7	23.3	0.6
BV/Sh. (INR)	315	360	405
Ratios			
Net D:E	0.5	0.6	0.5
RoE (%)	13.9	15.1	13.4
RoCE (%)	10.4	10.7	9.8
Payout (%)	15.2	13.2	14.3
Valuations			
P/E (x)	20.4	16.6	16.5
P/BV (x)	2.7	2.3	2.1
EV/EBITDA(x)	10.3	9.1	8.4
EV/ton (USD)	77	71	65
Div. Yield (%)	0.7	0.7	0.7
FCF Yield (%)	-0.2	-2.0	2.8

Shareholding pattern (%)

As of	Sep-25	Jun-25	Sep-24
Promoter	45.1	46.3	46.3
DII	22.8	25.1	25.0
FII	12.6	12.8	11.5
Others	19.5	15.7	17.2

FII Includes depository receipts

CMP: INR845 TP: INR1,100 (+30%)

Operating performance in line; Durg expansion on track

FY30 capacity target of 30mtpa maintained

- JK Lakshmi Cement (JKLC)'s 2QFY26 EBITDA was in line with our estimates at INR2.1b (+133% YoY, albeit on a low base) as the benefit of better realization was offset by higher-than-estimated opex/t. EBITDA/t increased 103% YoY to INR733 (in line). It reported PAT of INR809m (+22% vs. estimate, led by higher other income and lower ETR) vs. a loss of INR307m in 2QFY25.
- Management indicated that demand in Oct'25 was muted due to unseasonal rains and the festival effect; however, demand is likely to recover from mid-Nov'25. JKLC outperformed industry growth in 1HFY26. JKLC believes that the company will sustain above-industry growth in 2H as well. The company placed main plant and machinery orders for Durg expansion and expects commissioning of clinker capacity (2.3mtpa) by Mar'27 and grinding capacities (4.6mtpa) during FY27-28, in a phased manner. Post-Durg expansion, the company's capacity will increase to 22.6mtpa.
- We broadly retain our earnings estimates for FY26-28. The stock is trading at 9x/8x FY27E/FY28E EV/EBITDA. We value the stock at 11x Sep'27E EV/EBITDA to arrive at our TP of INR1,100. Reiterate BUY.

Sales volume up 15% YoY; realization/t improves 8% YoY

- Consolidated revenue/EBITDA/adj. PAT stood at INR15.3b/INR2.1b (up 24%/133% YoY and up ~9%/in line). Net profit stood at INR809m vs. a loss of INR307m in 2QFY25. Sales volume increased 15% YoY to 2.8mt. Realization/t was up 8%/3% YoY/QoQ at INR5,388/t (~5% above estimate).
- Opex/t rose 1% YoY (~5% above est.), led by a ~9% YoY rise in freight cost/t. Variable cost/other expenses per ton dipped ~2%/5% YoY. OPM surged 6.4pp YoY to ~14%; EBITDA/t rose ~103% YoY to INR733 in 2Q. Depreciation/finance costs rose ~4%/13% YoY. Other income was up ~130% YoY.
- In 1HFY26, revenue/EBITDA/Adj. PAT stood at INR32.7b/INR5.2b/INR2.3b (up ~17%/67%/275% YoY). OPM increased 4.7pp YoY to ~16%. Realization/t stood at INR5,305 (up ~4% YoY), while EBITDA/t stood at INR842 (up ~49% YoY). OCF stood at INR352m vs. INR52m in 1HFY25. Capex stood at INR252m vs. INR440m. Net cash inflow stood at INR99m vs. net cash outflow at INR388m in 1HFY25.

Highlights from the management commentary

- JKLC's sales mix toward the North and West markets improved, which led to higher realizations. Lead distance reduced to 395km from 399km in 1QFY26. Blended cement share was ~62% vs. ~66%/63% in 2QFY25/1QFY26.
- Premium product share was at ~26% of trade volume vs. ~23% in 1QFY26. Trade sales stood at ~53% vs. ~53%/56% in 2QFY25/1QFY26.
- The company acknowledged that the INR1,000/ton full-year target remains aspirational given the current competitive environment, though efforts continue to narrow the gap with regional peers.



Valuation and view

- JKLC's 2QFY26 operating performance was in line. It has posted robust volume growth of ~15% YoY, albeit on a low base. It remains confident of sustaining volume growth above industry levels, supported by entering into newer markets where it is also adding capacity in the next one to two years. Further, the company's realization improved QoQ, led by a better geo-mix, an increase in premium share, and higher non-cement revenue.
- We estimate a CAGR of ~10%/20%/31% in revenue/EBITDA/PAT over FY25-28 and project an EBITDA/t of INR864/INR954/INR987 in FY26E/FY27E/FY28E vs. INR718 in FY26. We further estimate its net debt will rise to INR26.4b by FY28 from INR14.2b as of Sep'25 due to the higher capex plan. The net debt-to-EBITDA ratio is estimated at 1.8x by FY28E vs 1.3x currently. The stock is trading at 9x/8x FY27E/FY28E EV/EBITDA. We value JKLC at 11x Sep'27E EV/EBITDA to arrive at our TP of INR1,100. **Reiterate BUY.**

Quarterly performance (consol	idated)										(11	NR b)
Y/E March		FY25				FY26				FY26E	FY26	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	(%)
Sales Volumes (mt)	3.02	2.48	3.03	3.60	3.33	2.84	3.18	3.76	12.13	13.11	2.73	4
YoY Change (%)	(0.4)	(9.3)	2.4	10.3	10.0	14.8	5.1	4.6	1.2	8.1	10.1	
Net Sales	15.6	12.3	15.0	19.0	17.4	15.3	16.7	19.9	61.9	69.3	14.1	9
YoY Change (%)	(9.6)	(21.6)	(12.1)	6.6	11.3	24.1	11.8	4.7	(8.8)	12.0	13.9	
EBITDA	2.2	0.9	2.0	3.5	3.1	2.1	2.5	3.6	8.6	11.3	2.0	4
YoY Change (%)	13.3	(58.9)	(33.2)	4.4	39.9	133.3	26.3	2.3	(17.8)	31.1	124.8	
Margin (%)	14.2	7.2	13.5	18.5	17.9	13.6	15.2	18.1	14.0	16.3	14.3	(68)
Depreciation	0.7	0.7	0.8	0.8	0.8	0.8	0.8	0.8	3.0	3.1	0.8	2
Interest	0.5	0.4	0.5	0.4	0.5	0.5	0.5	0.5	1.8	2.1	0.5	(1)
Other Income	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.2	0.5	0.9	0.1	84
PBT before EO expense	1.2	(0.2)	0.9	2.5	2.0	1.0	1.5	2.5	4.3	7.0	0.9	20
Extra-Ord. expense	0.4	-	-	-	-	-	-	-	0.4	-	-	
PBT	0.8	(0.2)	0.9	2.5	2.0	1.0	1.5	2.5	3.9	7.0	0.9	20
Tax	0.3	0.0	0.3	0.8	0.5	0.2	0.4	0.7	1.3	1.9	0.2	
Prior period tax adj.	-	-	-	-	-	-	-	-	-	-	-	
Rate (%)	32.3	(10.6)	29.7	31.7	26.5	21.5	26.5	28.5	33.6	26.5	22.5	
Reported PAT	0.5	(0.2)	0.6	1.7	1.5	0.8	1.1	1.8	2.6	5.1	0.7	21
Minority Interest	(0.0)	0.1	0.0	(0.1)	(0.0)	(0.0)	0.0	0.0	0.0	0.0	0.0	
Adj. PAT	0.9	(0.3)	0.6	1.8	1.5	0.8	1.1	1.8	3.0	5.1	0.7	22
YoY Change (%)	17.7	(133.1)	NA	11.9	62.6	NM	79.6	(0.2)	(36.3)	72.9	NM	
Per ton analysis (INR)												
Net realization	5,172	4,983	4,940	5,274	5,234	5,388	5,258	5,282	5,106	5,287	5,154	5
RM Cost	1,274	987	907	971	922	942	1,000	1,080	1,018	991	960	(2)
Employee Expenses	335	444	377	316	374	457	424	273	362	375	437	5
Power, Oil, and Fuel	1,132	1,295	1,157	1,086	1,137	1,295	1,150	1,064	1,158	1,154	1,110	17
Freight and Handling Outward	1,042	1,137	1,147	1,222	1,194	1,235	1,185	1,178	1,155	1,196	1,159	7
Other Expenses	653	759	686	703	672	725	698	732	699	707	752	(4)
Total Expenses	4,436	4,623	4,274	4,298	4,299	4,655	4,458	4,327	4,393	4,423	4,419	5
EBITDA	735	360	666	976	936	733	800	955	713	864	736	(0)

Source: Company, MOFSL





Estimate changes TP change Rating change

Bloomberg	HAPPYFOR IN
Equity Shares (m)	94
M.Cap.(INRb)/(USDb)	96 / 1.1
52-Week Range (INR)	1185 / 716
1, 6, 12 Rel. Per (%)	6/24/-16
12M Avg Val (INR m)	51

Consol. Financials & Valuations (INR b)

		(/
Y/E March	FY26E	FY27E	FY28E
Sales	15.2	17.9	22.3
EBITDA	4.4	5.4	7.0
Adj. PAT	2.8	3.5	4.8
EPS (INR)	30.1	37.5	51.4
EPS growth %	5.9	24.9	36.9
BV/Sh. (INR)	222	254	297
Ratios			
RoE (%)	14.4	15.8	18.7
RoCE (%)	13.2	14.5	17.2
Payout (%)	13.3	16.0	16.5
Valuations			
P/E (x)	33.7	27.0	19.7
P/BV (x)	4.6	4.0	3.4
EV/EBITDA (x)	21.2	17.7	13.6
Div. Yield (%)	0.4	0.6	0.8

Shareholding Pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	78.5	78.5	78.6
DII	17.0	17.0	17.1
FII	2.0	2.2	2.3
Others	2.5	2.3	2.0

Happy Forgings

CMP: INR1,018 TP: INR1,200 (+18%)

Buy

Record high margins despite weak export demand

Demand across key segments likely to revive from here

- Happy Forgings' (HFL) 2QFY26 PAT at INR734m was largely in line with our estimate. The key highlight of 2Q was its record high margins at 30.7% (+150bp YoY) in a weak demand environment, especially in exports.
- HFL's superior financial track record compared to its peers serves as a testament to its inherent operational efficiencies and is likely to be a key competitive advantage going forward. Given this, we expect HFL to continue to outperform core industry growth. Overall, we expect HFL to post a CAGR of 17%/20%/22% in standalone revenue/EBITDA/PAT during FY25-28E. We reiterate our BUY rating on the stock with a TP of INR1,200 (based on 27x Sep'27E EPS).

Margins improve sequentially despite global headwinds

- HFL's revenue was INR3.8b in 2QFY26, up 4.5% YoY, and was largely in line.
- Revenue growth was driven by 5.2% volume growth, while realizations remained largely stable YoY at INR251 per kg.
- Revenue growth was driven by healthy demand across domestic (CVs, tractors, PVs, and non-auto) segments, while exports remained muted due to weak end-market conditions and customer de-stocking amid the evolving tariff situation.
- Despite the adverse global macro, EBITDA margins expanded 150bp YoY to a record high level of 30.7%, ahead of our estimates of 28.8%.
- EBITDA came in at INR1.1b, up 10% YoY and 6% ahead of our estimates on the back of improved gross margins (+150bp YoY).
- However, lower other income at INR63m (INR83m in 2QFY25 and INR104m in Q1FY26) limited PAT growth.
- PAT stood at INR734m, up 10.2% YoY, and was broadly in line.
- HFL's 1HFY26 CFO stood at INR2.2b, while capex was INR2.1b. Cash surplus at the end of Sep'25 stood at INR3.15b.

Key highlights from the management commentary

- Revenue growth is expected to come from the execution of new orders in PV, off-highway (large axle for German OEMs), new lines for wind and heavy tractor, and the industrial business over the medium term. GST rate cuts are likely to further support growth in the domestic markets. Thus, FY27 revenue growth is likely to be much better than the current fiscal.
- With its focus on diversification, they expect the mix for CV + farm to come down to about 50% over the next few years, and the balance to be contributed by Industrial + Off-highway + PV + Others.
- CV business is likely to improve in the coming quarters led by a pick-up in domestic demand and revival of volumes from a key exports OEM.



- While the 2H outlook for the US/European tractor industry remains subdued with an anticipated uncertainty for FY27, the momentum in the off-highway segment is expected to improve in FY27 with new programs ramping up.
- For the new INR6.5b capex for heavy forgings, the company has already garnered orders worth INR3.5b.
- In the US, demand for components in the 50% tariff bracket has sharply reduced, and management is hopeful of a downward revision for this tariff in the coming quarters.

Valuation and view

- HFL is expected to outperform the industry on the back of its healthy order backlog. A recovery in domestic CV demand, a healthy tractor outlook, and strong order wins in Industrials and PVs should help to offset the weakness in export markets in the near term.
- HFL's superior financial track record compared to its peers serves as a testament to its inherent operational efficiencies and is likely to be a key competitive advantage going forward. Given this, we expect HFL to continue to outperform core industry growth. Overall, we expect HFL to post a CAGR of 17%/20%/22% in standalone revenue/EBITDA/PAT during FY25-28E. We reiterate our BUY rating on the stock with a TP of INR1,200 (based on 27x Sep'27E EPS).

Quarterly (Standalone)												(INR m)
		FY2	25			FY2	6E		FY25	FY26	2QE	Var
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE				(%)
Net operating income	3,415	3,611	3,543	3,520	3,538	3,774	3,827	4,018	14,089	15,157	3,792	-0.5
Change (%)	3.5	5.3	3.6	2.5	3.6	4.5	8.0	14.2	3.7	7.6	5.0	
RM/Sales (%)	43.5	41.2	42.0	41.3	42.1	39.7	41.8	42.4	42.0	41.5	42.0	
Staff Cost (%)	8.5	8.5	9.3	9.2	9.1	8.9	8.8	8.8	8.9	8.9	9.0	
Other Exp. (%)	19.4	21.2	20.1	20.4	20.3	20.7	20.6	19.7	20.3	20.3	20.2	
EBITDA	976	1,054	1,015	1,023	1,012	1,158	1,102	1,170	4,067	4,442	1,092	6.0
EBITDA Margins (%)	28.6	29.2	28.6	29.1	28.6	30.7	28.8	29.1	28.9	29.3	28.8	
Non-Operating Income	77	83	66	101	104	63	75	87	376	329	108	
Interest	14	16	21	24	23	19	18	18	75	78	22	
Depreciation	180	197	191	203	206	216	228	236	771	885	220	
EO Exp		-48			0	0	0	0		0	0	
PBT after EO items	859	973	868	897	886	986	931	1,004	3,597	3,807	958	
Tax	220	259	223	219	230	252	239	254	921	975	240	
Eff. Tax Rate (%)	25.6	26.6	25.7	24.4	25.9	25.5	25.7	25.3	25.6	25.6	25.0	
Rep. PAT	639	714	645	678	657	734	692	750	2,676	2,833	719	
Change (%)	-0.3	29.3	11.4	3.0	2.9	2.8	7.2	10.6	-68.1	5.9	0.6	
Adj. PAT	639	666	645	678	657	734	692	750	2,676	2,833	719	2.2
Change (%)	-0.3	20.6	11.4	3.0	2.9	10.2	7.2	10.6	10.1	5.9	7.8	

E: MOFSL Estimates





Indigo Paints

Estimate change TP change Rating change

Bloomberg	INDIGOPN IN
Equity Shares (m)	48
M.Cap.(INRb)/(USDb)	48 / 0.5
52-Week Range (INR)	1649 / 900
1, 6, 12 Rel. Per (%)	-6/-2/-43
12M Avg Val (INR M)	97

Financials & Valuations (INR b)

Y/E March	2026E	2027E	2028E
Sales	14.3	16.1	18.1
Sales Gr. (%)	6.5	12.5	12.5
EBITDA	2.6	3.0	3.4
EBIT Margin (%)	18.1	18.6	18.8
Adj. PAT	1.6	1.8	2.1
Adj. EPS (INR)	33.2	38.5	44.5
EPS Gr. (%)	11.4	16.0	15.5
BV/Sh.(INR)	241.9	280.5	320.2
Ratios			
RoE (%)	14.5	14.7	14.8
RoCE (%)	14.2	14.6	14.6
Valuation			
P/E (x)	30.2	26.0	22.5
P/BV (x)	4.1	3.6	3.1
EV/EBITDA (x)	17.1	14.4	12.2

Shareholding pattern (%)

6 harren (1.1)						
As On	Sep-25	Jun-25	Sep-24			
Promoter	53.9	53.9	53.9			
DII	19.7	19.3	16.1			
FII	11.8	11.7	12.3			
Others	14.6	15.1	17.6			

FII Includes depository receipts

CMP: INR1,007 TP: INR1,400 (+39%) Bu Recovery momentum building up; positive outlook for 2H

- Indigo Paints (INDIGOPN) reported standalone sales growth of 3% YoY in 2QFY26 as demand was impacted by extended monsoon. Management highlighted that Jul witnessed healthy offtake, Aug was soft, and Sep saw a recovery, with strong secondary sales and dealer inflows. Oct continued to see healthy traction, and the company expects double-digit growth in 2HFY26, aided by a pickup in demand momentum. Apple Chemie (subsidiary) sales grew 23% YoY. Consolidated sales rose 4% YoY to INR3.1b (est. INR3.0).
- Gross margin expanded 110bp YoY to 44.8% (est. 44.5%), led by favorable raw material prices and an improved product mix. EBITDA margin expanded 110bp YoY to 14.9% (above).
- INDIGOPN continues to focus on the premium and emulsion segments, with a deliberate shift away from the economy segment. It has consciously decided to not enter the low-margin general industrial segment, despite competitors pursuing it to boost revenue growth, as it affects margins and profitability. We model a CAGR of 13%/15% in revenue/EBITDA in FY26-28E. We model EBITDA margin of 18.1% for FY26 and 18.6% for FY27.
- We reiterate our BUY rating with a TP of INR1,400 (based on 35x Sep'27E EPS), considering its growth outperformance, synergies with Apple Chemie, consistent capacity and distribution expansion, and its favorable valuation multiples vs. peers.

Demand shows improvement; beat on operating performance Consolidated performance

- Mid-single-digit sales growth: Net sales grew by 4% YoY to INR3,121m (est. INR3,025m). Standalone revenue grew 3% YoY to INR2,985m. Apple Chemie revenue grew 23% YoY to INR136m.
- Premium outpace economy segment: Putty & cement paint's value and volume declined 2% and 7%, respectively. Emulsions reported 4% volume growth and 7% value growth. Enamel and wood coatings' volume/value grew 3%/6% YoY. Primers and distempers posted volume growth of 10% and value growth of 10%.
- **Expansion in margins:** Gross margin expanded 110bp YoY to 44.8% (est. 44.5%), led by a better product mix. Employee expenses were up 5% YoY, while other expenses were up 4% YoY. EBITDA margin expanded 110bp YoY to 14.9% (est. 14.2%).
- **Double-digit growth in profitability:** EBITDA rose 12% YoY to INR465m (est. INR430m). PBT increased by 11% YoY to INR338m (est. INR322m). APAT grew 11% YoY to INR251m (est. INR240m).



Highlights from the management commentary

- Industry demand has improved after nearly six months of softness, despite continued weather-related disruptions from the extended monsoon. Jul saw healthy offtake, Aug was weak, and Sep showed a recovery trend.
- The company highlighted that larger competitors have not significantly impacted the company's performance over the last two years. Despite unprecedented trade discounts offered by peers, the industry largely refrained from matching them, thereby preserving margins.
- For Apple Chemie, Maharashtra remains the key revenue contributor, while sales traction is strengthening in the Eastern and Southern regions.
- The Jodhpur water-based plant (90,000 KLPA capacity) is in the final stages of construction and is expected to be commissioned in 4QFY26.

Valuation and view

- We raise our EPS estimates by 5-6% for FY26 and FY27 on demand recovery and margin beat, led by an improving product mix.
- INDIGOPN's strategic shift to focusing on non-metro towns and increased investments in distribution and influencers as part of its Strategy 2.0 are proving to be a successful endeavor. That said, the company continues to focus on the premium and emulsion segments, with a deliberate shift away from the economy segment.
- Given the relatively small scale of INDIGOPN (INR13b revenue in FY25) in the paint industry, the company has been able to grow much faster than the industry. Consumers' rising acceptance of the brand and the expansion of its distribution network have been driving its outperformance. However, the changing competitive landscape will be a key monitorable. We reiterate our BUY rating with a revised TP of INR1,400 (premised on 35x Sep'27E EPS).

Consolidated Quarterly Perf	ormance										(INR m)
Y/E March		FY2	25			FY2	6E		FY25	FY26E	FY26E	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE	_		2QE	(%)
Net Sales	3,110	2,995	3,426	3,876	3,089	3,121	3,735	4,334	13,407	14,278	3,025	3.1%
Change (%)	7.8	7.4	-3.2	0.7	-0.7	4.2	9.0	11.8	2.6	6.5	1.0	
Raw Material/PM	1,661	1,686	1,829	2,061	1,671	1,723	1,979	2,294	7,237	7,667	1,679	
Gross Profit	1,449	1,309	1,597	1,815	1,418	1,397	1,755	2,041	6,170	6,611	1,346	3.8%
Gross Margin (%)	46.6	43.7	46.6	46.8	45.9	44.8	47.0	47.1	46.0	46.3	44.5	
EBITDA	474	415	572	874	443	465	661	1,012	2,335	2,582	430	8.3%
Margin (%)	15.2	13.9	16.7	22.6	14.3	14.9	17.7	23.4	17.4	18.1	14.2	
Change (%)	-3.5	-1.5	-8.1	3.3	-6.5	12.1	15.6	15.8	-1.9	10.6	3.5	
Interest	6	7	6	15	7	7	10	16	35	40	18	
Depreciation	152	154	147	132	148	151	160	167	585	626	145	
Other Income	42	51	31	60	60	30	45	66	185	200	55	
PBT	357	306	450	787	348	338	536	895	1,900	2,116	322	5.0%
Tax	90	83	92	213	87	85	135	225	478	532	81	
Effective Tax Rate (%)	25.3	27.2	20.4	27.0	25.0	25.2	25.2	25.2	25.2	25.2	25.2	
Minority Interest	5	-4	-2	5	1	1	1	0	4	4	1	
Adjusted PAT	262	226	360	569	259	251	400	669	1,418	1,580	240	4.8%
Change (%)	-15.6	-10.6	-3.3	6.0	-1.0	10.9	11.0	17.6	-3.8	11.4	5.8	

E: MOFSL Estimates





Go Fashion (India)

Estimate change	I .
TP change	I I
Rating change	←→
Bloomberg	GOCOLORS IN
Equity Shares (m)	54
M.Cap.(INRb)/(USDb)	33.8 / 0.4
E2 Maal: Damas (IND)	1252 / 624

54
33.8 / 0.4
1252 / 624
-11/-32/-53
86

Financials & Valuation	s Consol (INR b)
------------------------	-----------------	---

Y/E March	FY26E	FY27E	FY28E
Sales	8.9	10.2	11.5
EBITDA	2.7	3.2	3.6
Adj. PAT	0.9	1.2	1.4
EBITDA Margin (%)	30.6	31.2	31.0
Adj. EPS (INR)	16.6	21.8	25.9
EPS Gr. (%)	(4.0)	31.4	18.9
BV/Sh. (INR)	142.2	159.6	180.4
Ratios			
Net D:E	(0.5)	(0.6)	(0.6)
RoE (%)	11.0	12.8	13.6
RoCE (%)	17.7	20.1	21.6
Payout (%)	20.0	20.0	20.0
Valuations			
P/E (x)			
EV/EBITDA (x)	37.7	28.7	24.1
EV/Sales (X)	21.6	17.6	14.8
Div. Yield (%)	3.4	2.9	2.5

Shareholding pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	52.8	52.8	52.8
DII	35.0	34.6	32.8
FII	8.6	9.7	11.8
Others	3.6	3.0	2.6

FII Includes depository receipts

CMP: INR626 TP: INR750 (+20%) BUY Weak SSSG dents 2Q performance, valuations attractive

Go Fashion reported yet another muted quarter with revenue growth of 7%. A strong pickup in LFS (up 18% YoY) was offset by persistent weakness in same-store sales (-4%).

- Margin pressure persisted as pre-Ind AS EBITDA margin fell ~130bp YoY to 14.3%. EBITDA declined 1% YoY to INR320m due to negative operating leverage
- Overall, FY26 had a weak start, with 1H revenue/EBITDA/PAT performance standing at +4%/flat/-10%. We bake in 6%/4%/4% growth in 2H.
- We cut our FY25-28 revenue/EBITDA estimates by ~4% to reflect weakness in SSSG and calibrated store expansion. We expect 11%/10%/14% CAGR in revenue/EBITDA/PAT over FY25-28E.
- Valuations remain reasonable at ~32x 1-year forward earnings, though a sustainable turnaround in SSSG is key to re-rating. We maintain our BUY rating with a TP of INR750, based on 30x Dec'27E EPS.

Weak SSSG leads to negative operating leverage; In line with estimates

- Revenue was up 7% YoY at INR2.2b (in line with estimate) as strong growth in LFS was offset by the underperformance in EBO stores (-3.6% SSSG).
- EBO revenue grew by a modest 4% YoY to INR1.b, impacted by a 3.6% decline in SSSG.
 - ➤ Go Colors added 9 net new stores in 2Q (14 additions and 5 closures), and 36 net new stores in 1HFY26.
 - Management has trimmed the net store addition outlook to 80-90 (from 120-130 gross with limited closures earlier).
 - ➤ Growth was impacted by SSSG decline of 3.6% in 2Q (down 2.4% in 1HFY26).
- LFS revenue recovered strongly with 18% YoY growth, led by ~80 new store additions during the quarter (~300 in 1HFY26). Ecommerce channel declined 4% YoY.
- Gross profit at INR1.4b was up 7% YoY and margins contracted ~45bp to 62.6%.
- Due to negative operating leverage, pre-IND AS EBITDA declined by 1% YoY, with margins at 14.3% (down 125bp YoY).
 - Reported EBITDA at INRO.7b was up 5% YoY, with margins at 29.7% (down 70bp).
- Higher other income drove PAT growth of 6% YoY to INR218m.
- Core working capital increased to 135 days, led by a jump in receivables (up by 12 days to 52 days), while inventory largely remained stable at 97 days.
- Cash flow from operations (adj. for leases) declined to INR272m (vs. INR551m in 1HFY25), impacted by muted profitability and higher working capital requirements. After incurring a capex of INR196m, FCFF stood at INR76m (vs. INR318m YoY).



Highlights from the management commentary

- **Demand trends:** Demand is recovering, driven by strong festive sales in markets like Tamil Nadu and Maharashtra, though post-Diwali softness persists. West and North are improving and South is still lagging. Management is betting on refreshed designs and new launches to revive growth.
- Expansion strategy: FY26 store guidance is trimmed to 80-90 net store additions (vs. 120 gross) to safeguard margins during weak SSSG, with expansion to pick up only after demand stabilizes.
- Essential-wear pilot in two Chennai stores is getting good response with INR1,000 SPSF/month from the added space, exceeding internal benchmarks. These are extensions of existing stores, and the company plans to scale up the pilot to 18-20 locations to assess long-term potential.
- **Promoter pledges** rose due to the stock price correction but are set to reduce by more than 50% soon, with around 2.5m to 3.0m shares likely to be depledged in the next few months.

Valuation and view

- Go Fashion is poised to scale up its leadership in women's bottom wear through a strong D2C model and continued expansion into new cities, with ~14 stores added in 1HFY26 and a focus on Tier 2 and Tier 3 markets via additional EBOs.
- Management is tackling muted SSSG through fresh product launches in 2H.
 Strong festive-led volume recovery drives confidence in a sustainable rebound ahead.
- While pilot initiatives like essential wear and international expansion are gaining traction, management remains firmly focused on reviving core bottom-wear growth.
- We cut our FY25-28 revenue/EBITDA estimates by ~4% to reflect weakness in SSSG and calibrated store expansion. We expect a CAGR of 11%/10%/14% in revenue/EBITDA/PAT over FY25-28E.
- Valuations remain reasonable at ~32x 1-year forward earnings, though a sustainable turnaround in SSSG is key to re-rating. We maintain our BUY rating with a TP of INR750, based on 30x Dec'27E EPS.



Y/E March		FY	25			FY2	26E		FY25	FY26E	FY26	Var (%)
7	1Q	2Q	3Q	4Q	1QE	2QE	3QE	4QE	-		2QE	Est
Revenue	2,201	2,085	2,147	2,048	2,228	2,242	2,330	2,132	8,482	8,927	2,224	0.8
YoY Change (%)	16	10	6	13	1	7	9	4	11	5	15	
Gross margins (%)	61.8	63.1	64.1	64.3	63.0	62.6	62.9	65.1	63.3	63.4	63	
Change in bps (YoY)	44	240	264	75	119	-46	-122	86	156	11		
Total Expenditure	1,480	1,450	1,449	1,424	1,541	1,575	1,601	1,482	5,802	6,195	1,561	0.9
EBITDA	721	635	698	624	687	666	729	651	2,680	2,732	663	0.5
Change YoY (%)	12	12	3	16	-5	5	4	4	11	2	5	
EBITDA margins (%)	32.8	30.4	32.5	30.5	30.8	29.7	31.3	30.5	31.6	30.6	30	
Change in bps (YoY)	-100	47	-91	82	-194	-71	-121	3	-19	-99		
Depreciation	295	311	317	314	323	328	329	320	1,237	1,300	333	-1.5
Interest	110	115	116	122	120	122	127	128	464	497	139	-12.7
Other Income	58	71	58	66	52	73	68	68	254	262	57	27.6
PBT before EO expense	374	281	323	254	297	290	341	271	1,233	1,198	248	16.7
Extra-Ord expense	0	0	0	0	0	0	0	0	0	0	0	
PBT	374	281	323	254	297	290	341	271	1,233	1,198	248	16.7
Tax	88	76	79	55	74	72	86	68	298	300	63	15.1
Rate (%)	23.5	26.9	24.6	21.8	25.0	24.8	25.2	25.2	24.2	25.1	25.2	-1.4
Reported PAT	287	205	243	199	223	218	255	203	935	898	186	17.3
Adj PAT	287	205	243	199	223	218	255	203	935	898	186	17.3
YoY Change (%)	9	2	4	52	-22	6	5	2	13	-4		

Quarterly performance (INR m)

Consol P&L (INR m)	2QFY25	1QFY26	2QFY26	YoY%	QoQ%	2QFY26E	v/s Est (%)
Total Revenue	2,085	2,228	2,242	7	1	2,224	1
Raw Material cost	770	825	839	9	2	829	1
Gross Profit	1,315	1,403	1,403	7	0	1,396	1
Gross margin (%)	63.1	63.0	62.6	-46bps	-38bps	62.8	-16bps
Employee Costs	405	442	457	13	3	449	2
Other expenses	275	274	280	2	2	284	-1
Total Opex	680	716	737	8	3	732	1
EBITDA	635	687	666	5	-3	663	0
EBITDA margin (%)	30.4	30.8	29.7	-71bps	-111bps	29.8	-10bps
Depreciation and amortization	311	323	328	6	2	333	-2
EBIT	324	364	339	4	-7	330	2
EBIT margin (%)	15.5	16.4	15.1	-44bps	-125bps	14.9	25bps
Finance Costs	115	120	122	6	1	139	-13
Other income	71	52	73	3	40	57	28
Profit before Tax	281	297	290	3	-2	248	17
Tax	76	74	72	-5	-3	63	15
Tax rate (%)	26.9	25.0	24.8	-212bps	-20bps	25.2	-1bps
Profit after Tax	205	223	218	6	-2	186	17

Key Performance Indicators

Y/E March		FY2	5			FY2	6E	
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Total Stores	734	755	775	776	803	812	835	856
Additions	23	31	30	20	31	14	23	21
Closures	(3)	(10)	(10)	(19)	(4)	(5)	-	-
Net Additions	20	21	20	1	27	9	23	21
EBO	1,527	1,479	1,589	1,415	1,573	1,540	1,652	1,490
LFS	563	511	460	512	490	601	544	500
Online	70	60	60	55	76	58	62	58
Others	42	35	39	63	87	43	77	77
Total	2,203	2,085	2,147	2,046	2,226	2,242	2,335	2,124
Gross Margins (%)	61.8	63.1	64.1	64.3	63.0	62.6	62.9	65.1
EBITDA Margins (%)	32.8	30.4	32.5	30.5	30.8	29.7	31.3	30.5
PAT Margins (%)	13.0	9.8	11.3	9.7	10.0	9.7	11.0	9.5

Source: MOFSL, Company





The Economy Observer

Rural rules, urban follows

We had an opportunity to meet more than 40 investors in the last one month. The key area of interest among investors was the consumption trends in the rural and urban markets after the implementation of GST 2.0. We have composed a proprietary monthly rural and urban consumption tracker to simplify the analysis for our readers.

<u>Key Takeaway:</u> We observed that rural consumption continues to outperform urban consumption despite the income tax cuts and GST 2.0 reforms, which are aimed at boosting urban consumption. Undoubtedly, urban consumption has recovered since 22nd Sep'25 and also from 3QFY25; but rural consumption outshines because of income guarantee schemes, better rainfall outcomes, NBFC-led credit growth, easing input costs and steady MSPs.

The October high frequency data is overall positive consumption which is the first full month of GST implementation. Indicators like E-way bills, petrol consumption, mall footfalls, PMI manufacturing/services are strong.

- Our rural demand tracker shows that rural consumption has been on a steady uptrend since 2HFY25, strengthening further in 2QFY26 (up 7.7% YoY) to its highest level in 17 quarters.
- The upturn was supported by firm growth in real agri and non-agri wages, higher tractor and fertilizer sales, and robust farm credit. Better rainfall distribution and reservoir levels boosted sowing activity, while easing input costs and steady MSP procurement helped improve farm incomes.
- The urban demand tracker shows that spending remained subdued in 2QFY26, ahead of the festive season, with several high-frequency indicators showing softer momentum after a stable 1Q. Personal credit growth, petrol demand, and non-farm imports remained firm in 2QFY26, reflecting resilience in day-to-day discretionary spending, though passenger traffic stayed flat.
- Urban consumption in 3QFY26 is expected to pick up with the GST 2.0 implementation and passthrough of price cuts.
 Indicators released so far and our channel checks on retail side reflect positive turnaround on urban consumption. However, we also note sector wise variations.
- As per our consumer analyst' channel check, auto and jewelry sector have performed well; footwear, paints, FMCG and textile sector pickup has been mixed. In the FMCG segment, general trade (GT) feedback has been that demand has not seen much improvement in Oct either, with limited traction in festive-driven products. We do concur that any meaningful growth in alternate channels can create growth divergence for FMCG companies.
- Outlook: As the current wave of pent-up demand subsides with the end of the festive season, the key question is whether this momentum can be sustained into 2HFY26. Our view is that:
- Rural demand is expected to remain on a steady upward trajectory, underpinned by rising real wages (both agri and non-agri). Healthy rabi prospects, coupled with lower rural inflation, should help to sustain the ongoing improvement in consumption.
- Urban consumption remained weak through 2QFY26 but started improving toward late Sep'25, led by a strong rebound in jewelry demand, which stayed firm through Oct'25 despite high gold prices. In contrast, paints and FMCG categories remained soft, impacted by extended monsoons, pricing transitions under GST 2.0, and muted festive traction. With discretionary categories like jewelry gaining momentum and supply disruptions easing, we expect urban spending to revive in 3QFY26.
- Our base case for real GDP growth stands at 6.8% for FY26, with an upside potential (~20-30bp) if tariff-related uncertainties abate. Our nominal GDP growth is projected at 9% for FY26, tempered by a weaker deflator, reflecting subdued price pressures across key sectors.





8 November 2025 Results Flash | Sector: Oil & Gas

Petronet LNG

BSE SENSEX S&P CNX 83,216 25,492

CMP: INR279 Buy

Conference Call Details



Date: 10 November 2025
Time: 11:00 am IST
Dial-in details:
+91 22 7195 0000

UoP provisioning and waiver weigh on 2Q performance

- PLNG's 2QFY26 revenue was in line with our estimate at INR110b.
- EBITDA fell 7% YoY to INR11.2b (4% below our estimate).
- The company booked additional provisions of INR1.3b against UoP dues during the quarter. UoP trade receivables of INR289m were waived off during 2Q. EBITDA adjusted for UoP provisioning and waiver stood 10% above our estimate.
- Reported PAT was in line with our estimate at INR8.1b, down 5% YoY, supported by higher-than-expected other income.
- PAT adjusted for UoP provisioning, and the waiver stood 23% above our estimate.
- Spot LNG prices declined sequentially in 2Q, averaging USD11.8/mmbtu (USD12.4 in 1Q).

Operational performance:

- Total volumes came in line with our estimate at 228tbtu. No spot volumes were recorded during the quarter.
- Dahej utilization was in line with our estimates, while Kochi utilization stood 12% above our estimates.
- As of Sep'25, provisions on UoP dues stood at INR7.4b.
- UoP dues of INR13.9b (net of provision: INR6.6b) were included in trade receivables as of Sep'25. PLNG has obtained bank guarantees from some customers to recover UoP charges. While some customers have not given balance confirmations toward these dues, management is confident of recovering such charges.
- The Board declared an interim dividend of INR7/sh (FV: INR10/sh).

Standalone - Quarterly Earning	Model											(INR b)
Y/E March		FY	25			FY	26		2QE	Var	YoY	QoQ
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		(%)	(%)	(%)
Net Sales	134.2	130.2	122.3	123.2	118.8	110.1	126.3	141.0	113.6	-3%	-15%	-7%
YoY Change (%)	15.1	3.9	-17.1	-10.7	-11.4	-15.5	3.3	14.5	-12.8			
EBITDA	15.6	12.0	12.5	15.1	11.6	11.2	14.2	15.9	11.6	-4%	-7 %	-4%
Margin (%)	11.7	9.2	10.2	12.3	9.8	10.1	11.2	11.3	10.2			
Depreciation	1.9	2.0	2.1	2.1	2.1	2.1	2.1	1.9	2.0			
Interest	0.7	0.7	0.7	0.6	0.6	0.6	0.6	0.6	0.6			
Other Income	2.2	2.0	2.0	2.0	2.4	2.4	1.5	0.6	1.5			
PBT	15.2	11.4	11.7	14.5	11.4	10.8	13.0	14.0	10.5	3%	-5%	-5%
Rate (%)	24.9	25.7	25.8	26.0	25.1	25.6	25.2	20.7	25.2			
Adj PAT	11.4	8.5	8.7	10.7	8.5	8.1	9.7	11.1	7.8	3%	-5%	-5%
YoY Change (%)	44.5	3.6	-27.2	45.1	-25.5	-4.9	11.7	3.8	-7.4			
Margin (%)	8.5	6.5	7.1	8.7	7.2	7.3	7.7	7.9	6.9			
Key Assumptions												
Regas volume (Tbtu)	144	123	114	89	102	119	105	93	105	-3%	-29%	15%
Sales volume (Tbtu)	118	116	114	116	118	109	132	148	123	-4%	0%	2%
Total Volumes (Tbtu)	262.0	239.0	228.0	205.0	220.0	228.0	236.3	240.7	227.5	0%	-5%	4%
Dahej utilization (%)	112%	102%	96%	85%	94%	95%	100%	76%	96%	-1%	-6%	2%
Kochi utilization (%)	22%	22%	24%	25%	21%	27%	24%	23%	24%	12%	21%	31%





7 November 2025 Results Flash | Sector: Healthcare

Global Health

 BSE SENSEX
 S&P CNX

 83,216
 25,492

Conference Call Details



Date: 10th Nov 2025 Time: 2:00 pm IST Dial-in details: <u>Link</u>

Financials & Valuations (INR b)

Y/E MARCH	FY26E	FY27E	FY28E
Sales	42.3	49.0	55.4
EBITDA	9.1	12.5	14.8
Adj. PAT	6.5	8.1	9.9
EBIT Margin (%)	16.6	20.4	21.6
Cons. Adj. EPS (INR)	24.1	30.3	36.8
EPS Gr. (%)	24.4	26.0	21.5
BV/Sh. (INR)	143.3	168.3	198.6
Ratios			
Net D:E	0.1	0.0	(0.1)
RoE (%)	17.9	19.5	20.1
RoCE (%)	13.6	17.1	18.2
Payout (%)	15.3	17.6	17.6
Valuations			
P/E (x)	56.2	44.6	36.7
EV/EBITDA (x)	40.4	29.2	24.3
EV/Sales (x)	8.7	7.4	6.5
Div. Yield (%)	0.2	0.3	0.4
FCF Yield (%)	0.5	1.1	1.2

CMP: INR1,251

Performance broadly in line

- In 2QFY26, sales grew 15% YoY to INR11b (vs our est: INR10.1b).
- EBITDA margin was largely stable at 21% YoY (our est: 23.5%).
- Medanta's EBITDA declined 1.5% YoY to INR2.3b (in line).
- The company had a one-time gain of INR160m on account of reversed stamp duty payable to the Government of Delhi NCR due to the merger of Medanta Holding Private Limited and the Holding Company.
- Adjusting for the same, PAT grew 11.4% YoY to INR1.5b (in line).

Key operating metrics

- Mature hospital revenue (67% of total revenue) grew 5.4% YoY to INR7.2b. EBITDA stood at INR1.7b for the quarter, and margins contracted 120bp YoY to 23.5%.
- Developing hospital revenue (33% of total revenue) grew 29.7% YoY to INR3.6b. EBITDA stood at INR915m for the quarter, with margins contracting 450bp YoY to 25.6%.
- ARPOB grew by 5.5% YoY to INR65,570 in 2QFY26. The matured hospitals segment witnessed YoY ARPOB growth of 9.6%, and the developing hospitals segment witnessed YoY ARPOB growth of 2.3% for 2QFY26.
- Both IPD/OPD volumes increased 13%/15% YoY for the guarter.
- Occupancy levels were 63.7% (vs. 64.3% in 2QFY25) and 63.2% in 1QFY26.
- ALOS stood at 3.06 days (vs. 3.20/3.03 days in 2QFY25/1QFY26).
- OPD Pharmacy revenue increased 23.9% YoY to INR456m.
- International Patients revenue increased 48.5% YoY to INR762m.
- Heart/cancer/digestive/neuro/urology contributed ~65% of the revenue in 2QFY26.

Capex plans


- Medanta incurred INR4.3b of capex in 1HFY26.
- Maintenance capex is estimated at INR4.5b to be incurred over the next three years.
- The total project capex, estimated at INR 36.7b for the next five years, will be funded by a combination of debt funding and internal accruals.
- Medanta has added 393 beds in 1HFY26 and plans to add 647 more beds by the end of FY27.



Consolidated - Quarterly Earnings Model

Y/E March		FY	25			FY2	26		FY25	FY26E	FY26E	vs Est
INRm	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	(%)
Gross Sales	8,611	9,566	9,434	9,312	10,308	10,992	10,443	11,398	36,923	43,141	10,080	9%
YoY Change (%)	11.4	13.3	12.8	15.2	19.7	14.9	10.7	22.4	12.7	16.8	5.4	
Total Expenditure	6,699	7,222	7,023	7,066	8,038	8,683	7,885	8,571	28,008	33,177	7,712	
EBITDA	1,912	2,344	2,412	2,247	2,270	2,309	2,559	2,827	8,915	9,965	2,369	-3%
YoY Change (%)	3.7	7.3	8.9	17.6	18.7	-1.5	6.1	25.8	7.6	11.8	1.1	
Margins (%)	22.2	24.5	25.6	24.1	22.0	21.0	24.5	24.8	24.1	23.1	23.5	
Depreciation	515	555	519	493	451	497	529	577	2,082	2,054	521	
Interest	180	160	163	150	138	171	160	165	653	634	155	
Other Income	219	182	160	229	205	197	252	445	791	1,099	245	
PBT before EO expense	1,437	1,811	1,891	1,833	1,886	1,838	2,122	2,529	6,972	8,375	1,938	-5%
Extra-Ord expense/(Income)	0	0	0	-499	196	160	0	0	-499	356	0	
PBT	1,437	1,811	1,891	1,334	2,081	1,998	2,122	2,529	6,473	8,731	1,938	3%
Tax	374	503	462	321	492	414	499	592	1,659	1,996	450	
Rate (%)	26.0	27.8	24.4	24.0	23.6	20.7	23.5	23.4	25.6	22.9	23.2	
Minority Interest & Profit/Loss of												
Asso. Cos.	0	0	0	0	0	0	0	0	0	0	0	
Reported PAT	1,063	1,308	1,429	1,014	1,590	1,584	1,623	1,938	4,813	6,735	1,488	6%
Adj PAT	1,063	1,308	1,429	1,393	1,440	1,458	1,623	1,938	5,193	6,460	1,488	-2%
YoY Change (%)	4.2	4.5	15.6	9.4	35.6	11.4	13.6	39.1	8.6	24.4	13.8	
Margins (%)	12.3	13.7	15.1	15.0	14.0	13.3	15.5	17.0	14.1	15.0	14.8	

E: MOFSL Estimates







Anant Raj

BSE SENSEX S&P CNX 25,892 83,216

CMP: INR620

Conference Call Details



Date: 12th November 2025 Time: 16:00 IST Dial-in details:

+91- 22 6280 1488 /

+91-22 7115 8869

Financials & Valuations (INR b)

Y/E Mar	FY26E	FY27E	FY28E
Sales	21.7	27.3	51.0
EBITDA	7.7	8.7	20.6
EBITDA Margin (%)	35.6	31.7	40.4
PAT	5.0	4.5	11.0
EPS (INR)	14.7	13.0	31.9
EPS Gr. (%)	18.2	-11.5	146.1
BV/Sh. (INR)	135.4	147.9	179.3
Ratios			
RoE (%)	10.8	8.8	17.8
RoCE (%)	11.4	7.6	12.7
Payout (%)	3.4	3.9	1.6
Valuations			
P/E (x)	42.3	47.8	19.4
P/BV (x)	4.6	4.2	3.5
EV/EBITDA (x)	28.3	27.7	13.2
Div yld (%)	0.1	0.1	0.1

Strong financials backed by growth in real estate and data centers

Operational highlights

- **Real Estate:** The company has received additional approvals and is in the advanced stages of launching its luxury high-rise residential project, The Estate One, located on Golf Course Extension Road, Sector-63A, Gurugram. The project spans 5.1 acres with a total development area of approximately 1.1msf.
- Phase-N of Anant Raj Estate has commenced at Golf Course Extension Road, Sector-63A, Gurugram, covering 6.075 acres with a development potential of around 0.5msf, adding further value to The Estate Apartments and The Estate Floors.
- Approvals for Group Housing-3, spread over 5.21 acres, are progressing as planned and are expected to be received by 4QFY26.
- Project Navya is expected to begin Phase-2 deliveries from Dec'25, while deliveries at Ashok Estate, comprising 1.34msf, are nearing completion.
- Data Centers: The capacity expansion at Manesar and Panchkula has strengthened the company's presence in the data center business, with both facilities designed to function as mutual data center and disaster recovery (DR) sites.
- Anant Raj Cloud, a wholly owned subsidiary, is leading the expansion of data center, colocation, and cloud services across Manesar, Rai, and Panchkula, targeting a total IT load of 117MW by FY28, with full capex funding already secured.
- Data center expansion at Rai, Sonipat, has commenced, with an initial capacity of 20MW IT load and a total planned capacity of around 200MW.
- The company has successfully completed a QIP of INR11b to support its growth plans, receiving strong participation from both foreign portfolio investors (FPIs) and domestic institutional investors (DIIs).
- The company is net cash positive and has also prepaid INR1.3b of debt.

Performance highlights

- In 2QFY26, revenue came in at INR6.3b, up 23% YoY/6% QoQ (18% above estimates). In 1HFY26, revenue came in at INR12.2b, up 24% YoY.
- EBITDA was at INR1.7b, up 49% YoY/11% QoQ (11% below estimates). EBITDA margin stood at 26.6%, up 4.6pp YoY. In 1HFY26, EBITDA was at INR3.2b, up 48% YoY. EBITDA margin stood at 26%, up 4.1pp YoY.
- Adj. PAT was at INR1.4b, up 31% YoY/10% QoQ (12% above estimates). PAT margin was at 22%, up 1.3pp YoY. In 1HFY26, adj. PAT was at INR2.6b, up 34% YoY. PAT margin was at 21.6%, up 1.6pp YoY.

10 November 2025 67



Quarterly performance

Y/E March		FY2	25			FY2	6E		FY25	FY26	FY26E	2QE Variance
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			2Q Est.	(%/bp)
Net Sales	4,718	5,129	5,346	5,407	5,924	6,308	5,800	3,672	20,600	21,704	5,324	18%
YoY Change (%)	49.2	54.3	36.3	22.2	25.6	23.0	8.5	-32.1	38.9	5.4	3.8	
Total Expenditure	3,689	4,001	4,011	3,983	4,418	4,630	3,735	1,194	15,683	13,976	3,428	
EBITDA	1,030	1,128	1,336	1,424	1,507	1,678	2,065	2,478	4,917	7,728	1,896	-11%
Margins (%)	21.8	22.0	25.0	26.3	25.4	26.6	35.6	67.5	23.9	35.6	35.6	-900bp
Depreciation	55	81	82	87	79	106	310	666	305	1,162	285	
Interest	36	15	29	30	24	29	70	140	110	263	65	
Other Income	98	109	93	103	100	101	113	109	403	423	104	
PBT before EO expense	1,037	1,141	1,318	1,409	1,504	1,644	1,798	1,780	4,905	6,726	1,650	
Extra-Ord expense	0	0	0	0	0	0	0	0	0	0	0	
PBT	1,037	1,141	1,318	1,409	1,504	1,644	1,798	1,780	4,905	6,726	1,650	0%
Tax	142	97	223	228	257	275	452	708	690	1,693	415	
Rate (%)	13.7	8.5	16.9	16.2	17.1	16.7	25.2	39.8	14.1	25.2	25.2	
Minority Interest & Profit/Loss of Asso. Cos.	15	11	10	5	12	12	0	-24	41	0	0	
Reported PAT	895	1,044	1,094	1,181	1,247	1,369	1,345	1,072	4,215	5,033	1,235	
Adj PAT	910	1,056	1,104	1,186	1,259	1,381	1,345	1,048	4,257	5,033	1,235	12%
YoY Change (%)	79.7	75.7	53.7	38.2	38.3	30.8	21.8	-11.7	60.1	18.2	16.9	
Margins (%)	19.3	20.6	20.7	21.9	21.2	21.9	23.2	28.5	20.7	23.2	23.2	-129bp

Source: Company, MOFSL

We currently have a 'BUY' rating for Anant Raj. However, estimates are under review and we will revise them after the earnings call







JSW Cement

BSE Sensex S&P CNX 83,216 25,492

CMP: INR128 Neutral

Conference Call Details



Date: 10th November 2025 Time: 10:00 IST Dial-in details:

+ 91 22 6280 1366 + 91 22 7115 8267

Link for the call

Consol. Financials Snapshot (INR b)

Y/E MARCH	FY26E	FY27E	FY28E
Sales	68.2	84.1	98.3
EBITDA	12.7	16.2	19.2
Adj. PAT	3.7	4.5	5.4
EBITDA Margin (%)	18.7	19.3	19.5
Adj. EPS (INR)	2.3	2.9	3.6
EPS Gr. (%)	n/m	27.0	21.5
BV/Sh. (INR)	45.1	48.8	52.8
Ratios			
Net D:E	0.7	0.8	0.8
RoE (%)	7.4	6.2	7.0
RoCE (%)	7.4	7.4	7.8
Payout (%)	10.0	15.0	20.0
Valuations			
P/E (x)	2.3	2.9	3.6
P/BV (x)	2.8	2.6	2.4
EV/EBITDA(x)	17.1	14.0	11.9
EV/ton (USD)	115	93	83
Div. Yield (%)	0.2	0.3	0.6
FCF Yield (%)	-9.0	-2.9	2.1

Beat estimates; EBITDA/t at INR860 (est. INR657)

- ISW Cement (JSWC)'s 2QFY26 EBITDA was above our estimates, driven by higher volume and lower opex/t vs. our estimates. EBITDA increased 114% YoY to INR2.7b (~40% beat). EBITDA/t surged ~86% YoY to INR860 (vs. est. INR657). OPM increased 8.4pp YoY to ~19% (vs. est. ~14%). It reported PAT of INR864m (+115% beat) vs. a loss of INR644m in 2QFY25.
- The company has commissioned a 1.0mtpa GU in Sambalpur, Odisha, in Sep'25, for which clinker will be sourced from Shiva Cement (a subsidiary of JSWC). Work at its greenfield expansion in Nagaur, Rajasthan, is progressing as per schedule and is expected to be commissioned in early-4QFY26. In 2QFY26, its cement volume grew ~7% YoY, while GGBS volume increased ~21% YoY. Cement realization declined ~5% QoQ, while GGBS realization dipped ~1% QoQ.

Sales volume up 15% YoY; blended realization/t up 2% YoY

- Consolidated revenue/EBITDA/stood at INR14.4b/INR2.7b (up 17%/114% YoY and up ~7%/40% vs. estimates). Net profit stood at INR864m (115% above estimates) vs. a loss of INR644m in 2QFY25. Sales volume increased 15% YoY to 3.1mt (+7% vs. our estimates). Of this, cement volume stood at 1.7mt (up 7% YoY) and GGBS was at 1.4mt (21% YoY). Blended realization/t was up 2% YoY (down 2% QoQ) at INR4,619/t (in line).
- Opex/t declined 7% YoY (~5% below estimate), led by a ~5%/16%/1% YoY decline in variable cost/other expenses/freight cost per ton. Employee cost per ton declined ~17% YoY. EBITDA/t increased ~86% YoY to INR860.
- In 1HFY26, revenue/EBITDA stood at INR30.0b/INR5.9b (up ~12%/65% YoY). Adj. PAT stood at INR2.0b vs. net loss of INR795m in 1HFY25. EBITDA/t grew ~49% YoY to INR919. OCF stood at INR5.1b vs. INR1.9m in 1HFY25. Capex stood at INR9.6b vs. INR4.8b in 1HFY25. Net cash inflow stood at INR4.6b vs. INR3.0b in 1HFY25.

Highlights from the management commentary

- Variable cost declined due to a change in product mix, decline in slag prices and higher production driving operating efficiency. Fuel consumption cost stood at INR1.5/kcal vs. INR1.52/INR1.55 in 2QFY25/1QFY26. Lead distance declined to 283km from 288km in 2QFY25.
- Green power share stood at ~21%, similar to FY25. It targets to increase it to ~49% by 4QFY26 and ~63% by FY27.
- Net debt declined to INR32.3b vs. INR45.7b as of Jun'25. Net/debt to EBITDA (TTM) ratio stood at 2.8x vs. 4.3x as of Jun'25.

Valuation and view

JSWC reported a strong beat on earnings, driven by robust volume growth and better operating efficiency. Further, the company's net debt declined sharply on a QoQ basis, aided by improvement in profitability. During the conference call, we will seek management guidance on the sustainability of its profitability. We have a **Neutral** rating on the stock. However, we will review our assumptions after the conference call on 10th Nov'25 (Concall Link).



Quarterly performance (consolidate	d)											NR b)
Y/E March		FY	25			FY2	6E		FY25	FY26E	FY25	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	(%)
Sales Volumes (mt)	3.1	2.7	2.8	3.7	3.3	3.1	3.4	4.0	12.3	13.8	2.9	4
YoY Change (%)	-	-	-	-	7.8	0.1	0.2	0.1	-	12.6	-	
Net Sales	14.5	12	14	17.1	15.6	14.4	16.1	22.1	58.1	68.2	13.5	7
YoY Change (%)	NA	NA	NA	NA	7.8	17.4	12.5	29.4	0.0	17.3	0.0	
EBITDA	2.3	1	3	2.5	3.2	2.7	3.5	3.3	8.6	12.7	1.9	40
YoY Change (%)					38.8	113.7	39.8	32.5	-20.1	48.2		
Margin (%)	16.1	10.2	17.5	14.6	20.7	18.6	21.7	15.0	14.8	18.7	14.2	400
Depreciation	0.7	0.8	0.8	0.8	0.8	0.8	0.8	0.9	3.1	3.3	0.8	-1
Interest	1.4	1.1	2.2	1.2	1.0	1.0	1.2	1.6	5.9	4.9	1.1	-6
Other Income	0.2	0.3	0.3	0.2	0.2	0.2	0.2	0.4	1.0	1.1	0.3	-16
PBT before EO expense	0.4	-0.3	-0.2	0.7	1.6	1.1	1.7	1.1	0.5	5.6	0.3	245
Extra-Ord. expense	-	-	-	-	14.7	-	-	-	-	14.7	-	
PBT	0.4	-0.3	-0.2	0.7	-13.0	1.1	1.7	1.1	0.5	-9.1	0.3	245
Tax	0.3	0.0	0.3	0.6	0.6	0.5	0.2	0.1	1.2	1.5	0.1	
Prior period tax adj.	-	-	-	-	-	-	-	-	-	-	-	
Rate (%)	80.4	-3.9	-133.9	86.4	-5.0	41.2	12.0	12.8	0.0	0.0	22.0	
Reported PAT	0.1	-0.3	-0.5	0.1	-13.7	0.7	1.5	1.0	-0.7	-10.5	0.3	160
Share of loss/(profit) from JV	0.3	0.3	0.2	-0.1	-0.0	-0.2	0.2	0.6	1.0	1.0	-0.2	
Minority Interest	-0.1	-0.1	-0.1	-0.2	-0.1	-0.1	-0.1	-0.2	-0.5	-0.5	-	
Adj. PAT	-0.2	-0.6	-0.7	0.3	1.1	0.9	1.3	0.4	-0.1	3.7	0.4	115
YoY Change (%)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.0	
Per ton analysis (INR)												
Net realization	4,714	4,516	5,191	4,583	4,712	4,619	4,711	5,561	4,738	4,935	4,618	0
RM Cost	1,089	1,217	1,333	1,209	1,206	1,024	1,019	1,518	1,209	1,209	1,216	-16
Employee Expenses	326	327	308	257	245	271	251	382	301	292	285	-5
Power, Oil, and Fuel	744	623	765	639	642	726	751	602	690	676	617	18
Freight and Handling Outward	1,168	1,070	1,254	1,076	1,098	1,056	1,061	1,360	1,138	1,155	1,103	-4
Other Expenses	631	816	623	731	547	682	605	865	701	683	741	-8
Total Expenses	3,957	4,054	4,283	3,912	3,738	3,759	3,687	4,727	4,038	4,015	3,961	-5
EBITDA	757	462	908	671	975	860	1,024	833	699	920	657	31





10 November 2025 Results Flash | Sector: Automobiles

Craftsman Automation

BSE SENSEX S&P CNX 83,216 25,492

CMP:INR6764 Neutral

Conference Call Details



Date: 24th Oct'24 Time: 4PM IST Dial-in details:

Diamond pass link

+91 22 6280 1568 / +91 22 7115 8391

Financials & Valuations (INR b)

INR b	FY26E	FY27E	FY28E
Sales	74.4	83.4	94.9
EBITDA	11.4	13.7	16.0
Adj. PAT	3.7	5.5	7.2
EPS (INR)	156.2	229.2	303.4
EPS Gr. (%)	69.6	46.7	32.4
BV/Sh. (INR)	1,344	1,558	1,837
Ratios			
RoE (%)	12.3	15.8	17.9
RoCE (%)	10.1	12.1	14.2
Payout (%)	6.4	6.5	7.9
Valuations			
P/E (x)	43.3	29.6	22.3
P/BV (x)	5.0	4.3	3.7
Div. Yield (%)	0.1	0.2	0.4
FCF Yield (%)	-0.2	3.6	4.5

Better than expected revenue growth drives earnings beat

- Consolidated revenues grew 65% YoY to INR 20b (9% ahead of our estimates). Even on a standalone basis, revenue was about 12% ahead of our estimates
- Beat in standalone revenue was largely driven by a strong 24% QoQ revenue growth from the Aluminum segment
- Consolidated margins have largely come in line with our estimates at 15.1%
- However, given the better than expected revenue growth, EBITDA grew
 14% to INR 3b even on QoQ basis and was 9% ahead of our estimate of INR
 2.8b. Comparing QoQ as YoY growth for the consolidated entity is not comparable due to the Sunbeam acquisition in the numbers from this fiscal
- On a segmental basis, Aluminum segment margins have improved 160bp QoQ (down 230bp YoY) to 11.7% and was ahead of our estimate of 10.2%. On the other hand, powertrain segment margin declined 60bp QoQ to 14.6% and was below our estimate of 15.2%. Even Industrial segment margin declined 80bp QoQ to 1.4%, and below our estimate of 2.2%
- Overall, PAT grew 20% QoQ (+48% YoY) to INR 912m.
- On a consol basis, its CFO stood at loss of INR 1.3b largely due to highly adverse working capital.
- Further, it has invested about INR 5.7b in capex for H1. Thus, it has reported FCF loss of INR 7b as of Sep end.
- Valuation view: The stock trades at 43.3x/29.6x FY26E/FY27E EPS.

Quarterly (Consol) (INR Million)

		FY	25		FY26E			FY25	FY26E	2QE	
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			
Net operating income	11,512	12,140	15,761	17,493	17,840	20,016	18,824	17,698	56,905	74,379	18,319
Change (%)	10.9	3.0	39.5	58.3	55.0	64.9	19.4	1.2	27.8	30.7	50.9
RM/Sales (%)	56.3	55.6	52.7	54.2	53.9	54.7	54.0	53.3	54.5	54.0	53.9
Staff Cost (% of Sales)	6.4	6.9	8.5	8.3	8.1	7.2	8.0	9.1	7.7	8.1	8.0
Other Exp. (% of Sales)	20.1	21.6	26.2	23.6	23.2	23.0	22.6	21.8	23.2	22.6	23.0
EBITDA	1,973	1,928	1,990	2,436	2,649	3,019	2,899	2,806	8,327	11,373	2,766
EBITDA Margins (%)	17.1	15.9	12.6	13.9	14.9	15.1	15.4	15.9	14.6	15.3	15.1
Non-Operating Income	48	64	86	52	50	96	58	9	251	213	55
Interest	492	413	583	679	663	770	550	270	2166	2253	600
Depreciation	725	762	1035	949	1019	1090	1150	1233	3470	4492	1100
PAT Share from assoc.	61	-4	-2	-2	-2	-4	0	0	-10	0	0
PBT after EO items	744	821	313	755	937	1,253	1,257	1,312	2,951	4,841	1,121
Eff. Tax Rate (%)	28.5	24.9	58.6	11.6	25.7	27.5	23.0	18.2	23.3	23.0	23.0
Rep. PAT	532	617	129	668	696	909	968	1,074	2,263	3,728	863
Change (%)	-28.6	-34.7	-82.3	7.1	30.9	47.3	648.5	60.8	-25.7	64.7	39.9
Adj. PAT	532	617	242	750	757	912	968	1,074	2,263	3,728	863
Change (%)	-28.6	-34.7	-66.9	20.3	42.3	47.9	299.3	43.2	-25.7	64.7	39.9

E: MOFSL Estimates





Signature Global

BSE Sensex S&P CNX 83,216 25,492

CMP: INR1,108 Buy

Operating metrics likely to miss on full-year guidance

Operating performance

- Signature Global (SIGNATUR) recorded presales of INR20.1b, down 28% YoY and 24% QoQ (in line with our estimates). This was attributed to the absence of any material launches during the quarter. In 1HFY26, presales stood at INR46.5b, down 21% YoY.
- Area sold during the quarter stood at 1.3msf, down 44% YoY and 17% QoQ (9% above our estimates). In 1HFY26, volumes were 3msf, down 33% YoY.
- Average sales realization stood at INR15,000/sqft, up 28% YoY and down 8% QoQ (8% below our estimates). In 1HFY26, realizations stood at INR15,710/sqft, up 17% YoY.
- Total units sold during the quarter were ~573, down 46% YoY and 26% QoQ. In 1HFY26, units sold were 1,351, down 33% YoY.
- Collections stood at INR9.4b, up 2% YoY and 1% QoQ (8% below estimates).
 In 1HFY26, they stood at INR18.7b, down 12% YoY.
- In 2QFY26, the company acquired 33.47 acres of land with development potential of 1.76msf. In 1HFY26, the company acquired a total land of 2.3msf.
- Net debt increased to INR9.7b in 2QFY26 from INR8.9b in 1QFY26.
- Its project pipeline remains strong, comprising 17.1msf of recently launched projects, 24.3msf of upcoming developments, and 8.9msf under ongoing construction, all scheduled for execution over the next 2-3 years.
- **P&L performance:** In 2QFY26, the company reported revenue of INR3.4b, down 55%/61% YoY/QoQ (61% below estimate). In 1HFY26, revenue stood at INR12b, up 5% YoY.
- EBITDA loss stood at INR743m vs a loss of INR116m YoY. In 1HFY26, EBITDA loss stood at INR410m vs a loss of INR128m YoY.
- Adj. PAT loss in 2QFY26 stood at INR469m vs a profit of INR41m YoY. In 1HFY26, PAT loss stood at INR124m vs a profit of INR109m YoY.

Conference Call Details



Date: 10th Nov 2025 Time: 12:30 IST Dial-in details:

+91 22 6280 1144 /

+91 22 7115 8045

Financials & Valuations (INR b)

Tillallolais & Va	rinariciais & raidations (intris)							
Y/E Mar	FY26E	FY27E	FY28E					
Sales	43.6	74.0	105.0					
EBITDA	7.9	17.7	26.0					
EBITDA (%)	18.2	23.9	24.7					
Adj. PAT	7.8	17.6	26.0					
EPS (INR)	55.7	125.3	184.8					
EPS Gr. (%)	674.8	124.7	47.5					
BV/Sh. (INR)	107.5	232.7	417.5					
Ratios								
Net D/E	0.7	0.3	0.0					
RoE (%)	70.0	73.6	56.8					
RoCE (%)	26.0	40.9	40.9					
Payout (%)	0.0	0.0	0.0					
Valuations								
P/E (x)	19.0	8.4	5.7					
P/BV (x)	9.8	4.5	2.5					
EV/EBITDA (x)	20.1	9.0	5.7					
Div Yield (%)	0.0	0.0	0.0					



Quarterly performance												(INR m)
Y/E March		FY	25			FY	26		FY25	FY26E	FY26E	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			2Q	
Net Sales	4,006	7,493	8,277	5,204	8,657	3,385	12,208	19,351	24,980	43,601	8,720	-61%
YoY Change (%)	141.5	660.5	193.7	-25.0	116.1	-54.8	47.5	271.8	101.4	74.5	16.4	
Total Expenditure	4,019	7,609	8,142	4,766	8,324	4,128	9,989	13,233	24,535	35,673	7,135	
EBITDA	-13	-116	135	439	332	-743	2,220	6,118	446	7,927	1,585	NA
Margins (%)	-0.3	-1.5	1.6	8.4	3.8	-21.9	18.2	31.6	1.8	18.2	18.2	NA
Depreciation	52	68	75	79	76	78	88	74	274	315	63	
Interest	75	169	142	130	126	135	325	574	515	1,160	232	
Other Income	274	281	345	500	327	340	470	542	1,400	1,680	336	
PBT before EO expense	135	-71	263	730	458	-615	2,277	6,012	1,057	8,133	1,627	
Extra-Ord expense	2	0	0	3	1	1	0	-2	6	0	0	
PBT	133	-72	263	727	457	-616	2,277	6,014	1,051	8,133	1,627	
Tax	65	-113	-29	116	113	-147	84	250	39	299	60	
Rate (%)	48.8	157.9	-11.0	15.9	24.7	23.9	3.7	4.2	-3.9	-1.4	3.7	
MI & Profit/Loss of Asso. Cos.	0	0	0	0	0	0	0	1	1	1	0	
Reported PAT	68	41	291	611	344	-469	2,193	5,764	1,011	7,832	1,566	NA
Adj PAT	68	41	291	611	344	-469	2,193	5,764	1,011	7,832	1,566	NA
YoY Change (%)	-199.4	-121.3	1,195.2	46.4	408.8	-1,241.0	653.2	843.4	452.8	674.8	3,714.1	
Margins (%)	1.7	0.5	3.5	11.7	4.0	-13.8	18.0	29.8	4.0	18.0	18.0	
Key metrics												
Pre Sales (msf)	2.0	2.4	2.5	1.4	1.6	1.3	2.3	2.2	8.3	7.5	1.2	9%
Presales (INRb)	31.2	27.8	27.7	16.2	26.4	20.1	35.0	41.2	102.9	122.7	20	1%
ASP (INR/sqft)	15,369	11,681	11,124	11,912	16,296	15,000	15,000	18,754	12457	16381	16296	-8%
Collections (INRb)	12.1	9.2	10.8	11.7	9.3	9.4	17.9	21.0	43.8	62.7	10	-8%





8 November 2025 2QFY26 Results Flash | Sector: Cement

Birla Corporation

CMP: INR1,215 Buy

BSE Sensex S&P CNX 83,216 25,492

Conference Call Details



Date: 10th November 2025 Time: 14:30 IST Dial-in details: +91 22 6280 1458,

+91 22 6280 1458, +91 22 7115 8846 Link for the call

Financials & Valuations (INR b)

Y/E MARCH	FY26E	FY27E	FY28E
Sales	99.7	108.3	116.9
EBITDA	14.4	17.1	19.4
Adj. PAT	5.2	6.5	7.4
EBITDA Margin (%)	14.5	15.8	16.6
Adj. EPS (INR)	67.8	84.8	95.9
EPS Gr. (%)	60.5	25.2	13.1
BV/Sh. (INR)	969	1,044	1,129
Ratios			
Net D:E	0.4	0.4	0.5
RoE (%)	7.2	8.4	8.8
RoCE (%)	6.3	6.9	7.1
Payout (%)	15	12	10
Valuations			
P/E (x)	17.9	14.3	12.6
P/BV (x)	1.3	1.2	1.1
EV/EBITDA(x)	7.8	7.0	6.6
EV/ton (USD)	57	54	56
Div. Yield (%)	0.8	0.8	0.8

EBITDA beat; EBITDA/t at INR717 (est. INR559)

- Birla Corporation's (BCORP) 2QFY26 performance was above our estimates, driven by lower-than-estimated opex/t and better performance in the Jute business. EBITDA increased ~72% YoY to INR3.0b (~31% above our estimates). OPM expanded 4.7pp YoY to ~14% (est. ~11%). EBITDA/t increased ~61% YoY to INR717 (est. INR559). The company reported a PAT of INR905m (~139% above our estimate, aided by higher other income and lower interest cost).
- Cement sales during the quarter were affected by excessive rainfall across the company's key markets, subdued prices, and temporary disruptions from GST changes. Despite these challenges, it expects a demand recovery in the Q3FY26, driven by government infrastructure spending and improved rural housing demand, leading to ~4-5% YoY volume growth. The North and West are likely to drive this recovery, while the South and East remain oversupplied. Operational disruptions impacted clinker output, though realizations are expected to remain stable with a slight uptick as demand improves.

Volumes rise 7% YoY; OPM expands 4.7pp YoY

- Consol. revenue/EBITDA stood at INR22.1b/INR3.1b (up 13%/72%) YoY and in line/+31% vs estimates) in 2QFY26. Net profit stood at INR905m (+139% vs estimates) vs a loss of INR252m in 2QFY25. Sales volumes increased 7% YoY to 4.3mt (in line). OPM expanded 4.7pp YoY to ~14%.
- Opex/t remained flat YoY (-2% v/s estimates), with a ~2% decline in variable costs (-4% v/s estimate). Employee cost/freight expense per ton increased ~1%/4% YoY, whereas other expenses per ton declined ~1% YoY. EBITDA/t increased ~61% YoY to INR717. Depreciation/Interest costs dipped 7%/22% YoY, whereas other income increased 56% YoY. ETR stood at ~30.9% vs. 29.4% in 2QFY25.
- In 1HFY26, Revenue/EBITDA/Adj PAT stood at INR46.6b/INR6.5b/INR2.1b (up ~12%/50%/28x YoY). OPM expanded 3.5pp to ~14%. Realization increased ~4% YoY to INR5,161, while EBITDA/t increased ~38% YoY to INR722. OCF stood at INR2.1b vs INR3.1b in 1HFY25. Capex stood at INR2.2b vs INR2.1b. Net cash outflow stood at INR105m vs net cash inflow of INR1.0b in 1HFY25.

Highlights from management commentary

- The market remained challenging during the monsoon, though demand in North and Central India held steady. A demand revival is expected in the December quarter, supported by a healthy monsoon and higher rural incomes driving housing activity.
- The blended cement share increased to 89% from 83% in 2QFY25, while trade volume increased to 79% from 71% in 2QFY25. However, the Premium cement share (as % of trade volume) declined to 60% vs. 62% in 2QFY25.




■ BCORP increased its renewable power use to 30% of total consumption in 2QFY26 (vs. 25% last year). Its Chanderia and Durgapur plants began sourcing 6mw and 6.98mw of renewable power, respectively, with the share expected to rise to ~32% in 2HFY26. The Board has approved 9mw of Solar BESS at Chanderia and 5mw of solar power at Mukutban, while Birla Jute Mills is adding a 2.1mw rooftop solar plant by Dec'25

Valuation and view

- BCORP's 2QFY26 was above our estimates, driven by lower-than-estimated opex/t and better performance in the Jute business. Management is prioritizing its expansion plans and the timely execution of ongoing capex projects.
- We have a **BUY** rating on the stock. We will review our assumptions after the concall on 10th Nov'25 at 14:30 IST (<u>Link for the Call</u>).

Consolidated performance										(INR b)
Y/E March		FY2!	5			FY26E			FY26	Var.
T/E March	1Q	2Q	3Q	4Q	1QE	2Q	3QE	4QE	2QE	(%)
Cement Sales (MT)	4.4	4.0	4.5	5.2	4.8	4.3	4.8	5.4	4.2	2
YoY Change (%)	(0.7)	(5.0)	7.1	7.2	9.1	7.1	6.0	3.6	5.0	
Cement Realization	4,843	4,722	4,790	5,177	4,899	4,878	4,938	5,190	4,869	0
YoY Change (%)	(7.4)	(9.4)	(9.9)	(0.8)	1.2	3.3	3.1	0.3	3.1	
QoQ Change (%)	(7.2)	(2.5)	1.4	8.1	(5.4)	(0.4)	1.2	5.1	(0.6)	
Net Sales	21.9	19.5	22.6	28.1	24.5	22.1	24.5	28.7	21.4	3
YoY Change (%)	(9.1)	(14.6)	(2.4)	6.0	12.0	13.0	8.4	1.9	9.4	
Total Expenditure	19.3	17.8	20.1	22.8	21.1	19.0	20.5	24.7	19.0	(0)
EBITDA	2.6	1.8	2.5	5.3	3.5	3.0	3.9	4.0	2.3	31
Margin (%)	11.8	9.1	11.0	19.0	14.1	13.8	16.1	13.9	10.9	291
YoY Change (%)	-13.3	-38.7	-34.5	13.0	34.3	72.1	59.2	-25.5	-69.8	
Depreciation	1.5	1.5	1.4	1.4	1.3	1.3	1.5	1.6	1.4	(1)
Interest	0.9	0.9	0.8	0.7	0.7	0.7	0.7	0.7	0.7	(5)
Other Income	0.2	0.2	0.2	0.5	0.3	0.3	0.3	0.2	0.2	20
Profit before Tax	0.4	-0.4	0.4	3.7	1.8	1.3	2.0	1.9	0.5	159
EO (Income)/Expense	-	-	-	0.4	-	-	-	-	-	
Profit before Tax after EO	0.4	-0.4	0.4	3.3	1.8	1.3	2.0	1.9	0.5	159
Tax	0.1	-0.1	0.1	0.7	0.6	0.4	0.5	0.3	0.1	
Rate (%)	25.9	29.4	24.6	21.8	32.6	30.9	25.0	13.8	25.0	
Reported PAT	0.3	-0.3	0.3	2.6	1.2	0.9	1.5	1.6	0.4	139
Adj. PAT	0.3	-0.3	0.3	2.9	1.2	0.9	1.5	1.6	0.4	139
Margin (%)	1.5	-1.3	1.4	10.2	4.9	4.1	6.1	5.7	1.8	
YoY Change (%)	(45.4)	NM	(71.4)	52.2	266.6	NM	375.5	(43.0)	NM	
Per ton analysis (INR)	-									
Blended Realization	5,001	4,918	5,015	5,413	5,134	5,192	5,127	5,323	5,123	1
YoY Change (%)	(8.4)	(10.1)	(8.9)	(1.2)	2.7	5.6	2.2	(1.7)	4.2	
Raw Material	666	719	749	905	965	649	599	1,017	815	(20)
Staff Cost	337	354	320	254	318	357	314	257	350	2
Power and Fuel	1,004	1,025	1,025	892	825	1,052	990	943	950	11
Transport and Forwarding	1,322	1,249	1,319	1,337	1,348	1,299	1,330	1,357	1,320	(2)
Other Exp.	1,082	1,126	1,051	999	953	1,119	1,067	1,010	1,129	(1)
Total Expenditure	4,411	4,472	4,464	4,387	4,409	4,474	4,300	4,584	4,564	(2)
EBITDA	590	446	551	1,027	725	717	828	739	559	28

Source: Company, MOFSL Estimates







VA Tech Wabag

BSE Sensex S&P CNX 83,216 25,492

Time: 16:30 IST

Diamond pass link

Date: 10 November 2025

Conference Call Details

CMP: INR1,386 Buy

Healthy 2Q; revenue/Adj. EBITDA/PAT up 19%/17%/20% YoY Result highlights: 2QFY26

Revenue/Adj. EBITDA/PAT rose 19%/17%/20% YoY – beating our estimates by 2-14%, largely driven by forex gains.

- EBITDA margin adjusted to forex gain stood high at 14.4% while it was 10.7% on a reported basis.
- The company treats forex gains/losses as part of its core operations;
 hence, analyzing adjusted margins is more meaningful.

Result highlights: 1HFY26

- Revenue/Adj. EBITDA/PAT surged 18%/17%/20% YoY broadly in line with the guided trajectory.
- Adj. EBITDA margin stood at 13.8%, within the guided range of 13-15%.

Balance sheet analysis

- Net cash at 1H-end was INR5.6b (INR6.7b excluding HAM projects).
- Due to the nature of business and business cyclicality, working capital is elevated in 1H and typically eases out in 2H.
- The company remains focused on improving margins, tightening working capital, strengthening cash flows and return ratios, and maintaining a net cash profile.

Segment analysis: 2QFY26

- EPC revenue (83% mix) led the growth with a 22% YoY increase, whereas O&M revenue grew by 6% YoY.
- India revenue grew ~8% YoY (49% mix), while RoW markets rose a strong 25% YoY, sustaining healthy margins.
- Municipal revenue contributed 79% of revenue, while Industrial contributed 21% of the mix.
- In 1H, EPC revenue grew 18% YoY, and O&M revenue grew 14% YoY.

Order book analysis: 1HFY26

- Order intake for 1H was INR35b; the company is the preferred bidder in projects worth INR30b.
- Closing order book stood at INR160b (4.6x book-to-bill on TTM basis).
- Secured new orders in the Future Energy Solutions vertical, including UPW/ETP/ZLD system solutions for RenewSys Solar's Hyderabad cell facility and a compressed bio-gas BOT project in Uttar Pradesh with a 15year concession.



Quarterly Performance												(INRm)
Y/E March		F	/25			FY	26E		FY25	FY26E	FY26E	Var
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2Q Est.	%
Net Sales	6,265	7,003	8,110	11,562	7,340	8,345	9,428	13,518	32,940	38,631	8,181	2
YoY Change (%)	13.3	5.3	15.1	23.8	17.2	19.2	16.2	16.9	15.3	17.3		
Total Expenditure	5,452	6,067	7,106	10,154	6,384	7,452	8,177	11,525	28,717	33,538		
EBITDA – reported	813	936	1,004	1,408	956	893	1,251	1,993	4,223	5,092	1,053	-15
Margins (%)	13.0	13.4	12.4	12.2	13.0	10.7	13.3	14.7	12.8	13.2	12.9	
EBITDA – adj. to forex gain	759	1,030	1,051	1,400	820	1,205	1,301	2,043	4,302	5,368	1,053	14
Margins (%)	12.1	14.7	13.0	12.1	11.2	14.4	13.8	15.1	13.1	13.9	12.9	
Depreciation	19	13	13	14	14	17	15	15	59	61		
Interest	180	190	203	215	188	196	201	206	788	791		
Other Income	108	138	148	114	113	416	150	150	446	829		
PBT before EO expense	722	871	936	1,293	867	1,096	1,185	1,922	3,822	5,069		
Extra-Ord expense	0	0	0	0	0	0	0	0	0	0		
PBT	722	871	936	1,293	867	1,096	1,185	1,922	3,822	5,069		
Tax	152	221	207	316	209	260	278	452	896	1,199		
Rate (%)	21.1	25.4	22.1	24.4	24.1	23.7	23.5	23.5	23.4	23.7		
Minority Interest	-2	-3	0	0	0	0	0	0	-5	0		
Profit/Loss of Asso. Cos.	-22	53	-27	18	0	12	6	6	22	24		
Reported PAT	550	706	702	995	658	848	912	1,476	2,953	3,894		
Adj PAT	550	706	702	995	658	848	912	1,476	2,953	3,894	745	14
YoY Change (%)	10.0	17.3	11.6	37.4	19.6	20.1	29.9	48.4	20.2	31.9		
Margins (%)	8.8	10.1	8.7	8.6	9.0	10.2	9.7	10.9	9.0	10.1	9.1	

	 	••	ng	B 4	 •

Y/E March	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	% YoY	% QoQ
Revenue break-up (INR m)							
EPC	5,618	6,512	9,612	5,717	6,853	22	20
Municipal	4,044	4,601	8,219	4,182	5,381	33	29
Industrial	1,574	1,911	1,393	1,535	1,472	(6)	(4)
O&M	1,354	1,525	1,895	1,488	1,431	6	(4)
Municipal	1,211	1,341	1,624	1,235	1,155	(5)	(6)
Industrial	143	184	271	253	276	93	9
Total	6,972	8,037	11,507	7,205	8,284	19	15
Order book break-up (INR m)							
EPC	79,545	76,331	71,101	92,354	92,101	16	(0)
Municipal	68,618	65,725	57,851	80,449	80,537	17	0
Industrial	10,927	10,606	13,250	11,905	11,564	6	(3)
O&M	54,596	54,695	53,737	53,084	55,541	2	5
Municipal	44,944	43,907	42,422	42,014	44,715	(1)	6
Industrial	9,652	10,788	11,315	11,070	10,826	12	(2)
Framework	11,894	11,609	11,830	12,331	12,556	6	2
Total	1,46,035	1,42,635	1,36,668	1,57,769	1,60,198	10	2





7 November 2025 Results Flash | Sector: Midcaps

Prince pipes

 BSE SENSEX
 S&P CNX

 83,216
 25,492

CMP: INR316 BUY

Conference Call Details



Date: 10th Nov 25 Time: 11:30 am IST Dial-in details: click here

Healthy operating performance due to higher gross margins

Earnings beat our estimates

- Consolidated revenue declined 4% YoY and grew 2% QoQ to INR5.9b (est. INR6.3b).
- Total volume declined 1%/2% YoY/QoQ to 42.8KMT.
- Consolidated EBITDA grew 21% YoY/39% QoQ to INR551m (est. INR501m).EBITDA margin stood at 9.3% (est. 7.9%), which expanded 190bp YoY/250bp QoQ.
- EBITDA/kg stood at INR13/kg (up 22%/42% YoY/QoQ).
- Adj. PAT remained flat YoY and grew 3x QoQ to INR146m (est. INR128m).
- Gross debt stood at INR2.3b in Sep'25 vs INR2.6b in Mar'25.
- CFO stood at INR2b in Sep'25 compared to INR990m in Sep'24.

Consolidated - Quarterly Earning Model											(11)	NR m)
Y/E March		FY	25			FY	26		FY25	FY26E	FY26E	Var
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2Q	%
Gross Sales	6,045	6,221	5,777	7,197	5,804	5,946	6,659	8,005	25,239	26,414	6,330	-6
YoY Change (%)	9.2	-5.2	-6.6	-2.8	-4.0	-4.4	15.3	11.2	-1.7	4.7	1.8	
Total Expenditure	5,462	5,764	5,748	6,648	5,408	5,395	5,973	7,101	23,621	23,877	5,829	
EBITDA	583	457	30	548	396	551	686	905	1,618	2,537	501	10
Margins (%)	9.6	7.3	0.5	7.6	6.8	9.3	10.3	11.3	6.4	9.6	7.9	
Depreciation	257	276	264	273	307	325	315	320	1,070	1,267	310	
Interest	14	16	32	33	52	45	40	35	97	172	45	
Other Income	26	39	15	57	27	16	30	30	137	104	25	
PBT before EO expense	337	204	-252	299	64	198	361	580	588	1,202	171	
Extra-Ord expense	0	0	0	0	0	0	0	0	0	0	0	
PBT	337	204	-252	299	64	198	361	580	588	1,202	171	
Tax	90	57	-48	58	15	51	91	146	157	304	43	
Rate (%)	26.7	28.0	18.9	19.2	24.2	26.0	25.2	25.2	26.7	25.3	25.1	
Minority Interest & Profit/Loss of Asso. Cos.	0	0	0	0	0	0	0	0	0	0	0	
Reported PAT	247	147	-204	242	48	146	270	434	431	898	128	
Adj PAT	247	147	-204	242	48	146	270	434	431	898	128	14
YoY Change (%)	25.8	-72.1	-154.3	-55.8	-80.5	-0.5	-232.2	79.5	-73.8	108	-13	
Margins (%)	4.1	2.4	-3.5	3.4	0.8	2.5	4.1	L 5.4	1.7	3.4	2.0	







LIC India: Value of new business will continue to grow; R Doriaswamy, CEO & MD

- Confident of strong topline
- Expect to compensate lost GST input credit
- Biz opportunities were lost B/w GST announcement & implementation, affecting
 APE
- Last 8 days couldn't make up for the loss



Apollo Hospitals: Avg rev/patient up 9% aided by growth in high-end surgeries; Suneeta Reddy, MD

- Healthcare services biz grew 9% this quarter
- Looking at other countries such as Indonesia, Brunei for Medical Tourism
- Focused on restructuring Apollo Health and Lifestyle this quarter
- International patient revenue accounts for 5% of sales



Lupin Ltd: Expects muted Q4 & H2 despite stellar results; Ramesh Swaminathan, CFO

- Good growth led by products with exclusivity
- Focus on more complex products to ensure sustainability in margins
- Expect secular growth over a period of time
- Exclusivity period ending in 6 months will impact performance



Narayana Health: Over a period of time, margins for practice plus will improve; Sandhya J, Group CFO

- Good success has been observed for large operators
- Will continue to improve margin for India
- To acquire UK-Based practice plus group hospitals
- Synergies Will Come By FY26-end Or By Beginning Of FY27



Godrej Properties: Best ever Q2 results and an action packed H2 FY26; Gaurav Pandey, CEO & MD

- Reaffirms pre-sales target despite muted collections
- Co achieved 81% of annual development guidance
- Added 4 new projects, estimated sales area of 5.8 mn sq ft
- Expected booking value of INR 16250 crore

Read More







		CMP	TP	% Upside		EPS (INR	2)	EPS	Gr. YoY	(%)	P/E	(x)	P/B	(x)	ROE	(%)
Company	Reco	(INR)	(INR)	Downside	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY26E	FY27E	FY26E	FY27E
Automobiles																
Amara Raja Ener.	Neutral	980	940	-4	42.7	50.1	57.8	-11.5	17.4	15.5	23.0	19.6	2.2	2.0	10.1	10.8
Apollo Tyres	Buy	515	551	7	24.0	29.1	32.1	22.6	21.3	10.2	21.5	17.7	1.7	1.6	10.0	11.4
Ashok Ley.	Buy	141	166	17	6.0	7.2	8.5	10.1	19.7	17.0	23.4	19.5	6.3	5.5	28.8	30.0
Bajaj Auto	Neutral	8724	9070	4	338.9	370.8	407.5	13.2	9.4	9.9	25.7	23.5	6.9	6.3	28.1	28.1
Balkrishna Inds	Neutral	2320	2257	-3	78.0	96.7	107.3	-19.1	24.0	11.0	29.8	24.0	3.9	3.4	13.7	15.1
Bharat Forge	Neutral	1317	1109	-16	24.2	33.0	40.9	13.0	36.3	24.1	54.4	39.9	6.3	5.7	12.0	14.9
Bosch	Neutral		36375	-1	824.3		1.113.4	20.8	18.4	14.1	44.7	37.7	7.0	6.5	16.6	17.9
CEAT	Buy	4025	4523	12	161.3	210.5	241.8	32.1	30.5	14.9	25.0	19.1	3.4	2.9	14.1	16.4
Craftsman Auto	Neutral	6772	6391	-6	156.2	229.2	303.4	69.6	46.7	32.4	43.3	29.6	5.0	4.3	12.3	15.8
Eicher Mot.	Sell	6887	5772	-16	192.1	213.0	241.2	11.3	10.9	13.2	35.8	32.3	7.7	6.7	23.0	22.1
Endurance Tech.	Buy	2854	3311	16	72.0	84.4	99.5	22.5	17.2	17.9	39.6	33.8	6.1	5.4	16.5	16.9
Escorts Kubota	Neutral	3630	3672	10	107.5	125.5	136.7	6.9	16.7	8.9	33.8	28.9	3.9	3.6	12.1	12.9
Exide Ind	Neutral	377	404	7	15.3	16.7	17.7	21.1	9.1	5.7	24.6	22.5	2.1	1.9	8.4	8.5
Happy Forgings	Buy	1012	1200	19	30.1	37.5	51.4	6.0	24.6	37.1	33.7	27.0	4.6	4.0	14.4	15.8
Hero Moto	Buy	5296	6315	19	258.3	283.1	311.5	14.3	9.6	10.0	20.5	18.7	4.9	4.5	25.1	25.3
Hyundai Motor	Buy	2329	2801	20	73.6	87.5	105.6	6.0	18.9	20.7	31.6	26.6	9.2	7.3	32.4	30.6
M&M	Buy	3692	4122	12	120.5	144.7	167.6	22.1	20.1	15.8	30.6	25.5	6.1	5.1	21.5	21.8
CIE Automotive	Buy	431	502	16	21.5	23.2	25.7	-1.0	8.2	10.8	20.1	18.6	2.3	2.1	11.8	11.7
Maruti Suzuki	Buy	15478	18712	21	484.4	616.5	720.0	9.1	27.3	16.8	32.0	25.1	4.6	4.1	14.5	16.2
MRF	Sell		125764				6,658.0	15.7	16.0	12.5	31.2	26.8	3.3	2.9	11.1	11.6
Samvardh. Motherson	Buy	104	123	19	3.2	4.7	5.7	-11.2	47.8	21.0	32.8	22.2	3.0	2.7	9.4	12.8
Motherson Wiring	Buy	47	55	17	1.0	1.4	1.7	9.0	37.3	21.7	47.0	34.3	15.7	12.5	35.9	40.5
Sona BLW Precis.	Neutral	491	448	-9	11.2	12.4	13.9	13.8	10.6	11.7	43.7	39.5	5.0	4.7	11.9	12.2
Tata Motors	Neutral	406	687	69	41.9	54.5	74.7	-33.7	30.1	36.9	9.7	7.4	1.2	1.0	12.6	14.5
TVS Motor	Buy	3459	4159	20	76.2	96.4	121.9	33.6	26.5	26.5	45.4	35.9	12.7	9.9	31.7	31.0
Tube Investments	Buy	2983	3680	23	43.2	48.6	53.2	12.0	12.5	9.5	69.0	61.3	9.7	8.5	15.0	14.8
Aggregate								1.2	21.9	19.2	28.4	23.3	4.5	4.0	16.0	17.1
Banks - Private																
AU Small Finance	Buy	909	925	2	35.2	47.5	62.6	18.0	35	31.8	25.8	19.1	3.5	2.9	14.3	16.7
Axis Bank	Neutral	1223	1300	6	78.3	99.0	119.6	-8.2	26.4	20.8	15.6	12.4	1.9	1.7	12.8	14.4
Bandhan Bank	Neutral	154	175	14	9.8	18.2	23.5	-42.5	86	29.1	15.7	8.4	1.0	0.9	6.4	11.3
DCB Bank	Buy	174	165	-5	23.5	30.9	38.5	20.0	31.7	24.3	7.4	5.6	0.9	0.8	13.2	15.3
Equitas Small Fin.	Buy	61	70	15	0.2	5.7	9.0	-83.9	2,630.3	58.9	291.4	10.7	1.2	1.1	0.4	10.5
Federal Bank	Buy	237	260	10	16.4	19.9	24.4	-1.2	21.6	22.4	14.5	11.9	1.6	1.3	11.4	12.1
HDFC Bank	Buy	983	1175	20	49.1	54.7	64.7	11.5	11.5	18.3	20.0	18.0	2.7	2.4	14.3	14.3
ICICI Bank	Buy	1343	1700	27	72.8	82.7	95.7	9.0	13.6	15.8	18.4	16.2	2.9	2.5	16.7	16.5
IDFC First Bk	Neutral	82	80	-2	2.7	5.3	7.7	29.8	92.3	45.9	29.6	15.4	1.5	1.4	5.1	9.3
IndusInd	Neutral	797	800	0	13.7	49.8	73.5	-58.5	262.5	47.6	58.0	16.0	1.0	0.9	1.7	5.8
Kotak Mah. Bk	Buy	2089	2500	20	105.3	126.0	152.4	-5.4	19.6	21.0	19.8	16.6	2.4	2.1	11.7	12.7
RBL Bank	Buy	328	350	7	16.8	14.5	20.0	47.2	-13.9	37.9	19.5	22.7	1.2	1.2	6.5	7.5
Aggregate	Бау	320	330		10.0	14.5	20.0	4.4	19.9	20.3		16.0	2.5	2.2		13.5
Banks - PSU								7.7	13.3	20.5	13.2	10.0	2.5	2.2	12.5	13.3
BOB	Neutral	289	290	0	37.2	41.3	48.2	-1.6	11.0	16.7	7.8	7.0	1.1	1.0	14.6	14.7
Canara Bank	Buy	141	153	9	21.4	22.9	25.6	14.0	6.9	12.1	6.6	6.1	1.2	1.1	19.5	18.6
Indian Bank	Buy	874	900	3	93.1	96.4	107.2	14.9	3.5	11.2	9.4	9.1	1.6	1.4	18.6	17.0
Punjab Natl.Bank	Buy	122	135	10	14.4	18.9	22.1	-2.5	31.4	16.5	8.5	6.5	1.0	0.9		15.4
SBI	Buy	956	1075	12	95.5	103.8	120.4	9.9	9	16.0	10.0	9.2	1.6	1.3	16.9	15.5
Union Bank (I)	Neutral	153	155	1	21.8	24.0	27.5	-7.3	10	14.4	7.0	6.4	1.0	0.9	14.7	14.4
Aggregate								7.2	12	15	9	8.0	1.4	1.2	15.2	15.1
NBFCs																
AAVAS Financiers	Neutral	1573	1800	14	80.3	97.6	117.4	10.6	21.6	20.3	19.6	16.1	2.5	2.2	13.6	14.4
Aditya Birla Cap	Buy	338	380	12	15.2	19.5	25.3	18.9	28.2	29.7	22.2	17.4	2.6	2.3	12.3	14.2
																24.4
Bajaj Fin.	Neutral	1067	1090	2	32.9	42.6	53.8	21.8	29.4	26.5	32.4	25.1	5.8	4.9	19.4	21.1







Chedimanuma&rine Buy 1702 1935 14 600 780 97.0 81.5 30.0 24.4 28.4 21.7 48. 81.9 19.9 10.0 CreditAccess Buy 1348 1690 25 51.7 88.4 116.3 15.4 16.9 15.4 16.9 16.9 16.0 16.1 16.1 16.1 16.1 16.1 16.1 16.1			CMP	TP	% Upside		EPS (INR	3)	EPS	Gr. YoY	′ (%)	P/E	(x)	P/E	3 (x)	ROE	(%)
Cholamaninw.Refine Buy 1702 1935 14 600 78.0 97.0 18.5 30.0 24.4 28.4 21.7 48.8 19.9 18.9 10. CreditAccess Buy 1348 1690 25 51.7 88.4 116.3 15.4 50.0 18.5 30.0 24.4 28.4 21.7 48.8 19.9 18.9 17.0 10.0 10.5 15.0 15.0 14.5 15.3 28.2 18.9 17.0 10.0 10.5 15.0 19.5 18.5 18.0 19.5 18.5 18.0 19.5 18.5 18.0 19.5 18.5 18.0 19.5 18.5 18.0 19.5 18.5 18.0 19.5 18.5 18.0 19.5 18.5 18.0 19.5 18.5 18.0 19.5 18.5 18.0 19.5 18.5 18.0 19.5 18.5 18.0 19.5 18.5 18.0 19.5 18.5 18.0 19.5 18.5 18.0 19.5 18.5 18.0 19.5 18.5 18.5 18.5 18.5 18.5 18.5 18.5 18	Company	Reco	(INR)	(INR)	Downside	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY26E	FY27E	FY26E	FY27E
CerdinAccess Buy 1448 1490 25 51, 51, 88.4 16.3 55.4 70, 91.6 26.1 15.3 2.8 2.3 11.2 1 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2	Can Fin Homes	Neutral	881	915	4	75.9	79.5	92.8	18.0	4.7	16.7	11.6	11.1	2.0	1.7	18.4	16.7
Fusion Finance Buy 646 710 10 40.3 45.2 3 -2.0 17.5 14.8 -94.8 -94.8 -10. 41.1 NM 99 1.2 1.0 -1.6 19.9 1.1 1.0 -1.6 19.9 1.1 1.0 -1.6 19.9 1.1 1.0 -1.6 19.9 1.1 1.0 -1.6 19.9 1.1 1.0 -1.6 19.9 1.1 1.0 -1.6 19.9 1.1 1.0 -1.6 19.9 1.1 1.0 -1.6 19.9 1.1 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	Cholaman.Inv.&Fn	Buy	1702	1935	14	60.0	78.0	97.0	18.5	30.0	24.4	28.4	21.7	4.8	3.9	18.9	19.8
Five-Star Business Buy 646 710 10 40.3 45.2 54.6 10.6 12.3 20.6 15.0 14.3 2.6 2.2 13.3 1 III-RI Finance Buy 526 635 21 34.7 47.0 52.2 289.0 35.3 32.5 15.2 11.2 1.6 1.4 12.1 1.9 1.9 11.1 11.1 11.1 11.1 11.1 1	CreditAccess	Buy	1348	1690	25	51.7	88.4	116.3	55.4	70.9	31.6	26.1	15.3	2.8	2.3	11.2	16.6
IFLF Finance Buy \$26 635 21 347 470 622 2890 35.3 32.5 15.2 11.2 16 1.4 11.3 11.3 11.5 1	Fusion Finance	Buy	174	215	23	-2.0	17.5	24.8	-98.4	LP	41.1	NM	9.9	1.2	1.0	-1.6	11.1
HOB Financial Meutral 712 820 15 31.4 90.8 1950 150 190.9 236 27.6 17.4 2.8 2.4 12.1 1900me First Finan Buy 132 1450 28 59 39.2 13.9 20.9 14.7 6.4 50.1 6.7 18.8 1.0 0.9 16.5 16.5 16.5 16.5 18.5 18.5 18.5 18.5 18.5 18.5 18.5 18	Five-Star Business	Buy	646	710	10	40.3	45.2	54.6	10.6	12.3	20.6	16.0	14.3	2.6	2.2	17.3	16.5
Home First Final	IIFL Finance	Buy	526	635	21	34.7	47.0	62.2	289.0	35.3	32.5	15.2	11.2	1.6	1.4	11.3	13.6
Indistange Buy 262 285 9 39.2 31.9 20.9 91.47 54.4 50.1 67. 18.8 10. 0.9 10.5 18.8 11.1 11.1 12.2 12.6 13.9 20.9 91.47 54.4 20.3 20.4 20.4 20.3 20.4 20.3 20.4 2	HDB Financial	Neutral	712	820	15	31.4	40.8	50.5	15.0	29.8	23.6	22.6	17.4	2.8	2.4	14.2	15.0
1.	Home First Finan	Buy	1132	1450	28	53.2	64.2	76.0	25.4	20.8	18.3	21.3	17.6	2.7	2.4	16.1	14.4
1.	IndoStar	Buy	262	285	9	39.2	13.9	20.9	914.7	-64.4	50.1	6.7	18.8	1.0	0.9	16.5	5.1
Lichiga Fin Neutral 271 305 31 31 31 31 31 32 34 34 35 35 35 35 35 35	L&T Finance		304	330	9	11.9	16.1	20.2	12.6	34.9	25.4	25.4	18.9	2.7	2.4	11.1	13.6
Manspipuram Fin. Neutral 271 305 13 11.3 19.2 24.9 20.3 69.4 29.8 23.9 14.1 16. 15. 7.5 1.5																	13.3
MAS Financial Buy 308 380 23 200 248 302 18.7 24.0 21.6 15.4 12.4 19.0 17. 13.4 1 MSM Fin. Buy 313 350 12 202 24.7 28.4 5.0 52.4 14.6 15.5 12.7 1.8 1.6 12.6 17.6 18.4 19.4 MSM Fin. Buy 313 350 12 202 24.7 28.4 5.0 50.9 13.6 12.6 15.5 12.7 1.8 1.6 12.6 17.7 19.5 19.5 19.7 19.5 19.5 19.7 19.5 19.5 19.5 19.5 19.5 19.5 19.5 19.5																	11.3
M&M Fin. Method Fin Method																	14.6
Muthoot Fin Neutral 3230 3100 4 195.5 21.5 250.0 50.9 13.3 12.9 16.5 14.6 3.7 31.0 14.7 19 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1																	13.2
Priamal Enterp. Buy 1124 1460 30 63.7 106.8 177.6 17.9 17.7 17.5 10.5 0.9 0.8																	23.0
PNB Housing Buy 896 1080 21 88.2 96.4 117.3 18.4 9.3 21.7 10.2 9.3 1.2 1.3 1.5 1																	8.2
Poonawalla Fincorp Buy 463 605 31 8.7 21.8 32.0 783.5 15.0 26.0 53.3 21.3 3.6 3.1 7.6 1.6 1.7 PFC Buy 365 465 28 57.5 57.9 61.4 69.2 10.1 6.0 12.7 6.6 5.5 52. 1.1 10.9 20.7 1.5 Regco Home Fin Neutral 241 280 16 68.6 27.3 48.8 40.4 1.7 67.8 1.8 1.8 1.0 0.8 2.9 1.5 Spandana Sphoorty Neutral 241 280 16 68.6 27.3 48.8 40.4 1.7 67.8 1.8 1.8 1.0 0.8 2.9 1.5 Spandana Sphoorty Neutral 241 280 16 68.6 27.3 48.8 40.4 1.7 67.8 1.8 1.8 1.0 0.8 2.9 1.5 Spandana Sphoorty Neutral 241 280 16 68.6 27.3 48.8 40.4 1.7 1.7 1.8 1.8 1.2 1.2 1.2 1.2 1.2 Aggregat Taylor Tay																	12.4
PFC BUY 380 485 27 57.9 61.4 69.2 10.1 6.0 12.7 6.6 6.2 1.2 1.1 19.6 19.6 REC BUY 365 465 28 65.9 70.6 80.8 10.4 7.0 14.5 5.5 5.2 1.1 0.9 20.7 19.6 19.6 Spandana Sphoorty Neutral 241 280 16 -86.6 27.3 48.8 40.4 LP 67.8 18.4 18.9 18.9 18.0 18.0 18.2 19.2 19.4 19.5 18.9 18.0 18.0 18.2 19.4 19.5 18.4 18.9 18.4 18.5 18.5 18.5 18.5 18.5 18.5 18.5 18.5		•															
RECO More Fin Neutral 25 400 -6 69.9 73.6 80.8 10.4 7.0 14.5 5.5 5.0 1.1 0.9 20.7 18.8 18.9 19.0 19.0 19.0 19.0 19.0 19.0 19.0 19	·																15.8
Repco Home Fin Neutral 245 400 -6 69.9 73.6 84.4 -0.5 5.3 14.7 6.1 5.8 0.7 0.6 0.2 1.7 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 7.5 5.8 7.5 5.5 7.5 5.5 7.5																	18.2
Spandana Sphoorty Neutral 241 280 16 -86.6 27.3 45.8 -40.4 LP 67.8 NM 8.8 1.0 0.8 -29.0 1.0 51.7 1.8 15.8 15.8 13.0 2.1 16.1 2 15.8 15.8 13.0 2.0 2.1 15.0 2 2 15.0 2 2 15.0 2 2 15.0 2 2 15.0 2 2 15.0 2 3 3 3 3 3 2 2 2 2 2 2 2 3 3 3 2 2 2 2 3 3		•															19.2
Shriram Finance Buy 816 860 5 51.7 61.8 72.9 7.4 19.7 17.8 15.8 15.2 2.4 2.1 16.1 17.8 18.2																	11.7
NBFC-Non Lending																	10.2
NBFC-Non Lending Section Secti	Shriram Finance	Buy	816	860	5	51.7	61.8	72.9									16.8
360 ONE WAM Buy 1066 1400 31 31.1 36.9 43.7 20.4 18.7 18.4 34.3 28.9 5.3 4.4 16.5 16.5 Aditya Birla AMC Buy 764 1100 44 37.1 42.3 48.1 14.8 14.0 13.8 20.6 18.1 5.2 4.7 26.9 2 4.7 26.9 2 4.7 26.9 2 4.7 26.9 4.7 26.9 2 4.7 26.9 2 4.7 26.9 4.7 26.9 4.7 26.9 2.8 Anand Rathi Wealth Neutral 3124 2800 10 11 91.1 136.0 187.2 29.9 49.4 37.6 28.7 37.6 28.7 37.6 28.7 37.6 28.7 37.6 28.7 37.6 28.7 37.6 28.7 37.6 28.7 37.6 28.7 37.6 28.7 37.6 28.7 37.6 28.7 37.6 28.7 37.6 28.7 37.6 38.7 37.6 38.7 37.6 38.7 37.6 38.7 37.6 38.7 38.7 37.6 38.7 3	Aggregate								23.1	19.8	21.1	17.2	14.3	2.6	2.2	15.0	15.7
Aditya Birla AMC Buy 764 1100 44 37.1 42.3 48.1 14.8 14.0 13.8 20.6 18.1 5.2 4.7 26.9 Anand Rathi Wealth Neutral 3124 2800 -10 46.8 59.8 73.5 29.3 27.9 22.8 66.8 52.2 26.6 18.8 47.0 48.0 Angel One Buy 2617 2900 11 91.1 136.0 187.2 29.9 49.4 37.6 28.7 19.2 3.5 3.1 14.0 14.0 18.0 18.0 18.0 18.1 18.0 18.0 18.1 18.0 18.0	NBFC-Non Lending																
Anand Rathi Wealth	360 ONE WAM	Buy	1066	1400	31	31.1	36.9	43.7	20.4	18.7	18.4	34.3	28.9	5.3	4.4	16.5	17.0
Angel One Buy 2617 2900 11 91.1 136.0 187.2 -29.9 49.4 37.6 28.7 19.2 3.5 3.1 14.0 185.5 185.5 Neutral 2678 2250 -16 50.8 56.3 65.4 56.7 10.8 16.1 52.7 47.6 18.1 14.0 34.4 26.5 18.5 18.5 18.5 18.5 18.5 18.5 18.5 18	Aditya Birla AMC	Buy	764	1100	44	37.1	42.3	48.1	14.8	14.0	13.8	20.6	18.1	5.2	4.7	26.9	27.3
BSE Neutral 2678 2250 -16 50.8 56.3 65.4 56.7 10.8 16.1 52.7 47.6 18.1 14.0 34.4 26.4 Cams Services Buy 3798 4900 29 95.0 112.1 131.9 0.2 17.9 17.7 40.0 33.9 14.3 12.2 38.4 32.5 CDSL Neutral 1579 1520 -4 24.3 28.8 33.7 -3.2 18.6 17.2 65.1 54.9 16.4 14.5 26.9 24.5 LDSL Neutral 1579 1520 -4 24.3 28.8 33.7 -3.2 18.6 17.2 65.1 54.9 16.4 14.5 26.9 24.5 LDSL Neutral 1112 1300 17 21.8 26.4 31.6 152.0 21.0 19.8 51.0 42.1 13.2 11.5 27.4 28.5 LDSL Neutral 1112 1300 17 21.8 26.4 31.6 12.0 21.0 19.8 51.0 42.1 13.2 11.5 27.4 28.5 LDSL Neutral 1070 1200 12 18.0 257.7 277.0 87.1 25.1 7.5 45.8 36.6 22.9 20.4 52.7 51.5 LDSL Neutral 1070 1200 12 18.0 21.6 26.0 5.9 19.8 20.1 59.3 49.5 9.1 7.7 16.6 18.1 Nippon Life AMC Buy 850 1060 25 23.9 27.9 32.0 17.0 17.1 14.5 35.6 30.4 12.5 12.2 35.4 40.5 Nippon Life AMC Buy 7297 9100 25 306.8 362.7 430.0 10.8 18.2 18.5 23.8 20.1 6.5 5.6 29.2 20.1 VITI AMC Buy 1207 1700 41 54.7 78.1 90.4 14.4 42.9 15.7 22.1 15.4 2.9 27.7 13.2 14.5 Aggregate	Anand Rathi Wealth	Neutral	3124	2800	-10	46.8	59.8	73.5	29.3	27.9	22.8	66.8	52.2	26.6	18.8	47.0	42.0
Cams Services Buy 3798 4900 29 95.0 112.1 131.9 0.2 17.9 17.7 40.0 33.9 14.3 12.2 38.4 20 10 10 10 10 10 10 10 10 10 10 10 10 10	Angel One	Buy	2617	2900	11	91.1	136.0	187.2	-29.9	49.4	37.6	28.7	19.2	3.5	3.1	14.0	18.7
CDSL Neutral 1579 1520 -4 24.3 28.8 33.7 -3.2 18.6 17.2 65.1 54.9 16.4 14.5 26.9 24 14.5 14.5 14.5 14.5 14.5 14.5 14.5 14.	BSE	Neutral	2678	2250	-16	50.8	56.3	65.4	56.7	10.8	16.1	52.7	47.6	18.1	14.0	34.4	29.5
HDFC AMC Buy 5432 6800 25 134.6 153.2 177.1 16.8 13.8 15.6 40.4 35.5 13.1 12.0 33.9 18.5 18.5 18.5 19.5 19.5 19.5 19.5 19.5 19.5 19.5 19	Cams Services	Buy	3798	4900	29	95.0	112.1	131.9	0.2	17.9	17.7	40.0	33.9	14.3	12.2	38.4	38.8
KFin Technologies Neutral 1112 1300 17 21.8 26.4 31.6 12.0 21.0 19.8 51.0 42.1 13.2 11.5 27.4 24. MCX Neutral 9426 10700 14 206.0 257.7 277.0 87.1 25.1 7.5 45.8 36.6 22.9 20.4 52.7 51.0 NSDL Neutral 1070 1200 12 18.0 21.6 26.0 5.9 19.8 20.1 59.3 49.5 9.1 7.7 16.6 10.0 10.0 10.0 10.0 10.0 10.0 10.0	CDSL	Neutral	1579	1520	-4	24.3	28.8	33.7	-3.2	18.6	17.2	65.1	54.9	16.4	14.5	26.9	28.1
MCX Neutral 9426 10700 14 206.0 257.7 277.0 87.1 25.1 7.5 45.8 36.6 22.9 20.4 52.7 52.7 NSDL Neutral 1070 1200 12 18.0 21.6 26.0 5.9 19.8 20.1 59.3 49.5 9.1 7.7 16.6 17.0 Nippon Life AMC Buy 850 1060 25 23.9 27.9 32.0 17.0 17.1 14.5 35.6 30.4 12.5 12.2 35.4 45.0 Nippon Life AMC Buy 7297 9100 25 306.8 362.7 430.0 10.8 18.2 18.5 23.8 20.1 6.5 5.6 29.2 30.0 Neutral 2640 2800 6 54.0 69.4 90.1 14.3 28.4 29.9 48.9 38.1 63.1 49.0 29.2 20.0 UTI AMC Buy 1207 1700 41 54.7 78.1 90.4 14.4 42.9 15.7 22.1 15.4 2.9 2.7 13.2 14.5 15.4 15.4 15.4 15.4 15.4 15.4 15.4	HDFC AMC	Buy	5432	6800	25	134.6	153.2	177.1	16.8	13.8	15.6	40.4	35.5	13.1	12.0	33.9	35.3
NSDL Neutral 1070 1200 12 18.0 21.6 26.0 5.9 19.8 20.1 59.3 49.5 9.1 7.7 16.6 1 Nippon Life AMC Buy 850 1060 25 23.9 27.9 32.0 17.0 17.1 14.5 35.6 30.4 12.5 12.2 35.4 4 Nuvama Wealth Buy 7297 9100 25 306.8 362.7 430.0 10.8 18.2 18.5 23.8 20.1 6.5 5.6 29.2 3 Prudent Corp. Neutral 2640 2800 6 54.0 69.4 90.1 14.3 28.4 29.9 48.9 38.1 63.1 49.0 29.2 2 UTI AMC Buy 1207 1700 41 54.7 78.1 90.4 -14.4 42.9 15.7 22.1 15.4 2.9 2.7 13.2 1 Insurance HDFC Life Insur. Buy 749 910 21 8.4 10.0 11.5 0.2 18.9 14.7 89.2 75.0 2.5 2.2 15.4 1 Insurance HDFC Life Insur. Buy 616 720 17 8.7 11.0 13.2 6.6 26.1 19.9 70.4 55.8 1.7 1.5 11.7 1 Insurance Corp. Buy 924 1080 17 87.8 96.3 104.5 15.3 9.7 8.6 10.5 9.6 0.7 0.6 11.7 1 Insurance Insurance Buy 1619 2000 24 11.9 14.1 15.6 26.5 17.8 11.0 135.8 115.2 2.3 1.9 19.2 1 Insurance Buy 1999 2240 12 24.1 25.7 28.0 -0.3 6.7 9.0 83.1 77.9 2.4 2.0 18.1 15.1 Star Health Insu Buy 488 570 17 11.4 16.3 21.7 3.9 42.6 33.3 42.7 30.0 3.7 3.3 9.1 1 Insurance Chemicals Atul Buy 5687 7520 32 216.8 250.5 27.07 28.1 15.5 8.1 26.2 22.7 2.7 2.5 10.9 14.1 15.5 15.5 8.1 26.2 22.7 2.7 2.5 10.9 14.1 15.5 15.5 8.1 26.2 22.7 2.7 2.5 10.9 14.1 15.5 15.5 8.1 26.2 22.7 2.7 2.5 10.9 14.1 15.5 15.5 15.5 8.1 26.2 22.7 2.7 2.5 10.9 14.1 15.5 15.5 15.5 8.1 26.2 22.7 2.7 2.5 10.9 14.1 15.5 15.5 15.5 8.1 26.2 22.7 2.7 2.5 10.9 14.1 15.5 15.5 15.5 8.1 26.2 22.7 2.7 2.5 10.9 14.1 15.5 15.5 15.5 8.1 26.2 22.7 2.7 2.5 10.9 14.1 15.5 15.5 15.5 8.1 26.2 22.7 2.7 2.5 10.9 14.1 15.5 15.5 15.5 8.1 26.2 22.7 2.7 2.5 10.9 14.1 15.5 15.5 15.5 15.5 15.5 15.5 15.5	KFin Technologies	Neutral	1112	1300	17	21.8	26.4	31.6	12.0	21.0	19.8	51.0	42.1	13.2	11.5	27.4	29.2
Nippon Life AMC Buy 850 1060 25 23.9 27.9 32.0 17.0 17.1 14.5 35.6 30.4 12.5 12.2 35.4 4 Nuvama Wealth Buy 7297 9100 25 306.8 362.7 430.0 10.8 18.2 18.5 23.8 20.1 6.5 5.6 29.2 3 1 Prudent Corp. Neutral 2640 2800 6 54.0 69.4 90.1 14.3 28.4 29.9 48.9 38.1 63.1 49.0 29.2 2 1 1	MCX	Neutral	9426	10700	14	206.0	257.7	277.0	87.1	25.1	7.5	45.8	36.6	22.9	20.4	52.7	58.9
Nuvama Wealth Buy 7297 9100 25 306.8 362.7 430.0 10.8 18.2 18.5 23.8 20.1 6.5 5.6 29.2 3 Prudent Corp. Neutral 2640 2800 6 54.0 69.4 90.1 14.3 28.4 29.9 48.9 38.1 63.1 49.0 29.2 2 UTI AMC Buy 1207 1700 41 54.7 78.1 90.4 -14.4 42.9 15.7 20.1 18.2 40.2 33.5 10.1 8.7 25.1 2 18.9 14.7 20.1 18.2 40.2 33.5 10.1 8.7 25.1 2 18.9 14.7 20.1 18.9 14.7 89.2 75.0 2.5 2.2 15.4 16.1 16.1 16.1 16.1 16.2 17.0 18.2 18.9	NSDL	Neutral	1070	1200	12	18.0	21.6	26.0	5.9	19.8	20.1	59.3	49.5	9.1	7.7	16.6	16.9
Nuvama Wealth Buy 7297 9100 25 306.8 362.7 430.0 10.8 18.2 18.5 23.8 20.1 6.5 5.6 29.2 3 Prudent Corp. Neutral 2640 2800 6 54.0 69.4 90.1 14.3 28.4 29.9 48.9 38.1 63.1 49.0 29.2 2 UTI AMC Buy 1207 1700 41 54.7 78.1 90.4 -14.4 42.9 15.7 20.1 18.2 40.2 33.5 10.1 8.7 25.1 2 18.9 14.7 20.1 18.2 40.2 33.5 10.1 8.7 25.1 2 18.9 14.7 20.1 18.9 14.7 89.2 75.0 2.5 2.2 15.4 16.1 16.1 16.1 16.1 16.2 17.0 18.2 18.9	Nippon Life AMC	Buy	850	1060	25	23.9	27.9	32.0	17.0	17.1	14.5	35.6	30.4	12.5	12.2	35.4	40.6
Prudent Corp. Neutral 2640 2800 6 54.0 69.4 90.1 14.3 28.4 29.9 48.9 38.1 63.1 49.0 29.2 20.0 UTI AMC Buy 1207 1700 41 54.7 78.1 90.4 -14.4 42.9 15.7 22.1 15.4 2.9 2.7 13.2 13.4 14.7 20.1 18.2 40.2 33.5 10.1 8.7 25.1 20.1 18.2 10.1 18.2			7297	9100	25	306.8	362.7	430.0	10.8	18.2	18.5	23.8	20.1	6.5	5.6	29.2	30.2
UTI AMC Buy 1207 1700 41 54.7 78.1 90.4 -14.4 42.9 15.7 22.1 15.4 2.9 2.7 13.2 1 Aggregate 14.7 20.1 18.2 40.2 33.5 10.1 8.7 25.1 2 Insurance HDFC Life Insur. Buy 749 910 21 8.4 10.0 11.5 0.2 18.9 14.7 89.2 75.0 2.5 2.2 15.4 1 ICICI Lombard Buy 2020 2300 14 62.5 72.6 82.9 22.7 16.1 14.3 32.3 27.8 6.0 5.1 19.9 1 ICICI Pru Life Buy 616 720 17 8.7 11.0 13.2 6.6 26.1 19.9 70.4 55.8 1.7 1.5 11.7 1 Life Insurance Corp. Buy 924 1080 17 87.8 96.3 104.5 15.3 9.7 8.6 10.5 9.6 0.7 0.6 11.7 1 Max Financial Buy 1619 2000 24 11.9 14.1 15.6 26.5 17.8 11.0 135.8 115.2 2.3 1.9 19.2 1 Niva Bupa Health Buy 76 92 21 0.4 1.5 3.0 -68.2 293.3 104.5 204.4 52.0 3.6 3.4 2.0 1 SBI Life Insurance Buy 1999 2240 12 24.1 25.7 28.0 -0.3 6.7 9.0 83.1 77.9 2.4 2.0 18.1 1 Star Health Insu Buy 488 570 17 11.4 16.3 21.7 3.9 42.6 33.3 42.7 30.0 3.7 3.3 9.1 1 Chemicals Alkyl Amines Neutral 1778 1900 7 36.7 42.4 46.4 1.0 15.4 9.5 48.4 42.0 5.9 5.4 12.8 1 Atul Buy 5687 7520 32 216.8 250.5 270.7 28.1 15.5 8.1 26.2 22.7 2.7 2.5 10.9 1			2640	2800	6				14.3	28.4							
Aggregate HDFC Life Insur. Buy 749 910 21 8.4 10.0 11.5 0.2 18.9 14.7 89.2 75.0 2.5 2.2 15.4 10.0																	
Note																	
HDFC Life Insur. Buy 749 910 21 8.4 10.0 11.5 0.2 18.9 14.7 89.2 75.0 2.5 2.2 15.4 1 ICICI Lombard Buy 2020 2300 14 62.5 72.6 82.9 22.7 16.1 14.3 32.3 27.8 6.0 5.1 19.9 1 ICICI Pru Life Buy 616 720 17 8.7 11.0 13.2 6.6 26.1 19.9 70.4 55.8 1.7 1.5 11.7 1 Life Insurance Corp. Buy 924 1080 17 87.8 96.3 104.5 15.3 9.7 8.6 10.5 9.6 0.7 0.6 11.7 1 Max Financial Buy 1619 2000 24 11.9 14.1 15.6 26.5 17.8 11.0 135.8 115.2 2.3 1.9 19.2 1 Niva Bupa Health Buy 76 92 21 0.4 1.5 3.0 -68.2 293.3 104.5 204.4 52.0 3.6 3.4 2.0 1 SBI Life Insurance Buy 1999 2240 12 24.1 25.7 28.0 -0.3 6.7 9.0 83.1 77.9 2.4 2.0 18.1 1 Star Health Insu Buy 488 570 17 11.4 16.3 21.7 3.9 42.6 33.3 42.7 30.0 3.7 3.3 9.1 1 Chemicals Alkyl Amines Neutral 1778 1900 7 36.7 42.4 46.4 1.0 15.4 9.5 48.4 42.0 5.9 5.4 12.8 1 Atul Buy 5687 7520 32 216.8 250.5 270.7 28.1 15.5 8.1 26.2 22.7 2.7 2.5 10.9 1																	
ICICI Lombard Buy 2020 2300 14 62.5 72.6 82.9 22.7 16.1 14.3 32.3 27.8 6.0 5.1 19.9 10 10 10 10 10 10 10 10 10 10 10 10 10		Ruv	749	910	21	8.4	10.0	11 5	0.2	18 9	14 7	89.2	75.0	2.5	2 2	15 <i>A</i>	16.5
ICICI Pru Life Buy 616 720 17 8.7 11.0 13.2 6.6 26.1 19.9 70.4 55.8 1.7 1.5 1.5 1.5 1.1 1.5 1.1 1.5 1.5 1.1 1.5 1.5 1.5 1.5 1.1 1.5 1.5 </td <td></td> <td>19.9</td>																	19.9
Life Insurance Corp. Buy 924 1080 17 87.8 96.3 104.5 15.3 9.7 8.6 10.5 9.6 0.7 0.6 11.7 1 Max Financial Buy 1619 2000 24 11.9 14.1 15.6 26.5 17.8 11.0 135.8 115.2 2.3 1.9 19.2 1 Niva Bupa Health Buy 76 92 21 0.4 1.5 3.0 -68.2 293.3 104.5 204.4 52.0 3.6 3.4 2.0 SBI Life Insurance Buy 1999 2240 12 24.1 25.7 28.0 -0.3 6.7 9.0 83.1 77.9 2.4 2.0 18.1 15.5 Star Health Insu Buy 488 570 17 11.4 16.3 21.7 3.9 42.6 33.3 42.7 30.0 3.7 3.3 9.1 15.5 Star Health Insu Buy 488 570 17 11.4 16.3 21.7 3.9 42.6 33.3 42.7 30.0 3.7 3.3 9.1 15.5 Star Health Insu Buy 5687 7520 32 216.8 250.5 270.7 28.1 15.5 8.1 26.2 22.7 2.7 2.5 10.9 15.5 10.		•															
Max Financial Buy 1619 2000 24 11.9 14.1 15.6 26.5 17.8 11.0 135.8 115.2 2.3 1.9 19.2 1 Niva Bupa Health Buy 76 92 21 0.4 1.5 3.0 -68.2 293.3 104.5 204.4 52.0 3.6 3.4 2.0 20 SBI Life Insurance Buy 1999 2240 12 24.1 25.7 28.0 -0.3 6.7 9.0 83.1 77.9 2.4 2.0 18.1 1 Star Health Insu Buy 488 570 17 11.4 16.3 21.7 3.9 42.6 33.3 42.7 30.0 3.7 3.3 9.1 1 Chemicals Alkyl Amines Neutral 1778 1900 7 36.7 42.4 46.4 1.0 15.4 9.5 48.4 42.0 5.9 5.4 12.8 1 Atul Buy 5687 7520 32 216.8 250.5 270.7																	11.5
Niva Bupa Health Buy 76 92 21 0.4 1.5 3.0 -68.2 293.3 104.5 204.4 52.0 3.6 3.4 2.0 SBI Life Insurance Buy 1999 2240 12 24.1 25.7 28.0 -0.3 6.7 9.0 83.1 77.9 2.4 2.0 18.1 15 Star Health Insu Buy 488 570 17 11.4 16.3 21.7 3.9 42.6 33.3 42.7 30.0 3.7 3.3 9.1 15 Chemicals Alkyl Amines Neutral 1778 1900 7 36.7 42.4 46.4 1.0 15.4 9.5 48.4 42.0 5.9 5.4 12.8 15 Atul Buy 5687 7520 32 216.8 250.5 270.7 28.1 15.5 8.1 26.2 22.7 2.7 2.5 10.9 15 1	· · · · · · · · · · · · · · · · · · ·																19.4
SBI Life Insurance Buy 1999 2240 12 24.1 25.7 28.0 -0.3 6.7 9.0 83.1 77.9 2.4 2.0 18.1 1 Star Health Insu Buy 488 570 17 11.4 16.3 21.7 3.9 42.6 33.3 42.7 30.0 3.7 3.3 9.1 1 Chemicals Alkyl Amines Neutral 1778 1900 7 36.7 42.4 46.4 1.0 15.4 9.5 48.4 42.0 5.9 5.4 12.8 1 Atul Buy 5687 7520 32 216.8 250.5 270.7 28.1 15.5 8.1 26.2 22.7 2.7 2.5 10.9 1																	6.7
Star Health Insu Buy 488 570 17 11.4 16.3 21.7 3.9 42.6 33.3 42.7 30.0 3.7 3.3 9.1 1 Chemicals Alkyl Amines Neutral 1778 1900 7 36.7 42.4 46.4 1.0 15.4 9.5 48.4 42.0 5.9 5.4 12.8 1 Atul Buy 5687 7520 32 216.8 250.5 270.7 28.1 15.5 8.1 26.2 22.7 2.7 2.5 10.9 1	· · · · · · · · · · · · · · · · · · ·																
Chemicals Alkyl Amines Neutral 1778 1900 7 36.7 42.4 46.4 1.0 15.4 9.5 48.4 42.0 5.9 5.4 12.8 1 Atul Buy 5687 7520 32 216.8 250.5 270.7 28.1 15.5 8.1 26.2 22.7 2.7 2.5 10.9 1																	18.3
Alkyl Amines Neutral 1778 1900 7 36.7 42.4 46.4 1.0 15.4 9.5 48.4 42.0 5.9 5.4 12.8 1 Atul Buy 5687 7520 32 216.8 250.5 270.7 28.1 15.5 8.1 26.2 22.7 2.7 2.5 10.9 1		Buy	488	5/0	1/	11.4	10.3	21./	3.9	42.6	33.3	42.7	30.0	3./	3.3	9.1	11.7
Atul Buy 5687 7520 32 216.8 250.5 270.7 28.1 15.5 8.1 26.2 22.7 2.7 2.5 10.9 1		N · ·	47-0	4000	-	20-	42 :	46.	4.0	4	<u> </u>	40.	42.2	F ^		42.2	42 :
																	13.4
Clean Science Neutral 937 960 2 263 321 378 56 222 179 357 292 60 51 192 1																	11.4
	Clean Science	Neutral	937	960	2	26.3	32.1	37.8	5.6	22.2	17.9	35.7	29.2	6.0	5.1		19.0
Deepak Nitrite Sell 1722 1540 -11 47.9 61.7 64.1 -6.2 28.6 3.9 35.9 27.9 3.9 3.5 11.5 1	Deepak Nitrite	Sell	1722	1540	-11	47.9	61.7	64.1	-6.2	28.6	3.9	35.9	27.9	3.9	3.5	11.5	13.3







		CMP	TP	% Upside		EPS (INR	2)	EPS	Gr. Yo\	′ (%)	P/E	(x)	P/E	3 (x)	ROE	(%)
Company	Reco	(INR)	(INR)	Downside		•										
Ellenbarrie Industrial	Buy	463	640	38	9.4	15.6	18.7	59.3	65.3	20.2	49.2	29.7	6.4	5.2	17.5	19.3
Fine Organic	Sell	4353	3980	-9	136.8	138.7	158.2	7.7	1.4	14.1	31.8	31.4	5.1	4.5	17.4	15.2
Galaxy Surfact.	Buy	2236	2630	18	89.7	105.2	118.8	4.3	17.3	13.0	24.9	21.3	3.1	2.8	12.8	13.6
Navin Fluorine	Neutral	5971	5400	-10	108.2	129.8	149.4	86.0	19.9	15.1	55.2	46.0	8.0	7.0	17.2	16.3
NOCIL	Neutral	176	170	-3	3.7	4.9	6.1	-42.3	31.8	24.8	47.2	35.8	1.6	1.6	3.5	4.5
PI Inds.	Buy	3756	4310	15	98.8	118.0	134.3	-9.6	19.4	13.9	38.0	31.8	5.0	4.4	13.9	14.7
SRF	Buy	2898	3650	26	68.1	91.8	105.7	47.9	34.7	15.1	42.5	31.6	6.1	5.3	15.2	17.9
Tata Chemicals	Neutral	858	900	5	29.0	44.5	60.0	75.9	53.4	34.9	29.6	19.3	1.0	1.0	3.4	5.1
Vinati Organics	Buy	1644	2100	28	52.1	60.9	71.2	30.0	17.0	17.0	31.6	27.0	5.3	4.5	17.8	18.0
	Биу	1044	2100	20	32.1	00.5	71.2	15.1	20.2	11.5	37.2	30.9	4.5	4.0	12.0	12.8
Aggregate								13.1	20.2	11.5	37.2	30.3	4.5	4.0	12.0	12.0
Capital Goods ABB India	Buy	5014	5800	16	79.1	89.3	104.4	-10.6	12.9	16.8	63.4	56.1	13.7	12.6	22.6	23.4
	•	414	500		8.3	9.9	11.5	15.0	18.6	16.2	49.8	42.0	12.1	9.6	24.2	
Bharat Electronics	Buy			21												23.0
Bharat Dynamics	Buy	1447	1900	31	28.2	37.8	52.0	88.4	34.0	37.4	51.2	38.2	11.0	8.9	21.5	23.3
Cummins India	Buy	4294	4950	15	87.6	98.5	114.9	22.2	12.5	16.7	49.0	43.6	14.9	13.1	32.3	31.9
Hind.Aeronautics	Buy	4627	5800	25	141.2	161.2	197.9	13.0	14.2	22.7	32.8	28.7	7.4	6.2	22.6	21.8
Hitachi Energy	Sell	20879	18000		203.2	266.4	334.5	162.4	31.1	25.5	102.7		17.3	14.1	17.8	18.9
Kalpataru Proj.	Buy	1294	1500	16	52.7	73.5	85.6	33.9	39.6	16.4	24.6	17.6	2.8	2.4	11.9	14.7
KEC International	Neutral	759	950	25	34.9	44.2	53.6	62.6	26.9	21.1	21.8	17.2	3.3	2.9	16.2	17.9
Kirloskar Oil	Buy	964	1230	28	33.6	40.9	47.6	16.7	21.8	16.5	28.7	23.6	4.1	3.6	15.3	16.4
Larsen & Toubro	Buy	3882	4500	16	130.2	154.9	184.9	21.9	19.0	19.4	29.8	25.1	4.9	4.3	17.2	18.1
Siemens	Neutral	3035	3300	9	75.8	66.9	77.8	33.5	-11.7	16.3	40.1	45.4	6.0	5.3	14.9	11.7
Siemens Energy	Buy	3229	3800	18	32.4	41.5	61.4	65.3	28.2	47.8	99.7	77.8	26.3	19.7	26.4	25.3
Thermax	Sell	3191	3450	8	68.0	79.8	94.6	20.5	17.5	18.5	47.0	40.0	6.5	5.7	14.6	15.2
Triveni Turbine	Buy	515	620	20	11.8	14.0	16.8	4.4	19.0	19.8	43.7	36.8	11.0	9.1	27.7	27.1
Zen Technologies	Neutral	1359	1400	3	21.6	40.5	53.3	-26.0	87.6	31.8	63.0	33.6	6.5	5.5	10.9	17.7
Aggregate								21.3	17.3	20.6	39.6	33.8	7.4	6.4	18.7	18.9
Cement																
Ambuja Cem.	Buy	559	740	32	11.4	14.9	17.9	41.2	30.9	19.8	49.0	37.5	2.4	2.3	5.1	6.3
ACC	Neutral	1842	2040	11	88.2	116.3	136.1	23.9	31.9	17.0	20.9	15.8	1.7	1.5	8.5	10.1
Birla Corp.	Buy	1215	1600	32	67.9	84.8	95.9	60.7	25.0	13.1	17.9	14.3	1.3	1.2	7.2	8.4
Dalmia Bhar.	Buy	2040	2660	30	68.0	72.8	84.7	83.5	7.0	16.4	30.0	28.0	2.1	2.0	7.1	7.2
Grasim Inds.	Buy	2724	3410	25	84.4	105.4	127.0	13.9	24.9	20.5	32.3	25.9	3.3	3.2	-4.3	-1.1
India Cem	Sell	379	300	-21	-1.2	3.8	11.3	-95.2	LP	195.1	NM	99.3	1.2	1.2	-0.4	1.2
JSW Cement	Neutral	128	150	18	2.3	2.9	3.6	-510.2		21.5	55.3	43.6	2.8	2.6	7.4	6.2
J K Cements	Buy	5632	7000	24	146.1	187.9	217.1	41.1	28.6	15.6	38.6	30.0	6.1	5.2	17.1	18.7
JK Lakshmi Ce	Buy	845	1100	30	41.3	51.0	51.3	70.7	23.3	0.6	20.4	16.6	2.7	2.3	13.9	15.1
Ramco Cem			1060		16.0	24.6	34.6	309.6	53.6	40.3	64.4	41.9	3.1	3.0	5.0	7.3
	Neutral			3												
Shree Cem	Neutral				529.5	561.8	676.6	56.7	6.1	20.4	51.7	48.7	4.4	4.1	8.7	8.7
Ultratech	Buy	11851	14460	22	272.7	350.5	423.9	31.4	28.5	20.9	43.5	33.8	4.6	4.2	11.0	13.0
Aggregate								42.0	26.1	20.4	39.1	31.0	3.2	3.0	8.2	9.7
Consumer																
Asian Paints	Neutral		2500	-5	44.2	51.8	58.3	4.1	17.3	12.5	59.3	50.5			21.7	
Britannia	Buy	6161	7150	16	108.4	126.4	143.5	18.0	16.6	13.5	56.8	48.7	29.1	23.8	55.2	
Colgate	Buy	2168	2850	31	51.9	57.8	63.0	1.0	11.5	8.9	41.8	37.5	37.3	37.5	87.0	99.7
Dabur	Neutral	519	525	1	10.8	12.2	13.4	6.7	12.4	9.7	47.9	42.6	7.9	7.7	17.2	18.4
Emami	Buy	514	725	41	20.7	22.7	24.6	2.2	9.5	8.4	24.8	22.7	7.4	6.7	31.7	31.1
Godrej Cons.	Buy	1122	1400	25	21.3	25.9	30.1	15.2	21.6	16.0	52.6	43.3	9.2	8.8	17.8	20.8
HUL	Buy	2415	3050	26	45.8	52.1	56.4	3.3	13.8	8.2	52.7	46.3	11.3	10.9	21.6	24.0
ITC	Buy	404	515	27	16.8	18.5	19.8	5.4	9.6	7.4	24.0	21.9	7.0	6.7	29.6	31.3
Indigo Paints	Buy	1005	1400	39	33.2	38.5	44.5	11.4	16.0	15.5	30.3	26.1	4.2	3.6	14.5	14.7
Jyothy Lab	Neutral	312	365	17	10.7	11.9	13.3	4.7	11.8	11.2	29.2	26.2	5.4	5.0	18.8	19.8
L T Foods	Buy	405	550	36	20.5	26.9	31.8	17.6	31.3	18.1	19.7	15.0	3.2	2.7	17.3	19.6
Marico	Buy	711	850	20	14.0	16.3	18.1	13.4	15.8	11.4	50.7	43.8	22.0	20.3	44.5	48.2
Nestle	Neutral		1300	3	16.9	20.1	22.5	5.4	19.6	11.4		62.6			77.9	
ITCSUC	iveutial	1201	1300	J	10.5	20.1	22.3	J. +	19.0	11.0	, 4.0	02.0	JU.1	ر.1	, ,	05.0







Commons	Dose	CMP	TP	% Upside		EPS (INR	•		Gr. Yo	• •	P/E			(x)		E (%)
Company	Reco	(INR) 39733	(INR)	Downside	725.3		FY28E 937.2								47.7	
Page Inds	Buy		50000 1500	26		830.8		11.1	14.5	12.8	54.8 60.9	47.8	26.1	21.8		45.6
Pidilite Ind.	Neutral	1456 13147	14000	3 6	23.9 268.1	27.6 296.7	31.6	15.7 36.9	15.5	14.3	49.0	52.7 44.3	13.5 46.8	11.9 38.6	23.4 105.7	24.0
P&G Hygiene	Neutral						330.1		10.7	11.2						
Radico Khaitan	Buy	3309	3600	9	41.9	53.3	65.5	62.5	27.3	22.8	79.0	62.1	14.1	11.9	17.9	19.2
Tata Consumer	Buy	1166	1450	24	17.0	20.1	22.1	21.1	18.8	9.5	68.7	57.8	5.1	4.8	8.2	9.2
United Brew	Neutral	1788	1750	-2	16.4	26.9	34.8	-7.2	64.0	29.6	109.1		10.3	9.5	9.7	14.9
United Spirits	Neutral	1429	1575	10	23.0	25.6	28.2	16.8	11.1	10.2	62.0	55.8	10.9	9.1	17.5	16.3
Varun Beverages	Buy	470	580	23	9.1	10.7	12.8	18.3	18.4	18.9	51.8	43.8	8.4	7.4	17.3	18.0
Aggregate								8.3	14.2	10.6	45.0	39.4	10.8	10.1	23.9	25.6
Consumer Durables	NI t I	1.1.10	1610	42	24.5	24.2	27.5	4.5	27.2	20.4	FO 4	46.5	0.7	0.6	46.5	40.4
Havells India	Neutral		1640	13	24.5	31.2	37.5	4.5	27.2	20.4	59.1	46.5	9.7	8.6	16.5	18.4
KEI Industries	Buy	3940	4960	26	92.2	108.5	128.9	26.5	17.7	18.8	42.7	36.3	5.7	5.0	14.2	14.6
LG Electronics	Buy	1610	1800	12	33.2	39.0	45.1	2.4	17.2	15.8	48.4	41.3	14.7	11.9	33.7	31.9
Polycab India	Buy	7543	9110	21	176.2	199.0	237.5	31.2	12.9	19.4	42.8	37.9	9.5	8.0	22.2	21.1
R R Kabel	Neutral	1378	1470	7	39.7	43.2	50.9	44.2	8.6	17.9	34.7	31.9	6.2	5.3	19.2	17.9
Voltas	Neutral	1321	1340	1	23.0	31.4	38.0	-9.4	36.3	21.0	57.4	42.1	6.2	5.5	10.8	13.1
Aggregate								13.2	19.0	18.7	48.1	40.4	9.1	7.8	19.0	19.4
EMS																
Amber Enterp.	Buy	7232	8400	16	90.4	158.0	224.9	25.5	74.8	42.3	80.0	45.8	7.0	6.1	10.8	14.3
Avalon Tech	Buy	1038	1330	28	15.3	25.0	34.1	59.6	63.4	36.5	67.8	41.5	9.6	7.8	15.3	20.8
Cyient DLM	Buy	444	550	24	9.5	16.8	23.7	2.4	76.0	41.1	46.5	26.4	3.4	3.0	7.6	12.0
Data Pattern	Neutral	2616	2500	-4	48.2	62.8	80.6	21.6	30.3	28.5	54.3	41.7	8.3	6.9	16.4	18.1
Dixon Tech.	Buy	14846	22500	52	174.9	276.9	363.8	49.3	58.3	31.4	84.9	53.6	22.3	15.9	30.0	34.7
Kaynes Tech	Buy	6228	8200	32	83.3	131.9	194.9	90.2	58.3	47.7	74.7	47.2	8.3	7.1	14.2	16.2
Syrma SGS Tech.	Buy	799	940	18	15.3	22.4	30.6	58.3	46.4	36.8	52.3	35.7	7.1	6.0	14.5	18.3
Aggregate								53.5	54.7	37.6	71.5	46.2	11.3	9.1	15.8	19.8
Healthcare																
Alembic Phar	Neutral	922	1020	11	36.2	44.9	53.7	24.2	24.1	19.7	25.5	20.5	3.1	2.8	12.8	14.2
Alkem Lab	Neutral	5674	5270	-7	206.3	182.6	209.5	13.9	-11.5	14.7	27.5	31.1	4.9	4.5	19.2	15.1
Ajanta Pharma	Buy	2526	3000	19	83.0	98.7	111.0	11.1	18.9	12.5	30.4	25.6	6.9	5.8	24.9	24.5
Apollo Hospitals	Buy	7638	9015	18	130.1	155.6	193.1	29.4	19.6	24.1	58.7	49.1	10.6	8.7	20.5	20.2
Aurobindo	Buy	1123	1350	20	62.4	78.3	94.6	2.3	25.4	20.9	18.0	14.3	1.8	1.6	10.6	11.9
Biocon	Buy	380	408	7	4.1	8.8	11.6	99.0	117.4	31.7	93.5	43.0	2.1	2.0	2.2	4.7
Blue Jet Health	Buy	600	770	28	20.5	25.7	32.3	16.5	25.2	25.8	29.3	23.4	7.1	5.5	27.4	26.6
Cipla	Neutral	1504	1500	0	61.3	61.8	68.7	-2.3	0.9	11.1	24.5	24.3	3.4	3.0	13.8	12.4
Divis Lab	Neutral	6656	6925	4	92.6	114.7	137.1	14.0	23.9	19.5	71.9	58.0	10.6	9.4	15.5	17.1
Dr Reddy's	Neutral	1205	1250	4	68.9	63.1	68.5	2.4	-8.4	8.6	17.5	19.1	2.6	2.3	15.8	12.7
Dr Agarwal's Hea	Buy	505	600	19	4.0	5.2	7.9	50.5	31.1	50.4	126.6	96.6	8.0	7.4	6.5	7.9
ERIS Lifescience	Neutral	1590	1635	3	37.7	54.4	62.5	47.1	44.3	14.9	42.2	29.2	6.6	5.5	16.8	20.6
Gland Pharma	Buy	1861	2310	24	54.2	68.0	80.4	27.8	25.5	18.3	34.3	27.4	3.1	2.7	9.3	10.6
Glenmark	Buy	1815	2400	32	58.9	77.9	91.1	23.3	32.3	17.0	30.8	23.3	4.9	4.1	17.2	19.2
GSK Pharma	Neutral	2591	2800	8	59.8	69.3	78.5	10.9	15.9	13.2	43.3	37.4	17.6	13.7	40.6	36.7
Global Health	Buy	1251	1590	27	24.2	30.3	36.8	24.9	25.5	21.5	51.8	41.3	8.6	7.3	17.7	19.1
Granules India	Buy	555	625	13	23.0	30.7	37.6	16.7	33.7	22.4	24.1	18.0	3.2	2.7	14.1	16.3
IPCA Labs	Buy	1322	1570	19	40.9	50.8	60.1	13.7	24.2	18.4	32.3	26.0	4.3	3.8	14.0	15.4
Laxmi Dental	Buy	312	400	28	8.8	12.2	15.0	84.4	38.5	23.6	35.5	25.7	6.7	5.3	20.7	23.0
Laurus Labs	Buy	983	1110	13	13.4	16.8	19.6	131.5	25.0	16.8	73.1	58.5	10.2	8.9	14.7	16.2
Lupin	Neutral	1972	2100	7	101.3	98.9	101.4	40.8	-2.4	2.5	19.5	19.9	4.0	3.3	23.1	18.1
Mankind Pharma	Buy	2263	2800	24	46.0	59.5	72.3	-8.0	29.4	21.5	49.2	38.0	5.9	5.3	12.6	14.7
Max Healthcare	Buy	1136	1350	19	18.7	24.3	25.6	23.6	30.1	5.5	60.8	46.7	9.1	7.7	16.0	
Piramal Pharma	Buy	199	240	21	-0.3	1.4	3.5	-148.9	LP	146.9		138.8	2.9	2.9	-0.5	2.3
Rubicon Research	Buy	627	740	18	13.1	17.8	24.0	60.4	35.9	34.7	47.8	35.2	8.6	7.1	24.7	22.0
Sun Pharma	Buy	1693	1960	16	49.2	57.5	64.7	4.4	16.8	12.6	34.4	29.5	5.0	4.4	15.4	16.0
	1					J J	- ···		_0.0							
Torrent Pharma	Neutral	3580	3770	5	70.0	84.6	104.2	21.2	20.8	23.1	51.1	42.3	6.7	5.5	28.4	28.6







		CMP	TP	% Upside		EPS (INR	3	FPS	Gr. Yo\	/ (%)	P/E	(x)	P/R	s (x)	ROF	(%)
Company	Reco	(INR)	(INR)	Downside		•	•			• •						<u> </u>
Aggregate		()	(,					10.5	13.6	14.9	34.5	30.4	4.8	4.3	14.1	
Infrastructure																
G R Infraproject	Buy	1144	1433	25	79.9	101.1	116.5	7.0	26.4	15.2	14.3	11.3	1.3	1.1	9.3	10.7
IRB Infra	Neutral	44	45	1	2.2	2.8	3.9	92.9	27.6	39.7	20.6	16.1	1.3	1.2	6.4	7.7
KNR Constructions	Neutral	180	210	16	8.7	14.4	15.1	-38.2	65.9	5.2	20.8	12.5	1.2	1.1	6.0	9.2
Aggregate											18.5	14.1	1.3	1.2	6.9	8.3
Logistics																
Adani Ports	Buy	1449	1770	22	62.6	73.3	82.3	24.9	17.0	12.3	23.1	19.8	4.3	3.6	19.9	19.7
Blue Dart Express	Buy	6220	7900	27	139.6	197.1	204.9	35.4	41.2	3.9	44.6	31.6	7.8	6.4	18.8	22.3
Concor	Buy	522	670	28	18.3	22.8	26.4	7.5	24.4	16.1	28.5	22.9	3.0	2.8	10.9	12.6
Delhivery	Buy	430	570	32	3.4	6.3	8.3	52.3	83.0	32.1	125.8	68.7	3.3	3.2	2.7	4.7
JSW Infra	Buy	280	360	28	7.5	8.9	12.6	7.3	18.6	42.1	37.4	31.5	5.4	4.7	15.3	15.8
Mahindra Logistics	Neutral	343	330	-4	2.5	17.2	22.3	-149.9	595.7	29.3	138.3	19.9	2.9	2.5	3.3	13.4
Transport Corp.	Buy	1136	1500	32	61.5	66.9	76.2	14.9	8.8	14.0	18.5	17.0	3.4	2.9	19.8	18.2
TCI Express	Neutral	633	720	14	26.1	33.2	36.3	16.5	27.4	9.1	24.3	19.0	2.9	2.6	12.5	14.4
VRL Logistics	Buy	273	350	28	12.6	14.8	16.5	20.6	17.4	11.6	21.7	18.5	3.9	3.7	19.2	20.6
Aggregate											26.7	22.3	4.2	3.6	15.5	16.1
Media																
PVR Inox	Neutral	1154	1245	8	25.1	31.0	39.3	-262.6	23.6	26.5	46.0	37.2	1.6	1.5	3.4	4.1
Sun TV	Neutral	554	645	16	43.4	44.4	46.3	0.0	2.2	4.2	12.8	12.5	1.8	1.6	13.7	12.9
Zee Ent.	Neutral	99	100	1	6.3	7.5	8.8	-22.8	18.6	17.1	15.7	13.2	0.8	0.8	5.2	5.9
Aggregate								9.4	8.1	10.0	16.6	15.4	1.3	1.3	8.1	8.3
Metals																
Coal India	Buy	376	440	17	51.3	57.7	60.3	-10.6	12.4	4.6	7.3	6.5	2.0	1.8	27.6	27.0
Hindalco	Buy	790	920	16	74.1	75.0	79.1	-0.9	1.1	5.5	10.7	10.5	1.6	1.4	15.8	13.9
Hind. Zinc	Neutral	475	510	7	27.5	32.2	35.1	11.3	17.3	8.8	17.3	14.7	10.1	7.1	70.0	56.4
JSPL	Buy	1070	1240	16	58.8	87.1	97.9	41.9	48.1	12.5	18.2	12.3	2.1	1.8	12.1	15.8
JSW Steel	Buy	1172	1350	15	44.2	72.4	89.9	184.0	63.7	24.2	26.5	16.2	3.2	2.7	12.8	18.0
Jindal Stainless	Buy	733	875	19	36.4	44.7	49.2	19.2	23.0	10.0	20.2	16.4	3.1	2.7	15.4	16.2
Nalco	Neutral	234	250	7	25.6	24.2	24.5	-10.7	-5.5	1.2	9.1	9.7	2.0	1.7	23.7	18.7
NMDC	Buy	74	88	18	8.6	9.5	10.2	15.8	10.4	7.3	8.6	7.8	1.9	1.6	23.5	22.2
SAIL	Neutral	141	150	7	8.4	13.2	14.2	158.3	57	8.0	16.8	10.7	0.9	0.9	5.7	8.5
Tata Steel	Buy	181	210	16	9.2	14.2	15.6	174.9	54	9.7	19.6	12.7	2.3	2.0	12.1	16.5
Vedanta	Neutral	515	540	5	41.6	46.8	54.5	19.8	12	16.5	12.4	11.0	4.2	3.5	36.7	34.8
Aggregate								17.3	22.7	10.3	13.6	11.1	2.4	2.1	17.4	18.5
Oil & Gas																
Aegis Logistics	Neutral	760	770	1	23.3	24.3	26.0	23.3	4.3	7.0	33.8	32.5	5.4	4.8	16.7	15.7
BPCL	Neutral	367	395	8	49.1	37.5	31.3	54.2	-23.6	-16.6	7.5	9.8	1.6	1.4	23.3	15.4
Castrol India	Buy	191	260	36	9.6	9.7	10.7	2.7	1.1	10.2	19.9	19.6	7.7	7.1	40.1	37.5
GAIL	Buy	181	205	14	13.9	14.9	16.0	-3.6	7.5	7.3	13.0	12.1	1.5	1.4	12.4	12.2
Gujarat Gas	Buy	400	500	25	16.3	18.8	21.7	-1.8	15.1	15.6	24.5	21.3	3.0	2.7	12.7	13.5
Gujarat St. Pet.	Neutral	299	327	9	12.9	13.6	14.3	-10.2	5.6	5.3	23.2	22.0	1.5	1.4	6.6	6.6
HPCL	Buy	480	590	23	78.6	63.5	46.6	148.3	-19.2	-26.6	6.1	7.5	1.6	1.4	29.3	19.9
IOC	Neutral	169	152	-10	18.6	14.6	10.6	140.0	-21.7	-27.2	9.1	11.6	1.1	1.1	13.1	9.4
IGL	Buy	212	250	18	10.9	12.8	13.8	3.8	17.9	7.6	19.5	16.5	2.9	2.6	15.6	16.7
Mahanagar Gas	Buy	1217	1700	40	98.5	102.8	113.8	-7.3	4.4	10.7	12.4	11.8	1.9	1.7	15.7	15.0
Oil India	Neutral	434	426	-2	32.7	32.0	28.4	-12.9	-2.4	-11.1	13.3	13.6	1.4	1.3	11.3	10.2
ONGC	Neutral	252	240	-5	31.0	32.0	32.6	1.4	3.1	2.0	8.1	7.9	0.9	0.8	10.9	10.5
PLNG	Buy	279	400	44	24.3	30.9	26.3	-7.1	27.1	-15.0	11.5	9.0	1.9	1.7	17.8	20.1
Reliance Ind.	Buy	1478	1700	15	55.6	61.2	67.8	8.0	10.1	10.8	26.6	24.2	2.2	2.0	8.6	8.7
Aggregate								22.6	-1.4	-1.0	15.7	15.9	1.7	1.6	10.9	10.0
Real Estate																
Anant Raj	Buy	620	831	34	14.7	13.0	31.9	18.2	-11.5	146.1	42.3	47.8	4.6	4.2	10.8	8.8
Brigade Enterpr.	Buy	978	1494	53	38.1	54.0	78.1	35.9	41.7	44.6	25.6	18.1	3.7	3.1	15.3	18.4
DLF	Buy	760	1002	32	17.4	17.3	18.1	-1.5	-0.6	4.5	43.7	44.0	2.9	2.7	9.7	8.9
	,	-				-			-			-				







		СМР	TP	% Upside		EPS (INR	2)	FDS	Gr. Yo\	/ (%)	D/F	(x)	D/F	3 (x)	ROE	(%)
Company	Reco	(INR)	(INR)	Downside			•		FY27E	• •						
Godrej Propert.	Buy	2144	2843	33	82.3	80.0	126.4	78.4	-2.8	57.9	26.0	26.8	3.3	2.9	13.4	11.5
Kolte Patil Dev.	Buy	422	514	22	41.6	38.6	78.6	196.7	-7.2	103.8	10.1	10.9	2.3	1.9	30.2	19.1
Oberoi Realty	Neutral	1794	1779	-1	78.8	99.7	109.3	28.7	26.6	9.6	22.8	18.0	3.6	3.0	16.9	18.2
Lodha Developers	Buy	1228	1888	54	37.0	40.6	43.1	33.6	9.8	6.2	33.2	30.3	5.2	4.5	16.9	16.0
Mahindra Lifespace	Neutral	398	447	12	2.7	12.8	15.1	-32.4	380.6	17.6	148.8		2.5	2.4	2.2	7.8
SignatureGlobal	Buy	1057	1760	67	55.7	125.3	184.8	674.8	124.7	47.5	19.0	8.4	9.8	4.5	70.0	73.6
Sri Lotus	Buy	176	250	42	6.1	12.0	15.8	30.5	97.7	31.6	28.9	14.6	4.4	3.4	20.5	26.0
Sunteck Realty	Buy	443	574	30	9.4	8.4	15.8	-8.5	-10.5	88.5	47.2	52.7	1.9	1.9	4.1	3.6
Sobha	Buy	1701	1877	10	33.7	50.6	72.4	281.0	49.9	43.2	50.4	33.6	3.7	3.4	7.6	10.5
Prestige Estates	Buy	1740	2038	17	27.5	32.1	35.7	116.0	16.6	11.3	63.3	54.3	4.2	3.9	6.9	7.5
Phoenix Mills	Buy	1772	2003	13	46.1	50.2	69.5	67.4	9.0	38.3	38.5	35.3	5.3	4.6	14.7	14.0
Aggregate	-,							38.6	17.0	26.4	35.0	30.0	4.2	3.7	11.9	12.3
Retail																
Aditya Birla Fashion	Neutral	80	90	13	-5.1	-5.6	-4.6	-16.2	Loss	Loss	NM	NM	1.3	1.5	-9.7	-11.6
Aditya Birla Lifestyle	Neutral	130	155	19	1.8	2.2	2.6	35.7	27.4	16.1	74.3	58.3	10.7	9.0	15.5	16.8
Avenue Supermarts	Buy	4011	5000	25	45.0	53.9	64.8	8.1	19.9	20.2	89.2	74.4	10.7	9.4	12.8	13.4
United Foodbrands	Neutral	198	265	34	-8.1	-7.6	-7.1	16.6	Loss	Loss	NM	NM	2.3	2.6	-9.5	-9.9
Bata India	Neutral	1063	985	-7	16.3	21.4	25.6	-16.1	31.3	19.9	65.2	49.7	8.2	7.6	12.9	15.8
Campus Activewe.	Buy	278	315	13	4.8	6.2	7.8	20.1	29.5	27.1	58.5	45.2	9.8	8.3	16.7	18.3
Devyani Intl.	Buy	148	180	22	-0.1	1.2	2.2	-172.0		88.9	NM	127.0	29.6	38.7	-1.9	26.4
Go Fashion (I)	Buy	625	750	20	16.6	21.8	25.9	-4.0	31.4	18.9	37.7	28.7	4.4	3.9	11.0	12.8
Jubilant Food.	Neutral	577	700	21	5.8	8.2	10.8	62.1	41.3	32.5	99.7	70.5	18.3	18.0	18.4	25.5
Kalyan Jewellers	Buy	513	675	32	11.2	14.3	17.0	43.4	27.6	18.9	45.7	35.8	9.4	8.0	22.1	24.1
Metro Brands	Buy	1122	1400	25	14.9	17.8	20.9	6.9	19.1	17.7	75.3	63.2	15.1	13.1	22.1	22.8
P N Gadgil Jewellers	Buy	653	825	26	23.8	29.0	35.4	36.6	21.9	22.1	27.5	22.5	4.7	3.9	18.8	19.0
Raymond Lifestyle	Buy	1155	1405	22	35.2	54.5	66.7	113.5	54.6	22.5	32.8	21.2	0.7	0.7	4.8	7.1
Restaurant Brand	Buy	66	120	82	-3.2	-1.4	-0.2	-19.6	Loss	Loss	NM	NM	5.4	6.1	-23.4	-12.4
Relaxo Footwear	Sell	432	400	-7	8.3	9.4	10.6	21.6	12.8	12.9	51.8	46.0	4.8	4.4	9.5	10.0
Sapphire Foods	Buy	270	350	30	-0.3	2.0	3.1	-128.6	LP	54.6	NM	134.0	6.2	6.0	-0.7	4.6
Senco Gold	Neutral	332	385	16	17.2	18.4	22.7	38.9	6.9	23.5	19.3	18.1	2.4	2.2	13.4	12.8
Shoppers Stop	Neutral	473	520	10	1.4	-0.4	-1.3	127.4	PL	Loss	339.6		11.1	11.3	4.4	-1.3
Titan Company	Buy	3769	4500	19	56.8	67.2	79.5	34.3	18.4	18.2	66.4	56.0	22.1	17.3	37.7	34.7
Trent	Buy	4625	6000	30	52.4	58.9	67.2	21.3	12.4	14.1	88.3	78.5	21.6	17.1	29.6	25.9
Vedant Fashions	Neutral	640	725	13	16.3	17.2	18.6	1.6	5.6	8.1	39.4	37.3	8.1	7.3	19.9	18.9
Vishal Mega Mart	Buy	143	170	19	1.8	2.3	2.8	30.6	27.5	24.1	79.7	62.5	9.1	8.0	12.2	13.6
V-Mart Retail	Buy	818	1055	29	13.7	22.5	33.1	429.1	64.2	46.9	59.6	36.3	7.1	5.9	12.6	17.7
Westlife Foodworld	Neutral	576	675	17	-0.2	2.0	5.4	-129.3		165.1	NM	283.0		13.8	-0.6	5.0
Aggregate								29.7	24.0	22.2	77.4	63.6		9.9	14.3	15.6
Technology																
Cyient	Sell	1111	1050	-6	60.7	75.5	93.6	9.5	24.4	24.1	18.3	14.7	2.2	2.1	11.4	13.5
HCL Tech.	Buy	1512	1800	19	65.9	73.6	77.0	3.2	11.6	4.6	22.9	20.5	6.0	6.1	25.8	29.3
Hexaware Tech.	Buy	673	850	26	23.9	27.8	32.0	24.1	16.0	15.4	28.1	24.2	6.7	5.9	25.8	26.3
Infosys	Neutral	1477	1650	12	69.1	72.4	76.7	8.4	4.7	5.9	21.4	20.4	6.4	6.4	29.9	31.3
KPIT Technologies	Buy	1153	1500	30	29.8	37.2	45.6	2.6	24.7	22.7	38.7	31.0	8.9	7.5	25.4	26.5
LTI Mindtree	Buy	5569	6650	19	185.8	207.1	234.1	19.6	11.5	13.0	30.0	26.9	6.4	5.6	22.6	22.1
L&T Technology	Neutral	4086	4400	8	128.4	154.6	176.6	7.9	20.4	14.2	31.8	26.4	6.2	5.4	20.9	21.9
Mphasis	Neutral	2739	2900	6	100.3	111.2	124.8	12.4	10.9	12.2	27.3	24.6	5.0	4.6	19.1	19.6
Coforge	Buy	1740	2400	38	44.7	58.7	74.3	77.3	31.4	26.5	38.9	29.6	8.1	7.1	17.4	20.7
Persistent Sys	Buy	5780	6550	13	119.1	147.0	172.7	32.0	23.4	17.5	48.5	39.3	12.1	10.2	27.1	
TCS	Buy	2992	3500	17	141.8	149.5	156.1	5.6	5.5	4.4	21.1	20.0	11.0	10.6	53.1	
Tata Elxsi	Sell	5181	4400	-15	105.4	136.6	156.3	-16.4	29.6	14.4	49.2	37.9	9.8	8.9	21.3	24.5
Tata Technologies	Sell	673	570	-15	16.8	19.8	22.5	1.4	17.7	13.5	40.0	34.0	6.8	6.4	18.0	19.4
Tech Mah	Buy	1387	1900	37	60.1	78.0	86.3	25.3	29.8	10.7	23.1	17.8	4.4	4.2	19.2	24.1
Wipro	Sell	237	200	-15	12.5	12.6	13.1	-0.2	1.2	3.6	18.9	18.7	2.9	2.9	15.7	15.6
Zensar Tech	Neutral	699	730	4	31.7	34.1	36.5	11.8	7.4	7.2	22.0	20.5	3.6	3.3		17.0
· +	25.6.61	-		•		- ··-		0					. · •			•







		CMP	TP	% Upside	-	EPS (INR)	EPS	Gr. Yo	/ (%)	P/E	(x)	P/E	3 (x)	ROE	(%)
Company	Reco	(INR)	(INR)	Downside		•	•									
Aggregate								7.3	8.2	6.6	22.9	21.1	6.6	6.4	29.1	30.4
Telecom																
Bharti Airtel	Buy	2001	2365	18	52.4	67.1	87.4	72.8	28.1	30.3	38.2	29.8	8.3	6.4	24.5	26.4
Bharti Hexacom	Neutral	1757	1975	12	37.2	53.5	69.7	45.1	43.9	30.2	47.2	32.8	12.0	9.8	28.1	32.9
Indus Towers	Neutral	401	390	-3	25.9	30.1	30.3	41.3	15.9	0.8	15.5	13.3	2.7	2.7	19.0	19.8
Vodafone Idea	Neutral	10	10	4	-2.5	-2.4	-2.0	-35.8	Loss	Loss	NM	NM	-0.5	-0.4	NM	NM
Tata Comm	Neutral	1850	1750	-5	42.0	61.5	75.3	46.0	46.6	22.5	44.1	30.1	15.4	11.5	37.1	44
Aggregate								LP	99.5	65.6	116	58	12.6	11.0	10.9	19.0
Utilities																
Acme Solar	Buy	265	385	45	8.7	10.6	24.5	92.5	22.2	130.7	30.5	25.0	3.2	2.8	11.0	12.0
Indian Energy Exchange	Neutral	139	150	8	5.3	5.4	5.8	13.1	3.4	6.4	26.4	25.5	9.6	8.4	39.4	35.1
Inox Wind	Buy	150	168	12	3.9	6.6	7.4	11.0	69.8	12.7	38.5	22.7	4.5	3.8	12.5	18.1
JSW Energy	Buy	520	655	26	10.9	15.3	23.8	1.8	41.0	55.3	47.9	34.0	3.1	2.9	6.7	8.8
NTPC	Neutral	326	372	14	22.5	27.7	31.1	8.4	23.0	12.3	14.5	11.8	1.6	1.5	11.9	13.4
Power Grid Corpn	Neutral	272	300	10	17.6	19.0	19.9	5.3	8.3	4.7	15.5	14.3	2.6	2.4	17.0	17.2
Suzlon Energy	Buy	57	74	29	1.4	2.2	2.5	27.1	57.9	14.2	41.9	26.5	9.0	6.7	25.3	29.1
Tata Power Co.	Buy	393	480	22	13.4	17.5	20.3	9.2	31.1	16.0	29.4	22.4	3.2	2.9	11.4	13.5
Waaree Energies	Buy	3279	4000	22	137.3	158.2	177.5	110.9	15.2	12.2	23.9	20.7	7.1	5.3	34.6	29.3
Aggregate	•							12.9	20.8	13.6	19	16	2.6	2.3	13.2	14.4
Others																
APL Apollo Tubes	Buy	1800	2100	17	42.0	54.9	64.5	54.0	30.6	17.3	42.8	32.8	9.6	7.6	24.8	25.9
Astral	Buy	1557	1880	21	22.4	28.9	35.5	14.8	29.5	22.8	69.6	53.8	7.7	6.6	15.6	17.7
Cello World	Buy	636	700	10	16.3	22.1	25.2	6.5	35.1	14.2	38.9	28.8	5.4	4.7	14.4	17.8
Coromandel Intl	Buy	2149	2800	30	78.6	100.8	114.0	28.3	28.2	13.2	27.3	21.3	4.9	4.1	19.2	20.8
Dreamfolks Services	Buy	122	160	31	14.6	17.7	0.0	22.3	21.3	-100.0		6.9	1.7	1.4	23.4	22.5
EPL	Buy	195	280	43	13.8	16.7	19.4	21.7	21.5	15.7	14.2	11.7	2.4	2.1	17.6	18.9
Eternal	Buy	306	410	34	0.8	2.7	5.6	32.2	246.9			113.5	8.9	8.2	2.3	7.5
Godrej Agrovet	Buy	590	790	34	26.0	35.3	39.7	16.2	35.7	12.4	22.7	16.7	6.5	5.1	24.2	34.1
Gravita India	Buy	1710	2200	29	55.3	72.3	90.1	30.7	30.7	24.7	30.9	23.7	5.1	4.2	18.0	19.5
Indiamart Inter.	Buy	2449	2900	18	81.9	93.7	109.1	-10.6	14.3	16.4	29.9	26.1	5.7	5.0	20.7	20.3
Indian Hotels	Buy	692	880	27	13.0	15.7	17.4	12.8	20.9	10.9	53.2	44.0	7.6	6.5	15.4	16.0
Info Edge	Neutral	1346	1450	8	16.2	19.3	20.3	35.8	19.4	5.2	83.1	69.6	3.1	3.0	3.7	4.3
Interglobe	Buy	5582	7300	31	170.6	242.8	274.7	-9.3	42.4	13.1	32.7	23.0	13.8	8.8	53.0	46.9
Kajaria Ceramics	Buy	1125	1451	29	33.6	38.4	44.6	91.4	14.2	16.2	33.5	29.3	5.8	5.2	17.3	17.6
Lemon Tree Hotel	Buy	163	195	20	3.5	4.4	4.9	39.3	26.0	13.2	47.1	37.3	9.0	7.2	21.1	21.4
MTAR Tech	Buy	2420	2900	20	33.3	59.1	85.5	93.7	77.5	44.6	72.7	40.9	9.0	7.3	13.1	19.7
One 97	Neutral		1200	-11	13.1	19.0		-156.1			103.0		5.7	5.6	5.6	8.1
Prince Pipes	Buy	315	420	33	8.0	13.9	19.5	104.0	73.3	41.0	39.4	22.7	0.9	0.8	5.5	8.9
Quess Corp		226	280			16.7	19.2	-2.4	12.9	14.7	15.3	13.5	2.7		21.8	28.5
SBI Cards	Neutral Neutral	872	1000	24	14.8	35.4	43.7	22.9	42.8	23.7	35.2	24.7	5.2	3.2 4.4	15.9	19.3
Safari Inds.		2051	2700	15 32	24.8 42.7	50.0	59.1	46.3	17.0	18.3	48.0	41.0	8.8	7.4	20.0	19.5
SIS	Buy	333	410	23	30.7	37.8	41.6	39.4	23.1		10.9	8.8	0.8	0.7		17.2
	Buy									10.2						20.5
Supreme Inds.	Buy	3832	4850	27	78.5	107.8	129.6	3.8	37.2	20.3	48.8	35.6	7.8	6.8		
Swiggy	Buy	402	550	37	-17.2	-8.7	3.8	26.3	Loss	LP 16.0	NM 10.2	NM 16.2	13.0	15.6		-30.9
Team Lease Serv.	Buy	1723	2000	16	89.9	105.9	122.9	38.6	17.8	16.0	19.2	16.3	2.7	2.4	14.9	15.2
Time Technoplast	Buy	210	289	38	10.6	13.1	16.0	24.4	23.7	21.7	19.8	16.0	2.9	2.5	15.5	16.7
Updater Services	Neutral	201	230	14	17.7	21.0	23.2	-0.1	18.5	10.5	11.3	9.6	1.2	1.1	11.6	12.2
UPL	Neutral	748	740	-1	41.9	57.2	66.1	67.4	36.7	15.6	17.9	13.1	1.2	1.1	10.6	13.4
VIP Inds.	Buy	391	530	36	2.4	9.3		-145.4			163.7		8.5	7.1	5.4	18.3
VA Tech Wabag	Buy	1389	1900	37	61.3	73.1	87.8	28.7	19.2	20.2	22.7	19.0	3.5	3.0	15.3	15.7





Index	1 Day (%)	1M (%)	12M (%)
Sensex	-0.1	1.6	4.6
Nifty-50	-0.1	1.5	5.3
Nifty Next 50	0.1	1.0	-1.8
Nifty 100	0.0	1.4	4.1
Nifty 200	0.1	1.7	4.2
Company	1 Day (%)	1M (%)	12M (%)
Automobiles	0.6	-0.6	12.5
Amara Raja Ener.	-0.9	-2.6	-25.3
Apollo Tyres	1.9	7.7	3.6
Ashok Leyland	0.0	1.0	30.9
Bajaj Auto	0.0	-2.0	-11.5
Balkrishna Inds	-0.8	1.8	-19.0
Bharat Forge	-0.2	8.2	-9.0
Bosch	-0.6	-5.1	4.0
CEAT	1.4	16.0	40.1
Craftsman Auto	-0.1	1.2	34.8
Eicher Motors	1.2	-1.0	41.2
Endurance Tech.	0.7	-3.3	17.6
Escorts Kubota	-1.6	3.0	-0.4
Exide Inds.	-0.7	-6.3	-15.7
Happy Forgings	2.3	7.1	-10.6
Hero Motocorp	-0.6	-5.7	10.0
Hyundai Motor	-1.2	-5.2	26.9
M & M	2.0	5.7	27.6
CIE Automotive	0.4	5.2	-13.1
Maruti Suzuki	0.2	-3.9	37.0
MRF	0.9	3.2	31.1
Sona BLW Precis.	1.7	18.6	-30.3
Motherson Sumi	-0.1	-0.3	-14.8
Motherson Wiring	-2.1	0.9	9.0
Tata Motors	-0.5	-4.0	-18.2
TVS Motor Co.	0.3	-1.6	39.4
Tube Investments	0.4	-7.1	-24.9
Banks-Private	0.4	1.6	10.5
AU Small Fin. Bank	3.1	18.9	50.9
Axis Bank	-0.5	3.0	5.4
Bandhan Bank	0.5	-6.5	-15.3
DCB Bank	7.0	31.5	42.8
Equitas Sma. Fin	-0.1	5.0	-14.0
Federal Bank	0.6	19.1	15.2
HDFC Bank	-0.2	0.0	12.5
ICICI Bank	1.7	-2.4	5.0
IDFC First Bank	1.4	13.2	22.5
IndusInd Bank	1.4	6.4	-24.6
Kotak Mah. Bank	0.2	-1.8	19.5
RBL Bank	0.8	20.0	91.6
SBI Cards	0.2	-3.7	24.5
Banks-PSU	0.9	10.1	19.6
ВОВ	0.9	10.4	10.0
Canara Bank	1.0	9.8	33.9
Indian Bank	0.9	15.3	52.1
Punjab Natl.Bank	1.6	7.2	14.7
St Bk of India	-0.5	10.5	11.2

Index	1 Day (%)	1M (%)	12M (%)
Nifty 500	0.0	1.3	3.1
Nifty Midcap 100	0.6	2.7	4.8
Nifty Smallcap 100	-0.2	0.5	-3.7
Nifty Midcap 150	0.5	1.8	3.9
Nifty Smallcap 250	-0.2	-0.2	-5.0
Union Bank (I)	2.1	10.7	27.7
NBFCs	0.8	1.7	13.7
Aditya Birla Capital Ltd	3.4	11.4	66.3
AAVAS Financiers	-1.9	-6.0	-7.7
Bajaj Fin.	2.4	4.9	54.5
Bajaj Housing	0.1	-1.4	-20.9
Cholaman.Inv.&Fn	1.2	4.4	32.8
Can Fin Homes	0.4	9.5	2.6
CreditAcc. Gram.	0.7	-3.2	42.2
Fusion Microfin.	1.5	-9.9	-14.3
Five-Star Bus.Fi	3.5	21.3	-1.3
HDB FINANC SER	-1.2	-4.0	-1.5
Home First Finan	-0.4	-6.4	-1.0
Indostar Capital	2.8	6.8	-7.6
IIFL Finance	1.1	10.7	15.9
L&T Finance	10.3	17.1	
LIC Housing Fin.	0.0	0.6	110.6
MCX	1.9		-10.8
		14.9	46.8
M & M Fin. Serv.	0.4	10.9	18.1
Muthoot Finance	1.5	-0.4	77.1
Manappuram Fin.	-1.2	-7.0	76.0
MAS Financial Serv.	1.0	-0.6	2.2
PNB Housing	-1.4	0.7	-7.6
Power Fin.Corpn.	-1.5	-7.0	-17.7
REC Ltd	0.6	-3.4	-31.0
Repco Home Fin	-2.2	10.7	-12.9
Shriram Finance	3.0	22.4	32.9
Spandana Sphoort	0.8	-7.1	-35.7
Nippon Life Ind.	-2.0	-2.9	18.1
UTI AMC	0.6	-8.9	-11.1
Nuvama Wealth	-0.1	4.9	-1.3
Prudent Corp.	5.8	0.6	-10.3
NBFC-Non Lending		0.0	2.0
360 One	-0.2	-0.3	2.9
Aditya AMC	-0.6	-6.7	-7.0
Anand Rathi Wea.	0.6	7.1	57.7
Angel One	5.2	16.3	-9.4
BSE	9.1	20.0	64.9
CDSL	3.0	1.0	-1.4
Cams Services	1.5	-0.1	-18.6
HDFC AMC	0.8	-2.2	20.3
KFin Technolog.	4.7	5.9	7.2
MCX	1.9	14.9	46.8
NSDL	1.1	-10.7	
Nippon Life Ind.	-2.0	-2.9	18.1
Nuvama Wealth	-0.1	4.9	-1.3
Prudent Corp.	5.8	0.6	-10.3
UTI AMC	0.6	-8.9	-11.1





Company	1 Day (%)	1M (%)	12M (%)
Insurance			
HDFC Life Insur.	1.8	-0.8	5.3
ICICI Pru Life	1.9	2.0	-13.8
ICICI Lombard	1.0	6.0	5.4
Life Insurance	3.1	1.3	-0.6
Max Financial	2.1	2.0	30.9
Niva Bupa Health	0.8	-4.6	
SBI Life Insuran	1.4	12.0	25.7
Star Health Insu	0.4	2.6	-2.0
Chemicals	0.4	2.0	2.0
Alkyl Amines	-1.8	-5.7	-16.6
Atul	-1.4	-6.9	-29.3
Clean Science	-4.4		-36.8
		-11.6	
Deepak Nitrite	-0.7	-4.5	-38.9
Ellen.Indl.Gas	0.8	6.4	45.4
Fine Organic	-1.0	-5.9	-15.4
Galaxy Surfact.	-1.2	-1.3	-27.9
Navin Fluo.Intl.	-1.8	30.6	68.6
NOCIL	0.0	-5.0	-37.9
P I Inds.	0.2	4.9	-19.9
SRF	-0.1	-2.3	21.8
Tata Chemicals	-1.7	-6.9	-23.4
Vinati Organics	-1.6	-4.3	-14.7
Capital Goods	-0.2	-0.2	-1.1
АВВ	-4.0	-3.9	-28.3
Bharat Dynamics	0.7	-5.4	34.4
Bharat Electron	1.3	1.0	37.9
Cummins India	-0.6	8.2	20.7
Hind.Aeronautics	0.7	-4.4	4.3
Hitachi Energy	3.2	18.9	45.3
K E C Intl.	-3.5	-11.9	-27.7
Kalpataru Proj.	-0.7	1.8	2.0
Kirloskar Oil	-2.4	9.4	-17.7
Larsen & Toubro	0.0	4.1	6.5
Siemens	-1.6	-6.7	-13.7
Siemens Ener	1.3	-1.6	
Thermax	-2.0	0.0	-37.5
Triveni Turbine	-2.0	-1.5	-21.4
Zen Technologies	-1.1	-5.2	-27.3
Cement			
Ambuja Cem.	0.1	-2.0	-2.1
ACC	0.4	-0.9	-20.7
Birla Corp.	2.3	1.3	5.1
Dalmia Bhar.	-0.6	-9.2	13.3
Grasim Inds.	0.9	-3.0	6.3
India Cem	-2.7	-3.7	5.1
JSW Cement	-0.6	-8.6	
J K Cements	-1.2	-12.9	38.3
JK Lakshmi Cem.	-3.0	-0.9	8.9
The Ramco Cement	0.0	2.8	17.9
Shree Cement	-0.3	-7.3	10.5
UltraTech Cem.	-0.3 -0.5	-7.3 -2.7	7.2
Oillatelii Celli.	-0.5	-2.1	1.2

Commons	1 Day (9/)	104 (0/)	1204 (0/)
Company Consumer	1 Day (%)	1M (%)	12M (%)
Asian Paints	- 0.5	11.1	-4.7 -8.1
Britannia Inds.	2.4	4.6	8.2
Colgate-Palm.	-0.3	-2.9	-25.6
Dabur India	-1.0	5.4	-3.0
Emami Caranana	-1.7	-6.9	-23.4
Godrej Consumer	-2.1	-2.7	-10.9
Hind. Unilever	-0.9	-4.1	-2.5
ITC	-0.8	1.1	-10.6
Indigo Paints	1.6	-4.8	-38.2
Jyothy Lab.	-0.4	0.5	-37.3
L T Foods	-0.8	1.8	3.6
Marico	-0.2	-0.5	12.7
Nestle India	-0.3	7.3	11.6
Page Industries	0.0	-4.7	-11.8
Pidilite Inds.	0.8	-1.1	-7.9
P & G Hygiene	0.1	-7.7	-14.8
Radico Khaitan	3.9	10.5	39.1
Tata Consumer	-1.9	4.2	18.5
United Breweries	-1.2	-0.3	-7.8
United Spirits	0.9	5.7	-0.7
Varun Beverages	-0.3	6.9	-21.3
Consumer Durables	-0.4	2.0	-2.0
Havells	0.4	-3.6	-13.1
KEI Industries	0.8	-5.7	-1.3
LG Electronics	-0.5		
Polycab India	-0.7	-0.7	10.6
R R Kabel	-1.5	8.6	-11.1
Voltas	2.3	-3.7	-25.2
EMS			
Amber Enterp.	-7.7	-14.1	16.2
Avalon Tech	-1.9	-16.8	47.3
Cyient DLM	-0.6	-1.3	-33.0
Data Pattern	0.1	-7.3	9.3
Dixon Technolog.	-1.5	-13.8	-5.4
Kaynes Tech	-2.1	-18.0	7.7
Syrma SGS Tech.	1.4	-6.2	40.7
Healthcare	-0.4	1.3	-1.6
Ajanta Pharma	-1.7	2.6	-15.5
Alembic Pharma	0.7	0.6	-14.6
Alkem Lab	0.5	3.2	-0.9
Apollo Hospitals	-1.8	-0.8	2.9
Aurobindo	-1.6	3.0	-16.9
Biocon	-1.2	9.4	16.0
Blue Jet Health	6.5	-11.2	10.7
Cipla	0.3	-0.5	-4.5
Divis Lab	-3.3	9.0	11.7
Dr Agarwals Health	-0.2	-0.6	
Dr Reddy's	0.0	-3.5	-6.4
ERIS Lifescience	0.6	-0.3	22.4
Gland Pharma	-1.9	-4.0	3.3
Glenmark	0.1	-7.7	9.3
Global Health	-1.4	-6.6	16.4
Granules	0.4	-0.3	-3.1





Company	1 Day (%)	1M (%)	12M (%)
GSK Pharma	-0.7	-5.6	-0.9
IPCA Labs	0.8	-3.3	-15.6
Laurus Labs	0.2	13.8	98.4
Laxmi Dental	0.4	-4.4	
Lupin	0.8	2.4	-6.6
Mankind Pharma	-2.0	-8.8	-17.1
Max Healthcare	0.9	0.4	5.2
Piramal Pharma	-0.1	1.8	-31.9
Rubicon Research	-1.8		
Sun Pharma	0.3	2.3	-5.6
Torrent Pharma	0.7	1.2	13.2
Zydus Lifesci.	0.8	-4.4	-3.0
Infrastructure	-1.0	2.7	7.1
G R Infraproject	0.2	-8.0	-30.2
IRB Infra.Devl.	-0.8	7.2	-14.7
KNR Construct.	0.7	-7.6	-39.3
Logistics			
Adani Ports	0.8	3.5	7.0
Blue Dart Exp.	-1.7	10.6	-21.8
Delhivery	-2.9	-8.4	21.4
Container Corpn.	0.5	-2.0	-23.2
JSW Infrast	-1.3	-8.9	-11.0
Mahindra Logis.	0.3	-4.8	-9.5
Transport Corp.	-1.8	-7.1	-6.9
TCI Express	-4.4	-11.0	-35.6
VRL Logistics	1.5	2.1	-4.6
Media	-0.3	-5.9	-25.6
PVR INOX	0.9	5.5	-23.4
Sun TV	1.1	-5.0	-27.1
Zee Ent.	-1.0	-12.1	-20.9
Metals	1.4	2.7	11.0
Hindalco	0.3	2.9	22.0
Hind. Zinc	1.6	-3.1	-6.5
JSPL	2.3	3.5	12.9
JSW Steel	0.2	1.3	18.4
Jindal Stainless	0.3	-3.5	1.2
Nalco	1.8	8.1	-1.6
NMDC	1.5	-2.4	-6.8
SAIL	2.2	6.1	14.3
Tata Steel	2.3	5.8	20.2
Vedanta	2.0	9.2	12.5
Oil & Gas	0.1	4.2	2.7
Aegis Logistics	-0.7	-7.2	-4.9
BPCL	-0.2	7.4	16.6
Castrol India	0.4	-5.5	-9.5
GAIL	0.8	0.3	-14.2
Gujarat Gas	-0.4	-7.3	-26.2
Gujarat St. Pet.	-2.0	-7.4	-23.3
HPCL	1.4	5.6	20.9
IOCL	0.5	9.6	17.3
IGL	0.7	-3.5	-2.7
	0.7	-3.3	-2.1
	1 /	-7 F	_1 5 //
Mahanagar Gas Oil India	-1.4 0.2	-7.5 2.7	-15.4 -17.3

Company	1 Day (%)	1M (%)	121/1/9/\
Company PLNG	1.3	-3.1	12M (%) -19.7
Reliance Ind.	-1.2	6.7	13.2
	0.0	6.1	
Real Estate			-5.0
Anant Raj	-0.6	-15.7	-17.1
Brigade Enterpr.	-0.3	6.8	-14.3
DLF	0.1	3.0	-5.5
Godrej Propert.	-2.3	3.3	-23.8
Kolte Patil Dev.	1.4	-2.6	13.0
Mahindra Life.	-1.0	10.0	-16.1
Macrotech Devel.	-0.5	7.1	0.8
Oberoi Realty Ltd	0.7	9.6	-11.8
SignatureGlobal	-1.6	3.2	-23.5
Sri Lotus	1.0	-6.1	
Sobha	2.8	15.7	3.1
Sunteck Realty	-1.1	0.1	-21.2
Phoenix Mills	1.6	10.0	17.0
Prestige Estates	0.6	13.4	5.4
Retail			
Aditya Bir. Fas.	2.1	-7.0	-26.3
A B Lifestyle	-1.5	-11.8	
Avenue Super.	-1.7	-6.8	3.1
United Foodbrands	0.3	-14.8	-65.8
Bata India	1.1	-12.8	-20.8
Campus Activewe.	2.0	-0.4	-11.9
Devyani Intl.	-4.9	-10.6	-14.0
Go Fashion (I)	-2.5	-9.1	-47.6
Jubilant Food	-1.2	-6.1	-3.3
Kalyan Jewellers	0.0	5.1	-27.4
Metro Brands	-0.6	-11.5	-5.5
P N Gadgil Jewe.	0.9	-0.5	-12.2
Raymond Lifestyl	0.2	-1.9	-47.1
Relaxo Footwear	-1.4	-1.0	-44.6
Restaurant Brand	-1.5	-12.0	-28.7
Sapphire Foods	-3.1	-7.1	-15.0
Senco Gold	1.3	-4.5	-42.4
Shoppers St.	-0.5	-9.3	-27.7
Titan Co.	-0.1	10.3	20.8
Trent	-1.1	-1.3	-28.9
Vedant Fashions	-0.9	-7.6	-54.1
V-Mart Retail	-0.3	-0.3	-24.3
Vishal Mega Mart	1.5	-4.3	
Westlife Food	-1.7	-15.9	-25.7
Technology	-0.6	1.2	-15.9
Cyient	-2.6	-5.6	-42.1
HCL Tech.	-0.9	5.5	-17.4
Hexaware Tech.	-3.9	-3.0	
Infosys	0.7	1.3	-18.1
KPIT Technologi.	-0.5	-1.5	-20.0
LTIMindtree	-1.5	5.7	-5.4
L&T Technology	-0.3	-4.9	-20.5
Mphasis	-1.4	-2.9	-3.6
Coforge	-1.4	3.2	10.8
Persistent Sys	-1.0	9.7	0.8
TCS	-0.6	0.6	-27.9
103	-0.0	0.0	-27.9



Company	1 Day (%)	1M (%)	12M (%)
Tata Technolog.	-0.6	-5.6	-33.8
Tata Elxsi	-1.2	-3.9	-27.7
Tech Mah	-1.9	-3.6	-16.0
Wipro	-1.5	-2.9	-16.0
Zensar Tech	-0.6	-8.1	-5.2
Telecom	-1.2	4.0	5.3
Bharti Airtel	-4.5	3.7	27.0
Indus Towers	0.6	12.0	18.1
Idea Cellular	3.7	4.7	19.4
Tata Comm	0.4	11.3	2.4
Utilities	-0.5	-1.8	-14.5
ACME Solar Hold.	-1.5	-8.6	
Coal India	0.8	-2.3	-13.6
Indian Energy Ex	0.6	-1.9	-20.1
Inox Wind	-0.4	7.2	-30.6
JSW Energy	0.3	-5.3	-27.4
NTPC	-0.2	-3.5	-19.2
Power Grid Corpn	0.7	-5.9	-13.1
Suzion Energy	-3.7	6.2	-14.1
Tata Power Co.	0.4	0.2	-11.6
Waaree Energies	-2.8	-3.7	-2.2
Others		<u> </u>	
APL Apollo Tubes	0.8	3.7	18.1
Astral	-0.6	9.7	-13.0
Cello World	-1.2	7.1	-26.4
Coromandel Intl	-0.2	-6.2	20.7
Dreamfolks Servi	-1.6	11.9	-73.6
EPL Ltd	-0.5	-9.2	-28.6
Eternal Ltd	0.1	-9.4	19.9
Godrej Agrovet	-4.7	-12.5	-19.9
Gravita India	0.4	9.4	-25.6
Havells	0.4	-3.6	-13.1
Indiamart Inter.	-1.0	4.3	1.6
Indian Hotels	-0.8	-5.7	1.1
Info Edge	1.4	-2.8	-14.9
Interglobe	-1.9	-1.4	39.7
Kajaria Ceramics	-1.5	-6.5	-8.0
Lemon Tree Hotel	-2.0	-2.7	37.4
MTAR Technologie	1.9	23.0	45.6
One 97	2.0	8.8	69.2
Prince Pipes	0.8	-6.4	-33.7
Quess Corp	1.5	-8.8	-35.4
Safari Inds.	-1.4	-6.3	-9.1
SIS	-2.0	1.6	-15.3
Supreme Inds.	-0.4	-9.4	-18.1
Swiggy	-0.6	-4.6	
Time Technoplast	0.2	-5.2	0.5
Team Lease Serv.	2.3	-3.7	-36.7
Updater Services	-1.3	-21.0	-52.2
UPL	2.0	10.0	37.5
Voltas	2.3	-3.7	-25.2
V I P Inds.	-1.5	-8.6	-17.7
	1.0	3.0	

Investment in securities market are subject to market risks. Read all the related documents carefully before investing



NOTES



Explanation of Investment Rating					
Investment Rating	Expected return (over 12-month)				
BUY	>=15%				
SELL	<-10%				
NEUTRAL	> - 10 % to 15%				
UNDER REVIEW	Rating may undergo a change				
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation				

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH00000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (INCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL),NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf

Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx

MOFSL, it's associates, Research Analyst or their relatives may have any financial interest in the subject company. MOFSL and/or its associates and/or Research Analyst or their relatives may have actual beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance. MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may have any other potential conflict of interests at the time of publication of the research report or at the time of public appearance, however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

In the past 12 months, MOFSL or any of its associates may have:

received any compensation/other benefits from the subject company of this report

managed or co-managed public offering of securities from subject company of this research report,

received compensation for investment banking or merchant banking or brokerage services from subject company of this research report,

received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report.

MOFSL and it's associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.

Subject Company may have been a client of MOFSL or its associates during twelve months preceding the date of distribution of the research report.

Research Analyst may have served as director/officer/employee in the subject company.

MOFSL and research analyst may engage in market making activity for the subject company.

MOFSL and its associate company(ies), and Research Analyst and their relatives from time to time may have:

a) a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein.

(b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures. To enhance transparency, MOFSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement

Analyst ownership of the stock No

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Financial Services Limited (SEBI Reg No. INH00000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

MOTILAL Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and



under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com Contact: (+65) 8328 0276

Disclaimer:

This report is intended for distribution to Retail Investors.

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of tits affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No::022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028. AMFI: ARN .: 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.